<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18354" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Bladder Cancer</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Stephen W.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Soon-Sutton</surname>
            <given-names>Taylor L.</given-names>
          </name>
          <aff>Creighton</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Aeddula</surname>
            <given-names>Narothama R.</given-names>
          </name>
          <aff>Deaconess HS, IN University School Med</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Leslie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Taylor Soon-Sutton declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Narothama Aeddula declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>15</day>
          <month>8</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18354.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Bladder cancer, a prevalent malignancy affecting the urinary system, arises from the tissues of the bladder, a hollow organ responsible for storing urine. Urothelial carcinoma is the most frequent type, constituting over 90% of cases in industrialized nations. This type of cancer is notably common among older adults, with risk factors including smoking, chemical exposure, and chronic bladder inflammation. Presenting symptoms such as gross or microscopic hematuria, urinary frequency, and pelvic pain lead to its detection.</p>
        <p>Early diagnosis and treatment are crucial for improving outcomes, as bladder cancer can range from noninvasive forms, which are confined to the inner layers of the bladder, to invasive types that penetrate deeper and can spread to other parts of the body. Treatment primarily involves transurethral resection and intravesical chemotherapy instillations but may also include laser ablation, Bacillus Calmette-Guerin bladder treatments, radiation therapy, chemotherapy, or surgical removal of part or all of the bladder.</p>
        <p>This activity reviews the intricacies of bladder cancer, from its etiology to its therapeutic strategies. The latest advancements and comprehensive knowledge in diagnosing, treating, and managing this prevalent malignancy are discussed. Participants gain enhanced diagnostic acumen, learn evidence-based treatment protocols, and are updated on emerging research, fostering a deeper understanding of bladder cancer's evolving landscape and ultimately improving clinical practice.</p>
        <p>The activity also highlights the interprofessional team's role in improving care for patients with this malignant condition. Collaborating with an interprofessional team enhances patient outcomes by integrating diverse expertise, ensuring comprehensive treatment plans, and providing holistic care that addresses all aspects of the patient's health, thereby improving the overall management and prognosis of bladder cancer.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Screen for symptoms and risk factors associated with bladder cancer in high-risk populations.</p></list-item><list-item><p>Assess the TNM and clinical staging used in the classification and evaluation of bladder cancer.</p></list-item><list-item><p>Apply the latest therapeutic guidelines in the treatment of both non-muscle-invasive and muscle-invasive bladder cancer.</p></list-item><list-item><p>Communicate&#x000a0;the importance of collaboration among&#x000a0;an interprofessional team to enhance the delivery of care for patients affected by bladder cancer.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18354&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18354">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18354.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Bladder cancer, a prevalent malignancy affecting the urinary system, arises from the tissues of the bladder, a hollow organ responsible for storing urine (see <bold>Image.</bold> Bladder Cancer, Magnetic Resonance Image). Urothelial carcinoma is the most frequent type of bladder cancer, constituting over 90% of cases in industrialized nations. This type of cancer is notably common among older adults, with risk factors including smoking, chemical exposure, and chronic bladder inflammation.</p>
        <p>Presenting symptoms such as gross or microscopic hematuria, urinary frequency, and unexplained pelvic pain typically lead to its detection. Early diagnosis and treatment are crucial for improving outcomes, as bladder cancer can range from noninvasive forms that are confined to the inner layers of the bladder to invasive types that penetrate deeper and can spread to other parts of the body.</p>
        <p>Treatment primarily involves transurethral resection and intravesical chemotherapy instillations but may also include laser ablation, Bacillus Calmette-Guerin bladder treatments, radiation therapy, chemotherapy, or surgical removal of part or all of the bladder.</p>
        <p>This activity reviews the intricacies of bladder cancer, from its etiology to its therapeutic strategies. The latest advancements and comprehensive knowledge in diagnosing, treating, and managing this prevalent malignancy are discussed. Participants gain enhanced diagnostic acumen, learn evidence-based treatment protocols, and are updated on emerging research, fostering a deeper understanding of bladder cancer's evolving landscape and ultimately improving clinical practice. The role of the interprofessional team in improving care for patients with this common malignant condition.</p>
        <p>Collaborating with an interprofessional team enhances patient outcomes by integrating diverse expertise, ensuring comprehensive treatment plans, and providing holistic care that addresses all aspects of the patient's health. This improves the overall management and prognosis of bladder cancer.</p>
      </sec>
      <sec id="article-18354.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Urothelial carcinoma develops via two distinct pathways. One relates primarily to papillary neoplasms, and the other to flat or sessile lesions.</p>
        <p><bold>Non-muscle-invasive bladder cancers (NMIBC)&#x000a0;</bold>are typically low-grade papillary tumors&#x000a0;that&#x000a0;usually arise from simple hyperplasia and/or minimal dysplasia. This category also includes carcinoma in situ (CIS), a high-grade but superficial cancer.</p>
        <p>NMIBCs are&#x000a0;characterized by the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Activating mutations of fibroblast growth factor receptor 3 &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Inactivating mutations of <italic toggle="yes">STAG2</italic> &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>The loss of heterozygosity of chromosome 9&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Telomerase reverse transcriptase&#x000a0;</p>
          </list-item>
        </list>
        <p>Low-grade papillary&#x000a0;NMIBC can progress to a muscle-invading malignancy in about 10% of cases due to&#x000a0;cyclin-dependent kinase inhibitor 2A&#x000a0;loss.<xref ref-type="bibr" rid="article-18354.r1">[1]</xref></p>
        <p><bold>Muscle-invasive bladder cancer (MIBC)</bold> arises from flat dysplasia or carcinoma in situ &#x000a0;and is characterized by the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>The lesions show <italic toggle="yes">TP53</italic> mutations and loss of heterozygosity of chromosome 9.</p>
          </list-item>
          <list-item>
            <p>Invasive carcinoma can then acquire metastatic potential by gaining <italic toggle="yes">RB1</italic> and <italic toggle="yes">PTEN</italic> loss, together with other alterations.</p>
          </list-item>
          <list-item>
            <p>Copy number alterations and genetic instability correlate with tumor progression and a poorer prognosis.</p>
          </list-item>
          <list-item>
            <p>Overall, NMIBC usually shows diploid or near-diploid karyotypes as compared to muscle invading.</p>
          </list-item>
          <list-item>
            <p>MIBC is usually aneuploid, with numerous chromosomal alterations.<xref ref-type="bibr" rid="article-18354.r2">[2]</xref><xref ref-type="bibr" rid="article-18354.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>Results from recent studies have demonstrated 4 subtypes of&#x000a0;NMIBC based on abnormal ribonucleic acid (RNA) expression analyses.<xref ref-type="bibr" rid="article-18354.r4">[4]</xref> These abnormal prognostic molecular subtypes involve early cell cycle abnormalities, chromosomal instability, stem cell-like disorders, and immune depletion problems.<xref ref-type="bibr" rid="article-18354.r4">[4]</xref>&#x000a0;Of these, chromosomal instability, which involves p53 and deoxyribonucleic acid damage repair genes, as well as&#x000a0;apolipoprotein messenger RNA-editing enzyme, catalytic polypeptide, appears to be the most significant, as it has the highest recurrence and progression rates.<xref ref-type="bibr" rid="article-18354.r4">[4]</xref></p>
        <p>
<bold>Risk Factors</bold>
</p>
        <p>There are multiple known risk factors for bladder cancer. Important risk factors include smoking, schistosomiasis infection, and occupational exposure to certain chemicals.<xref ref-type="bibr" rid="article-18354.r2">[2]</xref><xref ref-type="bibr" rid="article-18354.r5">[5]</xref><xref ref-type="bibr" rid="article-18354.r6">[6]</xref>&#x000a0; Smoking is the most important known risk factor for bladder cancer as the average incidence in smokers is triple (2- to 6-fold) that of nonsmokers; the risk depends on smoking duration and intensity, with 10-pack-years generally considered the high-risk threshold.<xref ref-type="bibr" rid="article-18354.r7">[7]</xref> At least 50% of bladder cancers will be found in current or former smokers.<xref ref-type="bibr" rid="article-18354.r8">[8]</xref><xref ref-type="bibr" rid="article-18354.r9">[9]</xref><xref ref-type="bibr" rid="article-18354.r10">[10]</xref>&#x000a0;Cigarette smokers also tend to develop more aggressive tumors and have a worse prognosis.<xref ref-type="bibr" rid="article-18354.r11">[11]</xref>&#x000a0;Smoking cessation lowers the bladder cancer risk, which eventually approaches that of nonsmokers.<xref ref-type="bibr" rid="article-18354.r8">[8]</xref><xref ref-type="bibr" rid="article-18354.r10">[10]</xref>&#x000a0;Within the first 4 years after smoking cessation, the bladder cancer risk drops by 40% and is reduced by 60% after 25 years.<xref ref-type="bibr" rid="article-18354.r12">[12]</xref></p>
        <p>In developing countries, schistosomiasis infection is an important cause of bladder cancer. <italic toggle="yes">Schistosoma haematobium</italic> ova becomes embedded in the bladder wall, leading to irritation, chronic inflammation, squamous metaplasia, and dysplasia, ultimately progressing to squamous cell carcinoma of the urinary bladder (see <bold>Image.</bold> Poorly Differentiated Urothelial Carcinoma with Metaplastic Squamous Appearance). Worldwide, about 600 million people are at risk in endemic areas of Africa, Asia, the Caribbean, and South America.<xref ref-type="bibr" rid="article-18354.r13">[13]</xref></p>
        <p>Genetic and/or environmental factors also affect the development of bladder cancer but only account for about 7% of all such cases.<xref ref-type="bibr" rid="article-18354.r14">[14]</xref><xref ref-type="bibr" rid="article-18354.r15">[15]</xref><xref ref-type="bibr" rid="article-18354.r16">[16]</xref><xref ref-type="bibr" rid="article-18354.r17">[17]</xref><xref ref-type="bibr" rid="article-18354.r18">[18]</xref>&#x000a0;Chemicals associated with bladder cancer include arylamine and aniline dyes, formaldehyde, phenacetin, cyclophosphamide, and arsenic in the drinking water.<xref ref-type="bibr" rid="article-18354.r19">[19]</xref><xref ref-type="bibr" rid="article-18354.r20">[20]</xref><xref ref-type="bibr" rid="article-18354.r21">[21]</xref><xref ref-type="bibr" rid="article-18354.r22">[22]</xref></p>
        <p>Occupational exposure to paint, rubber, petroleum products, agricultural chemicals, and dyes correlates with an increased risk of bladder cancer. Occupations that typically have the most exposure to such chemicals include the following:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Agricultural crop production workers</p>
          </list-item>
          <list-item>
            <p>Barbers</p>
          </list-item>
          <list-item>
            <p>Bartenders and waiters</p>
          </list-item>
          <list-item>
            <p>Beauticians</p>
          </list-item>
          <list-item>
            <p>Chemical plant employees</p>
          </list-item>
          <list-item>
            <p>Dental office workers</p>
          </list-item>
          <list-item>
            <p>Dry cleaners</p>
          </list-item>
          <list-item>
            <p>Housecleaners</p>
          </list-item>
          <list-item>
            <p>Metalworkers (welding)</p>
          </list-item>
          <list-item>
            <p>Oil refinery workers</p>
          </list-item>
          <list-item>
            <p>Painters</p>
          </list-item>
          <list-item>
            <p>Paper production workers</p>
          </list-item>
          <list-item>
            <p>Pesticide production or use by agricultural workers</p>
          </list-item>
          <list-item>
            <p>Rope, string, and twine production workers&#x000a0;<xref ref-type="bibr" rid="article-18354.r23">[23]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18354.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>In the United States (US), bladder cancer is the fourth most common cancer in men, eighth in women, and fifth overall, with a man-to-woman ratio of 4:1.<xref ref-type="bibr" rid="article-18354.r24">[24]</xref>&#x000a0;While women have bladder cancer less often than men, they typically present with more advanced disease and have a poorer prognosis.<xref ref-type="bibr" rid="article-18354.r25">[25]</xref><xref ref-type="bibr" rid="article-18354.r26">[26]</xref><xref ref-type="bibr" rid="article-18354.r27">[27]</xref><xref ref-type="bibr" rid="article-18354.r28">[28]</xref><xref ref-type="bibr" rid="article-18354.r29">[29]</xref>&#x000a0;According to the National Cancer Institute, there were 82,290 new cases and 16,710 deaths from bladder cancer in the United States in 2023.&#x000a0;Bladder cancer represents 4.2% of all new cancers detected and 2.7% of all cancer deaths, with an overall 5-year relative survival rate of 77.9%.&#x000a0;The incidence of new cases and mortality rates are slowly declining in the US by about 1% a year.</p>
        <p>Bladder cancer is twice as common in White populations (the ethnic group with the highest incidence) compared to those in the Black population, and the risk increases with age, particularly in those older than 70. However, disease-specific survival is lower for Black individuals.<xref ref-type="bibr" rid="article-18354.r30">[30]</xref><xref ref-type="bibr" rid="article-18354.r31">[31]</xref>&#x000a0;In the US, almost all bladder cancer is urothelial, but worldwide, most (75% of cases) are squamous cell carcinomas, which correlates closely with the incidence of endemic schistosomiasis.<xref ref-type="bibr" rid="article-18354.r30">[30]</xref><xref ref-type="bibr" rid="article-18354.r32">[32]</xref><xref ref-type="bibr" rid="article-18354.r33">[33]</xref>&#x000a0;</p>
        <p>Worldwide, bladder cancer is the seventh most common malignancy overall. The reported incidence globally is 9.5/100,000 population/year for men and 2.4/100,000 for women.<xref ref-type="bibr" rid="article-18354.r13">[13]</xref>&#x000a0;In 2020, 213,000 individuals died from bladder cancer worldwide.<xref ref-type="bibr" rid="article-18354.r34">[34]</xref>&#x000a0;The incidence of bladder cancer is twice as high in developing nations compared to highly industrialized countries. According to the World Health Institute (WHO), Greece has the highest overall risk of bladder cancer, followed by the Netherlands, Italy, Denmark, Belgium, and Spain. The WHO reports the highest mortality rate in the world from bladder cancer is in Egypt, followed by Tunisia, Libya, Poland, and Mali.<bold/></p>
      </sec>
      <sec id="article-18354.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The most critical characteristics related to bladder cancer's aggressiveness and prognosis are its degree of invasiveness (penetration) into the bladder wall and its tumor cellular grade. Therefore, bladder cancers are classified into MIBC and NMIBC based on tumor invasiveness and low and high grade based on cellular characteristics.</p>
        <p><bold>Non-muscle-invasive bladder cancer </bold>is urothelial carcinoma that is confined to the mucosa and submucosa as it does not penetrate through the lamina propria into the underlying muscle layer.<xref ref-type="bibr" rid="article-18354.r35">[35]</xref><xref ref-type="bibr" rid="article-18354.r36">[36]</xref><xref ref-type="bibr" rid="article-18354.r37">[37]</xref>&#x000a0;This type tends to be less aggressive and is usually treated with localized therapy such as transurethral resection.<xref ref-type="bibr" rid="article-18354.r1">[1]</xref><xref ref-type="bibr" rid="article-18354.r36">[36]</xref>&#x000a0;NMIBC is the most commonly found type of bladder cancer and accounts for about 75% of the total cases. One exception is CIS, which is an aggressive and high-grade but relatively rare (1% to 3%) and superficial form of bladder cancer.<xref ref-type="bibr" rid="article-18354.r38">[38]</xref> While technically non-muscle-invasive, it is typically discussed and treated differently.<xref ref-type="bibr" rid="article-18354.r38">[38]</xref></p>
        <p><bold>Muscle-invasive bladder cancer&#x000a0;</bold>penetrates the lamina propria and enters the superficial or deep muscle layers of the bladder.<xref ref-type="bibr" rid="article-18354.r30">[30]</xref><xref ref-type="bibr" rid="article-18354.r35">[35]</xref><xref ref-type="bibr" rid="article-18354.r37">[37]</xref>&#x000a0;It may also extend to other tissues surrounding the bladder or elsewhere. MIBC accounts for about 25% of all bladder malignancies.<xref ref-type="bibr" rid="article-18354.r39">[39]</xref> This type of cancer is far more likely to metastasize than NMIBC and is treated much more aggressively, often with radical surgery and chemotherapy.<xref ref-type="bibr" rid="article-18354.r30">[30]</xref></p>
      </sec>
      <sec id="article-18354.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The urinary bladder wall is comprised of 4 layers: mucosa, submucosa, muscularis, and serosa. The mucosa has a normal urothelium layer consisting of a 3&#x02013; to 6-cell thick layer of stratified, uniform, nonsquamous (transitional cell) epithelium (urothelium). Large umbrella cells form on top, with an additional superficial glycosaminoglycans layer, which acts as a protective barrier to irritating urinary chemicals. Basal cells are found below, and intermediate cells are in between.&#x000a0;</p>
        <p>Bladder cancer originates from the basal cell layer (CIS, muscle-invasive urothelial cancer, and squamous cell carcinoma) or intermediate cells (noninvasive urothelial cancer).<xref ref-type="bibr" rid="article-18354.r40">[40]</xref>&#x000a0;The urothelium extends from the renal papilla to the urethra.<xref ref-type="bibr" rid="article-18354.r41">[41]</xref>&#x000a0;This is quite impermeable and chemically inert due to the protective glycosaminoglycans layer on the superficial mucosal surface, tight cellular junctions between the umbrella cells, and uroplakin proteins in the membrane of the umbrella cells, which block any mucosal penetration. Urothelial carcinoma stains positively for GATA-3, CK7, CK20, p63, thrombomodulin, and uroplakins II and III.</p>
        <p>Bladder cancer is classified by stage (muscle-invading or not) and grade (low grade or high grade). Based on its morphology and pathway, it may also be subdivided into papillary (papilloma, low malignant potential, and papillary carcinoma) and flat (urothelial&#x000a0;CIS and invasive) categories (see <bold>Image.</bold> Urothelial Carcinoma in Situ in the Setting of Cystitis Cystica and Glandularis).</p>
        <p>The WHO classifies urothelial carcinoma based on histopathology as low-grade or high-grade, depending&#x000a0;on the degree of nuclear anaplasia and architectural abnormalities. The histology of infiltrating urothelial cancer is variable (see <bold>Image.</bold> Urothelial Carcinoma, Prostatic Infiltration and <bold>Image.</bold> Urothelial Carcinoma, Perineural Invasion). Most T1 (non-muscle-invading) cancers are papillary, low, or high grade, whereas T2-T4 (muscle-invading) carcinomas tend to be non-papillary and high grade.</p>
        <p><bold>Low-grade urothelial bladder tumors</bold> typically appear as thin papillary fronds with frequent branching.<xref ref-type="bibr" rid="article-18354.r42">[42]</xref> Variation in nuclear polarity is common with enlarged irregular nuclei and frequent nucleoli.<xref ref-type="bibr" rid="article-18354.r42">[42]</xref> Mitoses may be present, and most tumor cells are aneuploid.<xref ref-type="bibr" rid="article-18354.r42">[42]</xref></p>
        <p><bold>High-grade urothelial cancers</bold> show a more disordered arrangement with cytological atypia than low-grade neoplasms.<xref ref-type="bibr" rid="article-18354.r42">[42]</xref>&#x000a0;Papilla are often fused with more cytological and architectural abnormalities than in low-grade tumors.<xref ref-type="bibr" rid="article-18354.r42">[42]</xref> Nuclei are pleomorphic, have prominent nucleoli, and have altered polarity with frequent mitoses present.<xref ref-type="bibr" rid="article-18354.r42">[42]</xref> CIS is often seen in adjacent mucosal areas, and aneuploidy is common.<xref ref-type="bibr" rid="article-18354.r42">[42]</xref></p>
        <p><bold>Carcinoma in situ</bold>&#x000a0;(CIS) of the urinary bladder describes a flat, superficial, high-grade urothelial malignancy with severe cytological atypia and nuclear anaplasia.<xref ref-type="bibr" rid="article-18354.r43">[43]</xref> Other characteristics include loss of polarity, cellular crowding, and pleomorphism with markedly enlarged hyperchromatic nuclei and large nucleoli.<xref ref-type="bibr" rid="article-18354.r43">[43]</xref> Loss of cellular adhesion results in denuded mucosal areas, common from shed cells, resulting in positive urinary cytological findings.<xref ref-type="bibr" rid="article-18354.r44">[44]</xref>&#x000a0;Urothelial&#x000a0;CIS typically stains negatively with CD44 but strongly positively with CK20 and p53. CIS of the bladder has a 60% rate of disease recurrence and/or progression.&#x000a0;CIS is relatively rare as a primary malignancy at no more than 3% of all bladder cancers, but it is frequently seen with invasive urothelial cancers and is considered a poor prognostic sign when detected.<xref ref-type="bibr" rid="article-18354.r43">[43]</xref><xref ref-type="bibr" rid="article-18354.r45">[45]</xref></p>
        <p><bold>Divergent differentiation</bold> is the term used to describe urothelial carcinoma together with non-urothelial histology.<xref ref-type="bibr" rid="article-18354.r45">[45]</xref> This is found&#x000a0;in 15% to 25% of all invasive bladder cancers.<xref ref-type="bibr" rid="article-18354.r45">[45]</xref> Possible associated morphologies with such "divergent differentiation" may occur single or in combination and include squamous, glandular, small-cell, micropapillary urothelial cancer, nested, microcytic, microtubular, sarcomatoid, high-grade neuroendocrine, and even trophoblastic lines.<xref ref-type="bibr" rid="article-18354.r46">[46]</xref><xref ref-type="bibr" rid="article-18354.r47">[47]</xref><xref ref-type="bibr" rid="article-18354.r48">[48]</xref>&#x000a0;All of these subtypes and variations are considered high-grade.<xref ref-type="bibr" rid="article-18354.r13">[13]</xref><xref ref-type="bibr" rid="article-18354.r48">[48]</xref>&#x000a0;The&#x000a0;percentage of such divergent differentiation should be reported when identified as it has prognostic significance.<xref ref-type="bibr" rid="article-18354.r46">[46]</xref><xref ref-type="bibr" rid="article-18354.r47">[47]</xref><xref ref-type="bibr" rid="article-18354.r49">[49]</xref></p>
        <p>Pathology plays a crucial role in managing bladder cancer. Most patients (75%) present with NMIBC at initial diagnosis, which correlates with better overall survival and prognosis. The most critical factor in the pathological assessment of urothelial carcinoma is identifying the extent of invasion to set proper staging, followed by the tumor grade. Bladder cancers can be unifocal or multifocal. Most cases present as multifocal, which&#x000a0;may be multiple&#x000a0;and independent or arise from a common origin.</p>
        <p>The pathology report should include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Depth of tumor penetration or invasion into the bladder wall (Microinvasion is defined as a depth of invasion &#x02264;2 mm.)&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Histological type and grade&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Location of the tumor: where in the bladder it was found&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Number of separate specimens or tumors&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Presence or absence of CIS&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Presence or absence of detrusor muscle in the specimen&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Presence and percentage of any divergent differentiation&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Size of the specimen</p>
          </list-item>
        </list>
        <p>In complex or difficult cases, an additional review by an experienced genitourinary pathologist is recommended.<xref ref-type="bibr" rid="article-18354.r46">[46]</xref><xref ref-type="bibr" rid="article-18354.r47">[47]</xref><bold/></p>
        <p><bold>Squamous cell malignancies</bold> constitute the majority of non-urothelial bladder cancer cases worldwide, although over 90% of bladder tumors in the US and industrialized countries are urothelial carcinomas.<xref ref-type="bibr" rid="article-18354.r50">[50]</xref></p>
        <p>In the US, squamous cell carcinoma of the bladder is related to chronic inflammation from foreign bodies, catheters, human papillomavirus (HPV) infections, cyclophosphamide exposure resulting in hemorrhagic cystitis, or schistosomiasis in travelers or immigrants.<xref ref-type="bibr" rid="article-18354.r51">[51]</xref><xref ref-type="bibr" rid="article-18354.r52">[52]</xref>&#x000a0;Squamous cell carcinoma is the second most common cancer type found in the bladder at about 5%.<xref ref-type="bibr" rid="article-18354.r53">[53]</xref>&#x000a0;Squamous cell carcinoma is followed by adenocarcinoma at 2% and neuroendocrine malignancies.<xref ref-type="bibr" rid="article-18354.r51">[51]</xref></p>
        <p>Up to approximately 40% of high-grade or invasive bladder cancers will have some squamous cell characteristics (polygonal cell shape, abundant light eosinophilic cytoplasm, distinct cell borders, and peritumoral lymphocytic aggregates).<xref ref-type="bibr" rid="article-18354.r45">[45]</xref>&#x000a0;The diagnosis of primary squamous cell carcinoma is reserved for keratin-forming squamous neoplasms that lack any typical urothelial components.<xref ref-type="bibr" rid="article-18354.r45">[45]</xref>&#x000a0;Squamous cell carcinoma of the bladder stains positive for cytokeratin CK 5/6, desmoglein 3, p63, CD44, and p40.</p>
        <p>Treatment is generally surgical, possibly with preoperative radiation therapy. Patients with disease not amenable to surgical resection may receive chemoradiation. Metastatic disease is uncommon but may be best treated with&#x000a0;carboplatin, gemcitabine, and paclitaxel.<xref ref-type="bibr" rid="article-18354.r54">[54]</xref>&#x000a0;Enrollment of patients with advanced disease in a clinical trial is strongly encouraged.</p>
        <p><bold>Adenocarcinoma of the bladder</bold> is far more likely to metastasize than squamous cell cancer; this cancer is typically classified as urachal or non-urachal. Urachal adenocarcinoma develops from the urachal remnant and is typically located in the dome of the bladder, often extending into the prevesical space. These malignancies are mucin-producing (90%) tumors that typically present as locally advanced with hematuria and a palpable lower abdominal mass.<xref ref-type="bibr" rid="article-18354.r55">[55]</xref><xref ref-type="bibr" rid="article-18354.r56">[56]</xref><xref ref-type="bibr" rid="article-18354.r57">[57]</xref>&#x000a0;Treatment is surgical, with a substantial number of patients able to receive partial cystectomies. Five-year overall survival has been reported at about 50%.<xref ref-type="bibr" rid="article-18354.r58">[58]</xref></p>
        <p>Non-urachal adenocarcinoma of the bladder tends to be associated with schistosomiasis or bladder exstrophy.<xref ref-type="bibr" rid="article-18354.r59">[59]</xref><xref ref-type="bibr" rid="article-18354.r60">[60]</xref>&#x000a0;Cystoscopic appearance may be papillary or flat; these&#x000a0;tumors are usually muscle-invasive neoplasms at presentation.<xref ref-type="bibr" rid="article-18354.r61">[61]</xref>&#x000a0;Extrinsic adenocarcinomas need to be excluded. Treatment is primarily surgical, but partial cystectomies are generally avoided due to poor outcomes.<xref ref-type="bibr" rid="article-18354.r62">[62]</xref><xref ref-type="bibr" rid="article-18354.r63">[63]</xref><xref ref-type="bibr" rid="article-18354.r64">[64]</xref><xref ref-type="bibr" rid="article-18354.r65">[65]</xref>&#x000a0;The prognosis for non-urachal adenocarcinoma of the bladder is usually bleak, with a 5-year overall survival of 35%.<xref ref-type="bibr" rid="article-18354.r66">[66]</xref></p>
      </sec>
      <sec id="article-18354.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Bladder cancer is primarily a tumor in adults who are 60 and older.&#x000a0;Hematuria, either gross or microscopic, is the most common initial symptom in patients with bladder cancer.&#x000a0;Over a third of patients with gross hematuria and slightly over 10% of those with microscopic hematuria will ultimately be diagnosed with bladder cancer. Other less common symptoms include painful micturition, increased urinary frequency, a pelvic mass, and constitutional symptoms such as fatigue and weight loss.</p>
        <p>A complete history and physical examination are recommended for all patients presenting with unexplained hematuria to identify risk factors for urothelial malignancy as well as other sources of bleeding such as medical kidney disease, renal neoplasms, urolithiasis, gynecological disorders, benign prostatic hyperplasia, and other nonmalignant genitourinary disorders.<xref ref-type="bibr" rid="article-18354.r67">[67]</xref>&#x000a0;In women, a pelvic examination, as well as a careful inspection of the external genitalia, introitus, and periurethral area, should be performed. The evaluation is the same for patients taking anticoagulants.<xref ref-type="bibr" rid="article-18354.r68">[68]</xref><xref ref-type="bibr" rid="article-18354.r69">[69]</xref><xref ref-type="bibr" rid="article-18354.r70">[70]</xref></p>
        <p>If a nonmalignant cause of the hematuria is discovered, repeat urinalyses should be performed following treatment and resolution of the disorder. If the hematuria remains, a risk-based evaluation should be performed.<xref ref-type="bibr" rid="article-18354.r67">[67]</xref>&#x000a0;For example, patients with microscopic hematuria due to a urinary tract infection should have a follow-up microscopic urinalysis after treatment to verify that the hematuria has also resolved.<xref ref-type="bibr" rid="article-18354.r67">[67]</xref></p>
        <p>There are no screening tests for the early detection of bladder cancer other than the finding of unexplained, persistent, gross, or microscopic hematuria. Gross hematuria may correlate somewhat with a more advanced disease stage.<xref ref-type="bibr" rid="article-18354.r46">[46]</xref>&#x000a0;Smoking history is a strong predisposing factor. A history of 10 pack-years or more is sufficient to increase the patient's bladder cancer risk significantly.&#x000a0;Medical renal disease as a source of hematuria should be suspected in patients with proteinuria, dysmorphic red blood cells, cellular casts on microscopic urinalysis, or kidney failure.<xref ref-type="bibr" rid="article-18354.r67">[67]</xref></p>
        <p>
<bold>High-Risk Factors for Bladder Cancer</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>A chronic indwelling catheter or foreign body</p>
          </list-item>
          <list-item>
            <p>Chemotherapy&#x000a0;(cyclophosphamide, ifosfamide)</p>
          </list-item>
          <list-item>
            <p>Concurrent irritative voiding symptoms</p>
          </list-item>
          <list-item>
            <p>History of pelvic radiation</p>
          </list-item>
          <list-item>
            <p>Increasing age</p>
          </list-item>
          <list-item>
            <p>Male sex</p>
          </list-item>
          <list-item>
            <p>Positive family history of bladder cancer, Lynch syndrome,&#x000a0;Peutz-Jeghers syndrome, or Cowden syndrome</p>
          </list-item>
          <list-item>
            <p>Smoking history of 10 or more pack-years</p>
          </list-item>
          <list-item>
            <p>Toxic chemical exposure
<list list-type="bullet"><list-item><p>Aromatic amines and hydrocarbons</p></list-item><list-item><p>Arsenic</p></list-item><list-item><p>Benzene products</p></list-item><list-item><p>Formaldehyde</p></list-item><list-item><p>Nitrosamine</p></list-item><list-item><p>Petrochemicals</p></list-item><list-item><p>Rubber&#x000a0;<xref ref-type="bibr" rid="article-18354.r67">[67]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p><italic toggle="yes">Schistosoma hematobium&#x000a0;</italic>is a risk factor for squamous cell carcinoma in those parts of the world where the parasite is endemic.</p>
      </sec>
      <sec id="article-18354.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Screening patients for bladder cancer is not recommended. Patients who are found to have hematuria on routine urinalysis should be considered for an evaluation of possible bladder cancer. Modalities used in diagnosing bladder cancer include imaging (eg, ultrasound, computed tomography, and magnetic resonance imaging), cystoscopy, cytology, transurethral resection, and biopsy.&#x000a0;(see&#x000a0;<bold>Image.</bold>&#x000a0;Bladder Cancer) Intravenous pyelography is no longer used.</p>
        <p><bold>American Urological Association Patient Risk-Stratification</bold>&#x000a0;<xref ref-type="bibr" rid="article-18354.r67">[67]</xref></p>
        <p>
<bold>Low-Risk Patients</bold>
</p>
        <p>Microhematuria and must have all of the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Women&#x000a0;younger&#x000a0;than 50, Men&#x000a0;younger than 40&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Smoking: Never smoked or &#x0003c;10 pack-years</p>
          </list-item>
          <list-item>
            <p>Urinalysis shows &#x02264;10 red blood cells/high power field (RBC/HPF) with no prior hematuria&#x000a0;</p>
          </list-item>
          <list-item>
            <p>No high-risk factors&#x000a0;</p>
          </list-item>
        </list>
        <p>Patients with microscopic hematuria at low risk for urothelial cancer should proceed with an ultrasound and cystoscopy or have a repeat urinalysis&#x000a0;in 6 months.</p>
        <p>
<bold>Intermediate-Risk Patients</bold>
</p>
        <p>Microhematuria and any of the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Women 50 to 59 years; men, 40 to 59 years</p>
          </list-item>
          <list-item>
            <p>Smoking: 10 to 30 pack-years</p>
          </list-item>
          <list-item>
            <p>Urinalysis shows 11 to 25 RBC/HPF</p>
          </list-item>
          <list-item>
            <p>One or more high-risk factors&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Previously categorized as low risk without further evaluation</p>
          </list-item>
        </list>
        <p>Patients with microscopic hematuria at moderate risk for urothelial cancer should proceed with ultrasound and cystoscopy.</p>
        <p>
<bold>High-Risk Patients</bold>
</p>
        <p>The patient does not qualify as low or intermediate risk&#x000a0;OR microhematuria and any of the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Gross hematuria</p>
          </list-item>
          <list-item>
            <p>Age 60 or older&#x000a0;(women and men)</p>
          </list-item>
          <list-item>
            <p>Smoking &#x0003e;30 pack-years</p>
          </list-item>
          <list-item>
            <p>Urinalysis shows &#x0003e;25 RBC/HPF</p>
          </list-item>
        </list>
        <p>Patients considered high risk or who fail to qualify as low or intermediate risk should be evaluated with a computed tomography (CT) urogram (ie, CT scan of the abdomen and pelvis without and with IV contrast) and a cystoscopy.</p>
        <p>
<bold>Imaging</bold>
</p>
        <p>Imaging is a critical diagnostic component for evaluating bladder cancer. Ultrasound may be used in patients considered low-risk (eg, microscopic hematuria, younger age, no significant smoking history, and no high-risk factors).<xref ref-type="bibr" rid="article-18354.r71">[71]</xref>&#x000a0;However, it is not as thorough or comprehensive as a CT urogram, and it will miss small tumors, cystic lesions, and CIS.<xref ref-type="bibr" rid="article-18354.r72">[72]</xref></p>
        <p><bold>A CT urogram</bold> is the gold-standard imaging modality for the upper urinary tract.<xref ref-type="bibr" rid="article-18354.r73">[73]</xref>&#x000a0;This imaging should be performed in all patients who are high-risk and those who do not otherwise qualify as low or intermediate risk.<xref ref-type="bibr" rid="article-18354.r67">[67]</xref>&#x000a0;A CT urogram is also indicated if a bladder tumor is confirmed on cystoscopy and the CT study has not already been performed. The incidence of finding a simultaneous urothelial malignancy at the same time as bladder cancer is quite low at 1.8%, except for trigonal neoplasms, where the reported incidence is 7.5%.<xref ref-type="bibr" rid="article-18354.r74">[74]</xref>&#x000a0;</p>
        <p>A CT urogram is optimally performed in&#x000a0;3 phases as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>The non-contrast phase optimizes the identification of calcifications and urinary calculi.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>An early arteriovenous phase study optimizes visualization of renal masses and neoplasms.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Delayed imaging (about 15 minutes after contrast injection) opacifies the entire urinary collecting system and is optimized for identifying filling defects in the bladder and upper urinary tracts (possible urothelial tumors).&#x000a0;Such upper urinary tract filling defects should be further evaluated with ureteroscopy.</p>
          </list-item>
        </list>
        <p>CT urography has a reported diagnostic accuracy of 91.5%, sensitivity of 86.3%, and specificity of 92.4%.<xref ref-type="bibr" rid="article-18354.r73">[73]</xref>&#x000a0;Its positive predictive value was 63.6%, with a negative predictive value of 97.8%.<xref ref-type="bibr" rid="article-18354.r73">[73]</xref>&#x000a0;A magnetic resonance imaging (MRI) urogram should be performed if intravenous contrast cannot be administered due to inadequate renal function or an allergy. If this cannot be done, a non-contrast CT scan with bilateral retrograde pyelograms is recommended.<xref ref-type="bibr" rid="article-18354.r71">[71]</xref> Filling defects in either the ureter or renal pelvis discovered on imaging should be further evaluated by ureteroscopy with biopsies, laser therapy, and/or selective cytology or washings for cytological examination.</p>
        <p><bold>Magnetic resonance imaging (MRI)</bold> is superior to CT scanning for the staging of muscle-invasive disease, with a sensitivity and specificity reported at &#x0003e;90%.<xref ref-type="bibr" rid="article-18354.r75">[75]</xref>&#x000a0;MRI can also detect a significant tumor recurrence sooner by identifying early bladder wall neovascularization.<xref ref-type="bibr" rid="article-18354.r76">[76]</xref><xref ref-type="bibr" rid="article-18354.r77">[77]</xref>&#x000a0;Newer modifications and improvements such as the Vesical Imaging-Reporting and Data System (VI-RADS), Synthetic Magnetic Resonance Imaging (SynMRI), multi-sequence MRI radiomics, and biparametric MRI techniques may be able to predict muscle invasion and histopathological tumor grade even better.<xref ref-type="bibr" rid="article-18354.r78">[78]</xref><xref ref-type="bibr" rid="article-18354.r79">[79]</xref><xref ref-type="bibr" rid="article-18354.r80">[80]</xref>&#x000a0;In general, pelvic lymph nodes &#x0003e;8 mm and abdominal nodes &#x0003e;10 mm in diameter should be considered pathological and consistent with metastasis.<xref ref-type="bibr" rid="article-18354.r81">[81]</xref></p>
        <p><bold>The 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET)</bold> is a test for metastatic urothelial malignant disease and may be helpful for staging before a radical cystectomy in selected patients, preferably in a clinical trial, but it should not be used for anatomical details or diagnostic imaging of the urinary tract and is not beneficial in the initial diagnosis of bladder cancer as its exact role is still being determined.<xref ref-type="bibr" rid="article-18354.r82">[82]</xref><xref ref-type="bibr" rid="article-18354.r83">[83]</xref><xref ref-type="bibr" rid="article-18354.r84">[84]</xref><xref ref-type="bibr" rid="article-18354.r85">[85]</xref><xref ref-type="bibr" rid="article-18354.r86">[86]</xref><xref ref-type="bibr" rid="article-18354.r87">[87]</xref><xref ref-type="bibr" rid="article-18354.r88">[88]</xref>&#x000a0;FDG-PET is highly specific for metastatic bladder cancer and provides superior sensitivity compared to CT scans.<xref ref-type="bibr" rid="article-18354.r86">[86]</xref><xref ref-type="bibr" rid="article-18354.r89">[89]</xref><xref ref-type="bibr" rid="article-18354.r90">[90]</xref></p>
        <p>
<bold>Cystoscopy</bold>
</p>
        <p><bold>Cystoscopy</bold> is considered the gold standard for the initial management of bladder cancer, with a reported 98% sensitivity.<xref ref-type="bibr" rid="article-18354.r67">[67]</xref><xref ref-type="bibr" rid="article-18354.r91">[91]</xref>&#x000a0;However, this high sensitivity rate has been questioned, suggesting that there may be a role for repeat cystoscopies, photodynamic enhancement techniques, and/or urinary biomarkers, particularly in high-risk or equivocal cases.<xref ref-type="bibr" rid="article-18354.r92">[92]</xref>&#x000a0;Diagnostic cystoscopy is usually&#x000a0;performed with minimal anesthetic in the office or clinic, but it may also be&#x000a0;performed in the operating room simultaneously with a biopsy or transurethral resection.</p>
        <p><bold>Non-muscle-invasive bladder cancer</bold> typically appears as&#x000a0;1 or more papillary lesions.&#x000a0;Cystoscopically, they are frond-like neoplasms with multiple, tiny vascularized projections that tend to bleed easily. The hematuria they produce ultimately results in their early discovery in most cases. They are&#x000a0;the most common (75%) forms of bladder cancer, are typically noninvasive, and tend to be low-grade histologically.<xref ref-type="bibr" rid="article-18354.r1">[1]</xref><xref ref-type="bibr" rid="article-18354.r36">[36]</xref> However, if undetected and untreated, they can progress and penetrate the lamina propria, becoming dangerous and muscle-invading, with a risk of metastasizing.</p>
        <p><bold>Muscle-invasive bladder cancer</bold> may appear as a solid tumor that is flat, sessile, or nodular. These tumors may also have a papillary appearance. They tend to be more dangerous and aggressive than NMIBC as they are more likely to be high-grade.</p>
        <p>Cystoscopy has been reported to demonstrate a sensitivity of 92% and specificity of 88% for MIBC, along with a positive predictive value of 72% to 78% and a negative predictive value of 92% to 96%, making it a reasonably reliable method of identifying MIBC.<xref ref-type="bibr" rid="article-18354.r39">[39]</xref><xref ref-type="bibr" rid="article-18354.r93">[93]</xref>&#x000a0;However, this does not negate the need for an accurate histological diagnosis and staging of bladder cancers with appropriate biopsies and transurethral cancer resections.</p>
        <p>Using this evaluation protocol (CT urogram and cystoscopy), the etiology of hematuria in approximately 57% of patients with asymptomatic microscopic hematuria and 92% of those with gross hematuria will be identified. A malignancy will be found in about 3% to 5% of patients presenting with microscopic hematuria and 23% with gross hematuria.</p>
        <p><bold>Carcinoma in situ (CIS)&#x000a0;</bold>classically appears as a flat, irregular patch of erythematous mucosa with a velvety or granular surface, which looks very similar to routine inflammation, making cystoscopic diagnosis extremely difficult. Most of the patients with CIS (80%) will present with irritative voiding symptoms, which doubles the risk of finding&#x000a0;CIS (from 5% to 10%) in patients with microscopic hematuria.<xref ref-type="bibr" rid="article-18354.r94">[94]</xref><xref ref-type="bibr" rid="article-18354.r95">[95]</xref>&#x000a0;However, several other urological disorders can cause these same symptoms, such as urolithiasis, urinary tract infections, and benign prostatic hyperplasia.</p>
        <p>Due to its similarity to inflammation,&#x000a0;CIS can be easily overlooked on standard cystoscopy. For this reason, any inflammatory bladder lesions in patients with urothelial carcinomas should be considered for biopsy and/or cautery at the time of transurethral bladder tumor resection (TURBT).&#x000a0; &#x000a0;&#x000a0;</p>
        <p>Carcinoma in situ (CIS) may be clinically classified as primary, secondary, concurrent, or recurrent as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Primary: CIS with no prior or concurrent disease</p>
          </list-item>
          <list-item>
            <p>Secondary: CIS diagnosed during surveillance of patients previously diagnosed with bladder cancer but not CIS</p>
          </list-item>
          <list-item>
            <p>Concurrent: CIS identified simultaneously with any other bladder cancer</p>
          </list-item>
          <list-item>
            <p>Recurrent: CIS identified in a patient with a previous diagnosis of CIS</p>
          </list-item>
        </list>
        <p><bold>Bladder biopsies&#x000a0;</bold>should be performed on all papillary and solid bladder neoplasms, as well as any suspicious erythematous lesions. If a TURBT is being performed, all erythematous areas should be considered suspicious and biopsied, along with possible fulguration. Cauterization or fulguration should be done to the biopsy bed and the superficial mucosa around the biopsy or resection site for about a 1 cm radius due to field change disease.</p>
        <p>All erythematous and suspicious mucosal lesions should also be biopsied. Random biopsies for mapping should be&#x000a0;performed if the cytology is positive or the tumor appears solid or sessile rather than papillary. Biopsies&#x000a0;may be&#x000a0;performed with cold cup biopsy forceps (flexible or preferably rigid) or transurethral resection. Electrosurgical resection is not preferred for biopsies as it causes cautery artifacts. Every effort should be made to obtain a deep sample, including muscle tissue, for staging, but it is absolutely essential to avoid a bladder perforation, which could spread malignant cells outside the bladder.</p>
        <p>Keeping the bladder relatively empty and using continuous flow instrumentation will keep the bladder wall relatively thick and immobile, minimizing the risk of accidental perforation. Tumor and biopsy locations should be carefully recorded as this is associated with progression and prognosis.<xref ref-type="bibr" rid="article-18354.r13">[13]</xref> Bladder cancers at the trigone, bladder neck, or prostatic urethra have an increased risk of nodal involvement and decreased survival.<xref ref-type="bibr" rid="article-18354.r96">[96]</xref><xref ref-type="bibr" rid="article-18354.r97">[97]</xref><xref ref-type="bibr" rid="article-18354.r98">[98]</xref><xref ref-type="bibr" rid="article-18354.r99">[99]</xref></p>
        <p>
<bold>Cytology, Fluorescence In Situ Hybridization, and Urinary Biomarkers</bold>
</p>
        <p>Cytology, fluorescence in-situ hybridization (FISH), and other urinary biomarkers are not currently recommended by the American Urological Association (AUA) or European Association of Urology (EAU) guidelines for the routine initial evaluation of patients with hematuria due to their high cost and relatively poor specificity.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref><xref ref-type="bibr" rid="article-18354.r47">[47]</xref><xref ref-type="bibr" rid="article-18354.r67">[67]</xref>&#x000a0;While they can be useful for monitoring progression in patients with known disease and borderline or equivocal situations, they&#x000a0;are not considered an adequate substitute for cystoscopy.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref>&#x000a0;Urinary biomarkers may also be useful in patients with persistent microscopic hematuria after a negative workup, particularly if they also have high-risk factors for&#x000a0;CIS and/or irritative voiding symptoms.<xref ref-type="bibr" rid="article-18354.r67">[67]</xref>&#x000a0;Urine-based biomarkers can potentially reduce unnecessary referrals and cystoscopic procedures, but none has yet reached a level of clinical reliability to replace cystoscopy.<xref ref-type="bibr" rid="article-18354.r100">[100]</xref><xref ref-type="bibr" rid="article-18354.r101">[101]</xref><xref ref-type="bibr" rid="article-18354.r102">[102]</xref></p>
        <p><bold>Urine cytology</bold>&#x000a0;has been recommended for high-risk patients with gross hematuria. Some healthcare professionals will also order it routinely for high-risk microhematuria patients, particularly those with a history of 10 or more pack-years of smoking. Cytology may also be useful in detecting and following CIS, which may be easily missed during cystoscopy.<xref ref-type="bibr" rid="article-18354.r67">[67]</xref><xref ref-type="bibr" rid="article-18354.r103">[103]</xref>&#x000a0;Cytology is quite reliable when positive, but it lacks sensitivity and will miss many malignancies, especially low-grade neoplasms. It is also highly dependent on the cytopathologist's skill and experience.<xref ref-type="bibr" rid="article-18354.r104">[104]</xref></p>
        <p>Cytology is considered a valuable tool for the follow-up of patients with high-grade bladder cancer and, especially,&#x000a0;CIS of the bladder.<xref ref-type="bibr" rid="article-18354.r30">[30]</xref><xref ref-type="bibr" rid="article-18354.r46">[46]</xref><xref ref-type="bibr" rid="article-18354.r105">[105]</xref>&#x000a0;A large review of 36 separate studies with over 14,000 patients showed the sensitivity of urinary cytology to be only 44% with a high specificity of 96%.<xref ref-type="bibr" rid="article-18354.r106">[106]</xref>&#x000a0;The first morning voided urine is unsuitable for cytological evaluations due to cytolysis.<xref ref-type="bibr" rid="article-18354.r47">[47]</xref>&#x000a0;Cytology diagnostic reports should indicate the specimen's adequacy and the presence of high-grade urothelial carcinoma, atypical cells, or "suspicious" findings for high-grade cancer.<xref ref-type="bibr" rid="article-18354.r13">[13]</xref></p>
        <p><bold>Bladder washing for cytology</bold> is typically obtained during cystoscopy using normal saline. With the bladder emptied by a catheter, 50 mL to 100 mL of normal saline is instilled and then immediately extracted using a catheter tip syringe. This procedure is repeated 3 to 6 times. Bladder washing provides larger numbers of well-preserved urothelial cells than standard voided urine cytology and detects more urothelial cancers.<xref ref-type="bibr" rid="article-18354.r107">[107]</xref><xref ref-type="bibr" rid="article-18354.r108">[108]</xref>&#x000a0;Washing can be performed immediately after TURBT to identify any invisible high-grade tumor and is often preferred in the follow-up of high-risk cancer cases, particularly in patients with CIS.<xref ref-type="bibr" rid="article-18354.r109">[109]</xref><xref ref-type="bibr" rid="article-18354.r110">[110]</xref>&#x000a0;Cytology and bladder washing may be performed together, with the voided cytology collected first. Labeling the specimens correctly to avoid any potential confusion&#x000a0;for the cytopathologist is important.</p>
        <p><bold>Fluorescence in-situ hybridization (FISH)</bold>&#x000a0;is a relatively sensitive genetic test marker for bladder cancer that&#x000a0;detects aneuploidy of chromosomes 3, 7, and 17 and the loss of the 9p21 locus.<xref ref-type="bibr" rid="article-18354.r111">[111]</xref>&#x000a0;Results are reported as either positive or negative, which makes interpretation easy. If the FISH test is positive, an increased frequency of surveillance is recommended, and further evaluation of the ureters and upper tracts bilaterally should be considered.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>About 27% of patients with NMIBC on surveillance with negative cystoscopies will have a positive FISH test, and two-thirds of these will develop recurrent bladder cancers within the next 2 to 3 years.<xref ref-type="bibr" rid="article-18354.r112">[112]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>A systematic review and meta-analysis reported the overall sensitivity and specificity of FISH testing as 68% and 64%, respectively.<xref ref-type="bibr" rid="article-18354.r113">[113]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>The FISH test is most useful for monitoring bladder cancer, especially after bacillus Calmette-Guerin (BCG) therapy, and in the initial diagnosis of high-risk</p>
          </list-item>
          <list-item>
            <p>A positive FISH test following BCG therapy is suggestive of an impending bladder cancer recurrence, particularly within the following 6 months.<xref ref-type="bibr" rid="article-18354.r114">[114]</xref><xref ref-type="bibr" rid="article-18354.r115">[115]</xref><xref ref-type="bibr" rid="article-18354.r116">[116]</xref><xref ref-type="bibr" rid="article-18354.r117">[117]</xref>&#x000a0;Close follow-up of such patients is therefore recommended.<xref ref-type="bibr" rid="article-18354.r114">[114]</xref>&#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>The FISH test has a significant rate of false negatives for bladder cancer and is expensive, which limits its clinical utility.</p>
          </list-item>
        </list>
        <p>Various other biomarkers for bladder cancer are available. They are primarily used to monitor the response to BCG therapy and where cystoscopy or cytology findings are equivocal or atypical, particularly in high-risk patients. Overall sensitivity ranges from 58% to 82%, and specificity from 78% to 88%.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref>&#x000a0;</p>
        <p><bold>Genetics-based urine testing</bold>, using urinary mRNA, is a promising urinary biomarker for recurrent bladder cancer.<xref ref-type="bibr" rid="article-18354.r118">[118]</xref><xref ref-type="bibr" rid="article-18354.r119">[119]</xref><xref ref-type="bibr" rid="article-18354.r120">[120]</xref> Preliminary results from a 2-year trial of 313 bladder cancer patients suggest that surveillance cystoscopies can be safely reduced by 54% using a new genetics-based urine test. The new urine test identifies 5 separate genes and identified bladder cancer recurrences earlier than cystoscopy.<xref ref-type="bibr" rid="article-18354.r121">[121]</xref> While preliminary, this data appears quite promising, but it will require publication of the final trial results, independent confirmation, and additional testing before it can become clinically accepted and available.</p>
        <p>Similarly, molecular markers for MIBC are still in the investigational stage and are not appropriate for use outside of a clinical trial.<xref ref-type="bibr" rid="article-18354.r13">[13]</xref></p>
        <p><bold>Enhanced cystoscopic diagnostic techniques </bold>use either drug-induced cystoscopic tumor cellular fluorescence or special image-processing techniques to help identify pathological urothelial tissue during cystoscopy.<xref ref-type="bibr" rid="article-18354.r122">[122]</xref><xref ref-type="bibr" rid="article-18354.r123">[123]</xref><xref ref-type="bibr" rid="article-18354.r124">[124]</xref>&#x000a0;These are very sensitive techniques for detecting CIS of the bladder and otherwise invisible superficial urothelial malignancies, reducing recurrences through better identification and elimination of affected urothelium, but their precise role is not yet clearly defined.<xref ref-type="bibr" rid="article-18354.r123">[123]</xref><xref ref-type="bibr" rid="article-18354.r125">[125]</xref><xref ref-type="bibr" rid="article-18354.r126">[126]</xref>&#x000a0;Overall, enhanced cystoscopic diagnostic techniques are significantly underutilized.<xref ref-type="bibr" rid="article-18354.r127">[127]</xref></p>
        <p>The AUA and EAU guidelines now recommend photodynamic cystoscopic enhancement, where available, at the time of initial therapy for NMIBC, at the first 3-month surveillance cystoscopy and thereafter for the first 2 years, prior to intravesical chemotherapy, and in cases where there is a new finding of positive cytology or abnormal/equivocal cystoscopic findings.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref><xref ref-type="bibr" rid="article-18354.r47">[47]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Photodynamic cystoscopic diagnostic enhancement,</bold> also called "blue light" cystoscopy, uses 5-aminolevulinic acid (5-ALA) or hexylaminolevulinate (HAL) to help identify and visualize malignant tissue changes in the bladder mucosa.<xref ref-type="bibr" rid="article-18354.r124">[124]</xref> This greatly enhances the diagnosis and localization of&#x000a0;CIS of the bladder.<xref ref-type="bibr" rid="article-18354.r128">[128]</xref><xref ref-type="bibr" rid="article-18354.r129">[129]</xref><xref ref-type="bibr" rid="article-18354.r130">[130]</xref><xref ref-type="bibr" rid="article-18354.r131">[131]</xref>&#x000a0;These medications cause the preferential accumulation of photoreactive porphyrins in malignant bladder mucosal urothelial cells. These become visible under blue cystoscopic light as the porphyrins fluoresce red, while normal tissue appears blue.<xref ref-type="bibr" rid="article-18354.r124">[124]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;
<list list-type="bullet"><list-item><p>5-ALA or HAL is instilled into the bladder 2 hours before the cystoscopy.<xref ref-type="bibr" rid="article-18354.r131">[131]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p></list-item><list-item><p>Blue light (380 to 440 nm) is used during the cystoscopy, and any malignant areas will fluoresce red.<xref ref-type="bibr" rid="article-18354.r132">[132]</xref><xref ref-type="bibr" rid="article-18354.r133">[133]</xref><xref ref-type="bibr" rid="article-18354.r134">[134]</xref><xref ref-type="bibr" rid="article-18354.r135">[135]</xref>&#x000a0;These highlighted areas can then be selectively biopsied, cauterized, or resected.</p></list-item><list-item><p>In 1 study, 5-year cancer-specific survival was improved over white light cystoscopy from 74% (with white light) to 91% using HAL and blue light.<xref ref-type="bibr" rid="article-18354.r136">[136]</xref>&#x000a0;</p></list-item><list-item><p>False positives from photodynamic-enhanced diagnostic cystoscopy may be seen when 5-ALA or HAL is taken up by mucosal cells due to localized inflammation, recent transurethral surgery, or intravesical therapy.<xref ref-type="bibr" rid="article-18354.r137">[137]</xref><xref ref-type="bibr" rid="article-18354.r138">[138]</xref><xref ref-type="bibr" rid="article-18354.r139">[139]</xref>&#x000a0; &#x000a0;&#x000a0;</p></list-item><list-item><p>Photodynamic cystoscopic enhancement is now available and FDA-approved for flexible cystoscopy in the office or clinic.&#x000a0; &#x000a0;</p></list-item><list-item><p>Bladder urine can cause a green discoloration, and visualization in recorded images may be "foggy" due to hardware or irrigation fluid issues. Advanced image processing techniques can correct these.<xref ref-type="bibr" rid="article-18354.r140">[140]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Narrow-band imaging </bold>is a technique to enhance the cystoscopic visualization of malignant bladder urothelium through enhanced digital image processing. Narrow-band imaging does not require fluorescent drugs but instead uses special image processing of bandwidths 415 and 540 nm (blue and green). This improves the identification and visualization of abnormal urothelial tissue but requires special equipment.<xref ref-type="bibr" rid="article-18354.r141">[141]</xref><xref ref-type="bibr" rid="article-18354.r142">[142]</xref><xref ref-type="bibr" rid="article-18354.r143">[143]</xref>&#x000a0;Overall results are similar to photodynamic cystoscopic enhancement with fluorescing drugs.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18354.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment strategy for urothelial cancer depends on whether there is histological evidence of muscle invasion (eg, therefore, it is either NMIBC or MIBC). This initial staging is determined after an initial biopsy and/or TURBT.</p>
        <p><bold>Transurethral resection of a bladder tumor </bold>is both diagnostic and therapeutic. Smaller tumors may be removed with cold cup biopsy forceps, which is preferred&#x000a0;due to the preservation of the histology without any cautery artifact. Transurethral resection is reserved for larger tumors. Attaining hemostasis is important as active bleeding will interfere with endoscopic visualization. However, unnecessary cautery should be avoided to minimize coagulation artifacts in the tissue specimens.</p>
        <p>A complete cystoscopic inspection of the bladder and urethra should be performed, with all lesions, masses, and erythematous patches carefully noted. While the patient is under full anesthesia, a bimanual examination should be performed to determine if there is any indication of a palpable mass or any evidence of possible tumor fixation to the pelvic sidewall or other structures.<xref ref-type="bibr" rid="article-18354.r144">[144]</xref><xref ref-type="bibr" rid="article-18354.r145">[145]</xref>&#x000a0;A standard TURBT should contain at least 3 separate specimens: the main tumor, a deep biopsy from the tumor base if any muscle invasion might be present, and a random biopsy sample from "normal" bladder mucosa.<xref ref-type="bibr" rid="article-18354.r1">[1]</xref><xref ref-type="bibr" rid="article-18354.r13">[13]</xref><xref ref-type="bibr" rid="article-18354.r36">[36]</xref><xref ref-type="bibr" rid="article-18354.r47">[47]</xref>&#x000a0;In addition, any abnormal mucosal areas should be biopsied with their location carefully documented and sent to pathology separately.<xref ref-type="bibr" rid="article-18354.r1">[1]</xref><xref ref-type="bibr" rid="article-18354.r13">[13]</xref><xref ref-type="bibr" rid="article-18354.r36">[36]</xref></p>
        <p>Possible involvement of the prostatic urethra has been reported in up to one-third of men with bladder cancer.<xref ref-type="bibr" rid="article-18354.r146">[146]</xref><xref ref-type="bibr" rid="article-18354.r147">[147]</xref><xref ref-type="bibr" rid="article-18354.r148">[148]</xref><xref ref-type="bibr" rid="article-18354.r149">[149]</xref><xref ref-type="bibr" rid="article-18354.r150">[150]</xref>&#x000a0;This risk is increased for patients who have a tumor located at the bladder neck, in the trigone, or if the patient has multifocal disease or CIS.<xref ref-type="bibr" rid="article-18354.r151">[151]</xref><xref ref-type="bibr" rid="article-18354.r152">[152]</xref><xref ref-type="bibr" rid="article-18354.r153">[153]</xref></p>
        <p><bold>TURBT </bold>tips include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>The bladder should not be overstretched or overfilled, as this will attenuate the bladder wall thickness; &#x000a0;should be filled enough so all major bladder folds are flattened to avoid overly deep unintended trauma and possible perforation.</p>
          </list-item>
          <list-item>
            <p>Continuous-flow instrumentation is recommended to minimize the motion of the bladder wall during resection. Adjust the flow rate to the minimum necessary to maintain a constant level of filling.</p>
          </list-item>
          <list-item>
            <p>The resection motion should generally be straight, towards the operator, and without actively angling the scope laterally.</p>
          </list-item>
          <list-item>
            <p>One helpful technique is to place the end of the resectoscope loop under the far edge of the tumor and gently lift it away from the bladder wall before electrifying the cutting loop to perform the resection. This will help minimize unintentional bladder wall damage.</p>
          </list-item>
          <list-item>
            <p>If there are multiple or large tumors, start resecting at the edge, where there will be complete visualization.</p>
          </list-item>
          <list-item>
            <p>The goal is to complete the resection in&#x000a0;1 area or&#x000a0;1 tumor at a time until it is flush with the rest of the bladder wall. At that point, consider using a cold cup biopsy for tissue samples and try to avoid an inadvertent perforation.</p>
          </list-item>
          <list-item>
            <p>Do not resect in a bladder diverticulum, as these areas do not have a muscle layer, and perforation may easily occur; careful fulguration may be used instead. A partial cystectomy may be appropriate in some situations.</p>
          </list-item>
          <list-item>
            <p>Regardless of the technique, a deeper biopsy, including muscle tissue, is recommended for staging. This deeper biopsy is usually sent as a separate specimen for identification.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>TURBT will fail to identify muscle invasion in about 30% of cases, usually due to inadequate tissue sampling or problems with postsurgical processing, handling, or analysis.<xref ref-type="bibr" rid="article-18354.r39">[39]</xref><xref ref-type="bibr" rid="article-18354.r154">[154]</xref><xref ref-type="bibr" rid="article-18354.r155">[155]</xref>&#x000a0;&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>A separate biopsy of the edge of the tumor should also be sent for a separate pathological examination if muscle invasion is suspected.</p>
          </list-item>
          <list-item>
            <p>There is evidence that laser ablation and bipolar resection are superior to monopolar transurethral resection for primary NMIBC.&#x000a0;(Laser ablation does&#x000a0;not yield any tissue for pathology.)</p>
          </list-item>
          <list-item>
            <p>Larger tumors may be resected in stages, starting with the endoluminal portion. The tumor should be resected until it is flush with the neighboring bladder wall. Deeper resection should be performed cautiously, and the specimen should be sent separately to help pathology with staging.</p>
          </list-item>
          <list-item>
            <p>Superficial cauterization should be done to the bladder mucosa for about a 1 cm margin around the base of any resected tumor.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>If available, enhanced cystoscopic techniques ("blue light" cystoscopy or narrow-band imaging) should be performed during the TURBT to enhance disease detection and allow for optimal therapy of all involved bladder mucosa.</p>
          </list-item>
          <list-item>
            <p>A biopsy should be taken from any abnormal urothelium at the time of the TURBT.</p>
          </list-item>
          <list-item>
            <p>Random mapping biopsies should be performed even from normal-appearing mucosa if the cytology is positive or the neoplasm is non-papillary.</p>
          </list-item>
          <list-item>
            <p>Any erythematous or suspicious areas should be biopsied and superficial cauterized, especially if highlighted by "blue light" fluorescence or narrow-band imaging.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>At the end of the procedure, the bladder should be thoroughly examined for any signs of a possible perforation, remaining tumor, or tumor fragments. Use the extra time to continue irrigation to facilitate the removal of as many floating malignant cells as possible.</p>
          </list-item>
        </list>
        <p>An en-bloc resection may also be done endoscopically and is preferred when technically feasible. This technique removes the entire tumor, along with surrounding stromal tissue and some underlying detrusor muscle, as a single specimen. A systemic meta-analysis has shown that en-bloc resection facilitates the pathological examination, decreases the incidence of inadvertent perforation, reduces the incidence of finding residual tumor on repeat resections, and lowers the risk of perforation.<xref ref-type="bibr" rid="article-18354.r156">[156]</xref><xref ref-type="bibr" rid="article-18354.r157">[157]</xref></p>
        <p><bold>The obturator reflex</bold> is a sudden, violent spasm of the adductor thigh muscles from unintended obturator nerve stimulation during TURBT. This stimulation causes the patient to experience a sudden and severe jerk of the hips and thighs without warning. This unexpected violent motion can easily result in an inadvertent bladder perforation during TURBT.<xref ref-type="bibr" rid="article-18354.r158">[158]</xref>&#x000a0;</p>
        <p>The obturator nerve passes close to the inferolateral wall of the bladder and bladder neck. During transurethral bladder surgery, electrosurgical resection or cautery (both monopolar and bipolar) can cause unintended stimulation of the nearby obturator nerve, resulting in an unintended reflex.<xref ref-type="bibr" rid="article-18354.r158">[158]</xref>&#x000a0;Minimizing electrosurgical current levels and avoiding bladder overdistension will also help reduce the risk of an inadvertent obturator reflex.<xref ref-type="bibr" rid="article-18354.r159">[159]</xref>&#x000a0;Using bipolar resection is thought to help as well, but studies have failed to show a consistent benefit.<xref ref-type="bibr" rid="article-18354.r159">[159]</xref><xref ref-type="bibr" rid="article-18354.r160">[160]</xref>&#x000a0;</p>
        <p>Effective elimination of the obturator reflex can be done by neuromuscular blockade during general anesthesia or using an obturator nerve block.<xref ref-type="bibr" rid="article-18354.r158">[158]</xref><xref ref-type="bibr" rid="article-18354.r161">[161]</xref>&#x000a0;Spinal anesthesia alone will not block the obturator reflex.<xref ref-type="bibr" rid="article-18354.r159">[159]</xref>&#x000a0;Performing an obturator nerve block when using spinal anesthesia for a TURBT will reduce the incidence of obturator reflex reactions and bladder perforations.<xref ref-type="bibr" rid="article-18354.r162">[162]</xref><xref ref-type="bibr" rid="article-18354.r163">[163]</xref></p>
        <p><bold>Intravesical instillation of a chemotherapy agent</bold>&#x000a0;(usually mitomycin C [40 mg/20 mL sterile water], gemcitabine [2000 mg/50 mL normal saline], or epirubicin [50 mg/50 mL normal saline])&#x000a0;immediately after a TURBT (within 24 hours) has been shown to reduce the incidence of urothelial cancer recurrence and progression significantly.<xref ref-type="bibr" rid="article-18354.r164">[164]</xref><xref ref-type="bibr" rid="article-18354.r165">[165]</xref><xref ref-type="bibr" rid="article-18354.r166">[166]</xref><xref ref-type="bibr" rid="article-18354.r167">[167]</xref><xref ref-type="bibr" rid="article-18354.r168">[168]</xref><xref ref-type="bibr" rid="article-18354.r169">[169]</xref><xref ref-type="bibr" rid="article-18354.r170">[170]</xref><xref ref-type="bibr" rid="article-18354.r171">[171]</xref>&#x000a0;TURBT surgery releases tumor cells, which can be implanted elsewhere in the bladder.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopup/167194#link_33766464">[174]</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopup/167194#link_32727757">[175]</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopup/167194#link_24996129">[176]</ext-link>&#x000a0;This process can be impeded by a single intravesical chemotherapy bladder instillation within 24 hours of the resection.</p>
        <p>Intravesical instillation should not be performed if there is a known or suspected bladder perforation, active bleeding, continuous irrigation, or if the resection is particularly extensive.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref>&#x000a0;Gemcitabine is typically the preferred agent as it is equally effective but has been associated with fewer adverse events than other agents.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref></p>
        <p>Techniques for enhancing the effectiveness and pharmacodynamics of this intravesical chemotherapy include the following:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>The pH should be lowered. This can be accomplished by oral sodium bicarbonate starting the night before surgery, preoperatively, and intravenously during the TURBT procedure.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>The duration of the intravesical therapy should be at least&#x000a0;1 hour. If possible, a longer dwell time of&#x000a0;2 hours is suggested.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Urine production during the instillation period should be minimized. Intraoperative and postoperative IV fluids should be minimized to limit urine production for the first 2 hours after surgery and avoid dilution of the intravesical chemotherapeutic agent.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>A&#x000a0;high concentration of the intravesical chemotherapeutic agent should be used.<xref ref-type="bibr" rid="article-18354.r172">[172]</xref><xref ref-type="bibr" rid="article-18354.r173">[173]</xref><xref ref-type="bibr" rid="article-18354.r174">[174]</xref></p>
          </list-item>
        </list>
        <p>A single intravesical chemotherapy instillation after&#x000a0;TURBT has been shown to reduce the recurrence rate from 10% to 15% when compared to TURBT alone in a number of studies, including&#x000a0;3 separate meta-analyses.<xref ref-type="bibr" rid="article-18354.r175">[175]</xref><xref ref-type="bibr" rid="article-18354.r176">[176]</xref><xref ref-type="bibr" rid="article-18354.r177">[177]</xref><xref ref-type="bibr" rid="article-18354.r178">[178]</xref><xref ref-type="bibr" rid="article-18354.r179">[179]</xref><xref ref-type="bibr" rid="article-18354.r180">[180]</xref><xref ref-type="bibr" rid="article-18354.r181">[181]</xref>&#x000a0;Results from a single trial of combination intravescial chemotherapy with mitomycin C and epirubicin showed a relative risk reduction of 31%.<xref ref-type="bibr" rid="article-18354.r182">[182]</xref>&#x000a0;While promising, this result requires further testing for confirmation.<xref ref-type="bibr" rid="article-18354.r180">[180]</xref></p>
        <p>The rationale for this treatment is that during TURBT surgery, numerous malignant cells are released into the bladder and may implant on the bladder wall. They become quickly covered by extracellular matrix but are initially susceptible to intravesical agents.<xref ref-type="bibr" rid="article-18354.r183">[183]</xref>&#x000a0;Preparing a bladder diagram of tumor locations is also recommended.<xref ref-type="bibr" rid="article-18354.r165">[165]</xref></p>
        <p><bold>Operative reports</bold>&#x000a0;of&#x000a0;TURBTs should optimally contain all of the elements as follows:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Describe the number, location, and estimated size of the bladder tumors (single largest diameter and aggregate size).&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Describe the American Joint Commission on Cancer clinical stage (cTa, cT1, cTis, cT2, cT3, cT4).&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Describe tumor morphology (nodular, solid, papillary, flat, sessile) .&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Indicate if this was a primary or recurrent tumor.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Indicate if there was any evidence or suspicion of CIS.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Indicate if any immediate postoperative intravesical chemotherapy was used, the drug used, the indwelling duration, and the dose.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Indicate if the resection was visually complete and if a deeper biopsy was performed.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Report any random biopsies taken and from where.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Report findings from the bimanual examination.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Report if there was any evidence of perforation or if no such perforation was performed.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Report the results of a complete cystoscopic evaluation of the bladder and urethra.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Report whether any muscle was visually resected.<xref ref-type="bibr" rid="article-18354.r184">[184]</xref><xref ref-type="bibr" rid="article-18354.r185">[185]</xref></p>
          </list-item>
        </list>
        <p><bold>Repeat or "Second Look" TURBT</bold>&#x000a0;is often recommended within 6 weeks of the original resection, as indicated below. Care should be taken to avoid bladder perforations, but underlying muscle tissue needs to be present in the specimen. Repeat or "second look" TURBTs have been shown to increase recurrence-free survival, improve outcomes from BCG therapy, and provide important prognostic information if performed within 6 weeks of the original surgery.<xref ref-type="bibr" rid="article-18354.r186">[186]</xref><xref ref-type="bibr" rid="article-18354.r187">[187]</xref><xref ref-type="bibr" rid="article-18354.r188">[188]</xref><xref ref-type="bibr" rid="article-18354.r189">[189]</xref><xref ref-type="bibr" rid="article-18354.r190">[190]</xref><xref ref-type="bibr" rid="article-18354.r191">[191]</xref></p>
        <p>Indications for a "second look" TURBT include the following:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>High-grade superficial papillary (high-grade Ta) or any invasive carcinoma into the submucosa or lamina propria (any T1), even if bladder muscle was found in the original specimen&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Highly multifocal tumor&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Incomplete initial resection of the bladder tumor and/or visible tumor left behind&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Large bladder tumor (defined as &#x0003e;3 cm)&#x000a0;<xref ref-type="bibr" rid="article-18354.r36">[36]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>Such second-look TURBTs have found residual cancer in half of all Ta cancers, resulting in upstaging in 15% of cases. These procedures also found persistent tumor in about half of the T1 lesions (48%), and 30% were upstaged to include muscle invasion.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref>&#x000a0; (Cancer risk staging for low-, intermediate-, and high-risk NMIBC malignancies can be found below in the "Postoperative and Rehabilitation Care" section)</p>
        <p><bold>Non-muscle-invasive bladder cancer&#x000a0;</bold>is managed primarily with transurethral (endoscopic) resection, which includes all Ta and T1 lesions. This procedure may be followed by risk-based intravesical therapy, like Bacillus Calmette-Gu&#x000e9;rin (BCG).&#x000a0;CIS is usually treated with BCG as first-line therapy.</p>
        <p><bold>Low-risk bladder NMIBC malignancies</bold> will do well with a single intravesical chemotherapy instillation and routine surveillance cystoscopy.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref>&#x000a0;(See surveillance protocol below in "Postoperative and Rehabilitation Care.")&#x000a0;Additional intravesical chemotherapy installations have not shown any additional benefit beyond the first, single, initial treatment for low-risk malignancies.<xref ref-type="bibr" rid="article-18354.r192">[192]</xref><xref ref-type="bibr" rid="article-18354.r193">[193]</xref><xref ref-type="bibr" rid="article-18354.r194">[194]</xref><xref ref-type="bibr" rid="article-18354.r195">[195]</xref>&#x000a0;Low-risk, noninvasive malignancies rarely metastasize, so a cystectomy is rarely indicated. Intravesical chemotherapy or BCG can be considered in selected cases.</p>
        <p><bold>Intermediate-risk NMIBC urothelial</bold>&#x000a0;<bold>cancers</bold> should be considered for a 6-week induction course of Bacillus Calmette&#x02013;Gu&#x000e9;rin (BCG) immunotherapy or intravesical chemotherapy with mitomycin C, doxorubicin, or epirubicin.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref>&#x000a0;All meta-analyses have shown reduced recurrences using such therapies, with BCG and mitomycin showing the best overall results.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref>&#x000a0;Given the difficulty in obtaining BCG due to shortages, its increased&#x000a0;adverse effects, and complications, intravesical mitomycin is usually preferred for intermediate-risk disease.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref>&#x000a0;&#x000a0;</p>
        <p>Mitomycin C intravesical treatment efficacy can be enhanced by the following:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>No oral fluids for 8 hours prior to the instillation&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Urinary alkalinization therapy (1.3 g sodium bicarbonate by mouth taken the evening prior to, the following, and one-half hour before the instillation&#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Complete evacuation of the bladder just prior to the instillation. (Checked by a bladder scanner or a quick urethral catheterization)&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>High concentration of mitomycin C (40 mg in 20 mL sterile water)<xref ref-type="bibr" rid="article-18354.r172">[172]</xref></p>
          </list-item>
        </list>
        <p>Intermediate-risk patients who have a complete response to an initial induction course of intravesical chemotherapy may be considered for maintenance BCG therapy for&#x000a0;1 year.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref></p>
        <p><bold>High-risk NMIBC malignancies, including CIS</bold>, are best treated after TURBT, with a 6-week course of BCG induction (1 dose weekly for 6 weeks), which has been shown to provide superior results to all other immuno- or chemotherapies.<xref ref-type="bibr" rid="article-18354.r196">[196]</xref><xref ref-type="bibr" rid="article-18354.r197">[197]</xref><xref ref-type="bibr" rid="article-18354.r198">[198]</xref><xref ref-type="bibr" rid="article-18354.r199">[199]</xref>&#x000a0;Transurethral resection and/or fulguration is of limited value in&#x000a0;CIS of the bladder due to the extent of the disease, so BCG is considered first-line therapy.<xref ref-type="bibr" rid="article-18354.r38">[38]</xref><xref ref-type="bibr" rid="article-18354.r200">[200]</xref>&#x000a0;Treatment of squamous cell carcinoma of the bladder is primarily surgical, as radiation, chemotherapy, and combined chemoradiation therapy do not appear to provide an overall survival benefit.<xref ref-type="bibr" rid="article-18354.r53">[53]</xref></p>
        <p><bold>Bacillus Calmette&#x02013;Gu&#x000e9;rin</bold>&#x000a0;is a weakened form of <italic toggle="yes">Mycobacterium bovis</italic> (cowpox). Initially designed as a vaccine for tuberculosis, it is now also used as an immunotherapy for high-grade urothelial cancer.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopup/166673#link_30844212">[117]</ext-link> Compared to chemotherapy, BCG has been shown to decrease disease recurrences and reduce progression (up to 37% compared to no BCG therapy) of high-grade urothelial carcinoma. The mechanism of action of BCG against tumor cells is incompletely understood. Originally, it was thought that the immune response to BCG was cross-reacting with bladder tumor cell antigens, but this simplistic mechanism has been largely disproven. Now it appears that BCG has a direct toxic effect on high-grade bladder cancer cells and a local immune-stimulating effect, which allows easier identification of BCG-affected tumor cells by the body's natural anti-tumor cellular defenses (macrophages, natural killer cells, neutrophils, and T lymphocytes.)<xref ref-type="bibr" rid="article-18354.r201">[201]</xref><xref ref-type="bibr" rid="article-18354.r202">[202]</xref></p>
        <p>BCG initially attaches to malignant urothelial cells due to a unique cellular fibronectin protein interaction with the bacteria, after which the BCG becomes internalized. Once inside the tumor cell, the BCG causes an increase in&#x000a0;intracellular cytokine production (granulocyte-macrophage colony-simulating factor, interferon-&#x003b3;, interleukins 1, 2, 6, and 8, and tumor necrosis factor).<xref ref-type="bibr" rid="article-18354.r38">[38]</xref><xref ref-type="bibr" rid="article-18354.r203">[203]</xref>&#x000a0;Nitric oxide production may also be increased, which further slows tumor growth.<xref ref-type="bibr" rid="article-18354.r204">[204]</xref><xref ref-type="bibr" rid="article-18354.r205">[205]</xref></p>
        <p>For optimal efficacy from BCG bladder instillations, the following conditions are required:</p>
        <list list-type="bullet">
          <list-item>
            <p>The patient is not immunocompromised.</p>
          </list-item>
          <list-item>
            <p>There is a relatively small tumor burden.</p>
          </list-item>
          <list-item>
            <p>Direct contact of the BCG with the tumor is possible (superficial disease).</p>
          </list-item>
          <list-item>
            <p>The dose used is sufficient to generate an immunological reaction.</p>
          </list-item>
          <list-item>
            <p>There is sufficient BCG available to complete the course of therapy.</p>
          </list-item>
        </list>
        <p>BCG is particularly useful in CIS, where it is relatively easy to meet the above criteria as the tumor is completely superficial. In such cases, complete eradication of CIS is possible in 70% or more of these patients.<xref ref-type="bibr" rid="article-18354.r206">[206]</xref>&#x000a0; Standard treatment is 6 weekly installations, followed by 3 weekly installations at 3 months and 6 months, then every 6 months afterward for maintenance therapy, which should be continued for 3 years.<xref ref-type="bibr" rid="article-18354.r207">[207]</xref><xref ref-type="bibr" rid="article-18354.r208">[208]</xref><xref ref-type="bibr" rid="article-18354.r209">[209]</xref>&#x000a0;Recently, an alternate protocol utilizing 12 weekly induction BCG installations with no maintenance therapy has shown good efficacy; it utilizes fewer treatment vials per patient, making this treatment modality more efficient when BCG is in short supply.<xref ref-type="bibr" rid="article-18354.r210">[210]</xref></p>
        <p>There does not appear to be any significant difference between different BCG strains or dosage amounts, except that adjustments should be made as needed to maintain efficacy and tolerability.<xref ref-type="bibr" rid="article-18354.r211">[211]</xref> Reduced dosages (ie, one-half, one-third) still appear to maintain efficacy, but there is no evidence that combination therapy with other chemotherapy agents improves the results.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref>&#x000a0;If recurrent or persistent disease is found after completing the initial 6-week course of BCG, a second induction course may be given.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref></p>
        <p><bold>Recurrent or persistent disease and/or positive cytologies after full intravesical BCG therapy</bold> suggests undetected disease. The upper urinary tracts should evaluated with contrast-enhanced imaging along with upper tract cytologies, and a prostatic urethral biopsy should be considered before administering further intravesical therapy.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Recurrent high-grade Ta disease should be managed by TURBT and intravesical therapy. A radical cystectomy should not be considered until such therapies have been tried and failed.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p>For recurrent high-grade T1 disease after an initial 6-week course of BCG, a radical cystectomy should be considered in eligible patients.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p>Recurrent high-grade urothelial cancer (CIS or NMIBC) within 6 months of starting BCG therapy constitutes a BCG failure, and additional immunotherapy should not be given.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref>&#x000a0;The patient is then a candidate for radical cystectomy or alternative intravesical chemotherapy.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p>Recurrent high-grade urothelial cancer (CIS or NMIBC) within&#x000a0;1 year of completion of appropriate and adequate BCG therapy is an indication for a radical cystectomy. If the patient does not want such surgery or is otherwise unfit, alternative intravesical chemotherapy protocols may be used, but a clinical trial is recommended if possible.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Expected symptoms from BCG therapy</bold> include dysuria, urinary frequency, hematuria, urgency, general malaise, and fever.<xref ref-type="bibr" rid="article-18354.r212">[212]</xref> Such symptoms typically develop within 48 hours of BCG instillation and are often dose-related.<xref ref-type="bibr" rid="article-18354.r213">[213]</xref><xref ref-type="bibr" rid="article-18354.r214">[214]</xref>&#x000a0;The dose of BCG may be reduced in patients who do not tolerate it well. The morbidity and severity of the adverse events can often be minimized by reducing the BCG dosage. Still, about 8% of patients will not be able to tolerate BCG treatment due to&#x000a0;adverse effects.<xref ref-type="bibr" rid="article-18354.r212">[212]</xref></p>
        <p><bold>BCG-osis</bold>, also known as disseminated BCG, occurs in less than 1% of patients receiving BCG therapy. This condition may present with mild flu-like symptoms or as a major systemic septic infection, ultimately proving fatal in some cases.<xref ref-type="bibr" rid="article-18354.r213">[213]</xref><xref ref-type="bibr" rid="article-18354.r215">[215]</xref>&#x000a0;BCG-osis may occur years after the last BCG instillation, so clinicians should maintain a level of suspicion even long after BCG therapy has ceased.</p>
        <p>Severe cases are quite rare at only a fraction of 1% and are thought to be due to disseminated BCG-related sepsis and/or hypersensitivity to <italic toggle="yes">Mycobacterium bovis</italic>.<xref ref-type="bibr" rid="article-18354.r216">[216]</xref>&#x000a0;These cases may present with mental status changes, chills, high-grade fevers, granulomatous prostatitis, arthritis, pneumonitis, granulomatous epididymo-orchitis, respiratory failure, hypotension, liver failure, jaundice, hepatitis, and various coagulopathies.<xref ref-type="bibr" rid="article-18354.r217">[217]</xref>&#x000a0;Negative blood cultures do not exclude the diagnosis, as BCG-osis is still found in about 40% of such cases.<xref ref-type="bibr" rid="article-18354.r217">[217]</xref>&#x000a0;Treatment involves antituberculosis medications (ethambutol, isoniazid, and rifampicin) and oral steroids.<xref ref-type="bibr" rid="article-18354.r213">[213]</xref>&#x000a0;Antituberculosis&#x000a0;treatment is typically continued for at least 3 to 6 months.</p>
        <p>
<bold>Therapy for BCG failures</bold>
</p>
        <p>Radical cystectomy should be the primary option for consideration in patients who are surgical candidates with tumors refractory to conservative management such as BCG therapy.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref>&#x000a0;</p>
        <p><bold>Nonsurgical alternatives </bold>include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pembrolizumab, an alternative IV immunotherapy, may be considered for patients with recurrent CIS that returns within a year of completing BCG therapy.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref>&#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Valrubicin has been US Food and Drug Administration (FDA)-approved for intravesical therapy in CIS patients who fail BCG therapy and cannot or will not undergo a cystectomy. However, the complete response rate is only 18%.<xref ref-type="bibr" rid="article-18354.r218">[218]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Nadofaragene is another FDA-approved intravesical therapy for patients with CIS who&#x000a0;are not responding to BCG therapy.<xref ref-type="bibr" rid="article-18354.r219">[219]</xref>&#x000a0;Early data from phase III trials indicates an initial complete response of just over 50% at 3 months, and about 45% of these patients maintained their response for 1 year.<xref ref-type="bibr" rid="article-18354.r219">[219]</xref>&#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Nogapendekin alfa inbakicept plus BCG was recently FDA-approved as intravesical therapy for treating high-risk BCG-unresponsive&#x000a0;CIS of the bladder. This approval was based on a study of 160 patients with BCG-unresponsive&#x000a0;CIS in which the complete response rate was 71% with a median response duration of over 2 years and cancer-specific overall survival of almost 100%.<xref ref-type="bibr" rid="article-18354.r220">[220]</xref> Cystectomy was avoided for over 90% of patients in this very high-risk group during the 2-year follow-up period.<xref ref-type="bibr" rid="article-18354.r220">[220]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Experimental treatments under investigation include intravesical gemcitabine, gemcitabine alternating with mitomycin or docetaxel, and intravesical paclitaxel.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref><xref ref-type="bibr" rid="article-18354.r221">[221]</xref><xref ref-type="bibr" rid="article-18354.r222">[222]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Other investigational therapies include&#x000a0;immune checkpoint inhibitors, oncolytic virus regimens, recombinant fusion proteins, immune modulation therapies, cytotoxic agents (cabazitaxel, cisplatinum, and gemcitabine,) and targeted small molecule kinase inhibitors.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref><xref ref-type="bibr" rid="article-18354.r223">[223]</xref></p>
          </list-item>
        </list>
        <p><bold>A systematic review</bold> of the currently available treatment modalities available for patients who fail BCG who are not candidates for cystectomy suggested the following protocol as follows:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>For&#x000a0;CIS only, intravesical nadofaragene, CG0070 adenovirus, or mitomycin C hyperthermic intravesical chemotherapy&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>For&#x000a0;CIS with Ta or T1 disease, intravesical nogapendekin alfa inbakicept plus BCG, intravesical radiofrequency-induced chemohyperthermia, or electromotive mitomycin C administration&#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>For Ta or T1 disease, intravesical nogapendekin alfa inbakicept plus BCG, intravesical hyperthermic chemotherapy with epirubicin, or electromotive mitomycin C followed by mitomycin C chemohyperthermia&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>If the above treatment fails, then combination chemotherapy with cabazitaxel, cisplatin, and gemcitabine is suggested.<xref ref-type="bibr" rid="article-18354.r219">[219]</xref><xref ref-type="bibr" rid="article-18354.r220">[220]</xref><xref ref-type="bibr" rid="article-18354.r224">[224]</xref></p>
          </list-item>
        </list>
        <p><bold>Due to BCG shortage issues, the National Comprehensive Cancer Network has recommended adjustments </bold>as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>BCG should be prioritized for CIS and high-grade T1 cancers, particularly at 3 and 6 months after induction.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Induction and maintenance dosages may be reduced (one-half or one-third) to allow for more treatments from a single vial.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Alternative intravesical agents may be used (mitomycin C, gemcitabine, etc).&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Consider early radical cystectomy in patients at high risk for recurrence or progression.</p>
          </list-item>
        </list>
        <p>Intravesical gemcitabine for an hour, followed by docetaxel for&#x000a0;2 hours, has been successfully used as an alternative to BCG therapy and for BCG failures.<xref ref-type="bibr" rid="article-18354.r221">[221]</xref><xref ref-type="bibr" rid="article-18354.r225">[225]</xref><xref ref-type="bibr" rid="article-18354.r226">[226]</xref>&#x000a0;It is associated with reduced&#x000a0;adverse effects, fewer treatment discontinuations, better tolerability, and equal or greater efficacy (as defined by progression-free, cancer-specific, and overall survival) than BCG treatments.<xref ref-type="bibr" rid="article-18354.r221">[221]</xref><xref ref-type="bibr" rid="article-18354.r225">[225]</xref><xref ref-type="bibr" rid="article-18354.r226">[226]</xref>&#x000a0;</p>
        <p>Long-term analysis has demonstrated that intravesical gemcitabine followed by docetaxel for high-risk NMIBC patients who failed BCG therapy provided a 5-year cancer-specific survival of 91%, and 75% of patients were able to avoid cystectomy.<xref ref-type="bibr" rid="article-18354.r222">[222]</xref>&#x000a0;These results indicate that intravesical gemcitabine combined with docetaxel therapy may be reasonably considered an alternative to BCG treatment for suitable high-risk bladder cancer patients.<xref ref-type="bibr" rid="article-18354.r225">[225]</xref></p>
        <p>Chemohyperthermia (heated intravesical chemotherapy, HIVEC), electromotive drug administration (EMDA), and radiofrequency-induced thermo-chemotherapy (RITE) are promising technologies designed to improve bladder wall penetration of intravesical chemotherapeutic agents. Still, they are not yet recommended by guidelines due to insufficient clinical data and evidence.<xref ref-type="bibr" rid="article-18354.r227">[227]</xref><xref ref-type="bibr" rid="article-18354.r228">[228]</xref><xref ref-type="bibr" rid="article-18354.r229">[229]</xref><xref ref-type="bibr" rid="article-18354.r230">[230]</xref>&#x000a0;However, they are not unreasonable to use where available during BCG shortages.<xref ref-type="bibr" rid="article-18354.r230">[230]</xref></p>
        <p>An abstract from the&#x000a0;2023 European Society of Medical Oncology (ESMO) by Necchi and associates described their early results with a&#x000a0;unique investigational implantable drug delivery device (TAR-200) allowing for the sustained delivery of intravesical chemotherapy to the bladder for patients with high-risk BCG-unresponsive CIS. This intravesical device using gemcitabine has shown a complete response rate of 77%, of which over 90% have been maintained over a median of 48 weeks. It is now being tested in combination with cetrelimab, an investigational programmed cell death receptor-1 (PD-1) monoclonal antibody.&#x000a0;Further studies are needed to determine and verify the duration and optimal usage of such therapies.</p>
        <p>Cretostimogene is a unique investigational oncolytic immunotherapy that has produced durable complete response rates of more than 75% lasting over a year in patients with BCG-unresponsive CIS. These preliminary results are quite encouraging.</p>
        <p>
<bold>MUSCLE-INVASIVE BLADDER CANCER&#x000a0;</bold>
</p>
        <p>MIBC accounts for approximately 25% of all primary bladder cancer cases.<xref ref-type="bibr" rid="article-18354.r13">[13]</xref><xref ref-type="bibr" rid="article-18354.r30">[30]</xref>&#x000a0;Once a malignant bladder tumor invades the detrusor muscle, even superficially, there is a markedly increased rate of metastases and reduced life expectancy as the overall 5-year recurrence-free survival rate is only about 50%.<xref ref-type="bibr" rid="article-18354.r30">[30]</xref><xref ref-type="bibr" rid="article-18354.r31">[31]</xref><xref ref-type="bibr" rid="article-18354.r231">[231]</xref></p>
        <p>Staging is done with CT or MRI urogram imaging plus a chest x-ray or CT.<xref ref-type="bibr" rid="article-18354.r30">[30]</xref> Despite advances in imaging technology, upstaging after surgery due to unanticipated extravesical disease is found in as many as 40% of cases.<xref ref-type="bibr" rid="article-18354.r232">[232]</xref><xref ref-type="bibr" rid="article-18354.r233">[233]</xref><xref ref-type="bibr" rid="article-18354.r234">[234]</xref>&#x000a0;Preoperative imaging that demonstrates hydronephrosis has been found to be a strong predictor of extravesical disease and a more guarded prognosis.<xref ref-type="bibr" rid="article-18354.r233">[233]</xref><xref ref-type="bibr" rid="article-18354.r234">[234]</xref></p>
        <p><bold>Involvement of the prostatic urethra</bold> may be found in as many as one-third of all patients with MIBC.<xref ref-type="bibr" rid="article-18354.r146">[146]</xref><xref ref-type="bibr" rid="article-18354.r148">[148]</xref><xref ref-type="bibr" rid="article-18354.r149">[149]</xref>&#x000a0;The risk is highest with tumors located in the trigone or bladder neck as well as in patients with CIS, positive cytologies without visible lesions, and in multifocal disease.<xref ref-type="bibr" rid="article-18354.r151">[151]</xref><xref ref-type="bibr" rid="article-18354.r152">[152]</xref><xref ref-type="bibr" rid="article-18354.r153">[153]</xref>&#x000a0;A prostatic urethral biopsy&#x000a0;involves a limited transurethral prostate resection from the bladder neck to the verumontanum between 5 and 7 o'clock.<xref ref-type="bibr" rid="article-18354.r13">[13]</xref>&#x000a0;Any abnormal appearing urethral tissue should also be biopsied.<xref ref-type="bibr" rid="article-18354.r13">[13]</xref></p>
        <p><bold>The initial management of MIBC</bold>&#x000a0;is transurethral (endoscopic) resection, but it will require further therapy once it has been staged as a T2 or higher lesion. Higher-stage lesions are managed with local palliative therapy and as metastatic cancers (see "Medical Oncology" section)</p>
        <p><bold>Treating MIBC without metastases</bold> is generally neoadjuvant cisplatin-based neoadjuvant chemotherapy followed by&#x000a0;radical cystectomy with bilateral pelvic lymphadenectomy.<xref ref-type="bibr" rid="article-18354.r13">[13]</xref><xref ref-type="bibr" rid="article-18354.r235">[235]</xref>&#x000a0; In men, removal of the prostate and seminal vesicles is usually included, especially if urethral or prostatic involvement is demonstrated or suspected. In women, the uterus, cervix, ovaries, and anterior vaginal wall are usually removed.<xref ref-type="bibr" rid="article-18354.r235">[235]</xref>&#x000a0;Perioperative pharmacologic thromboembolic prophylaxis is recommended for patients undergoing radical cystectomy surgery.<xref ref-type="bibr" rid="article-18354.r30">[30]</xref>&#x000a0;There does not appear to be any difference in overall complications, progression-free survival, or overall survival between robotic and open surgical cystectomies.<xref ref-type="bibr" rid="article-18354.r236">[236]</xref><xref ref-type="bibr" rid="article-18354.r237">[237]</xref><xref ref-type="bibr" rid="article-18354.r238">[238]</xref><xref ref-type="bibr" rid="article-18354.r239">[239]</xref><xref ref-type="bibr" rid="article-18354.r240">[240]</xref></p>
        <p><bold>Indications for a radical cystectomy</bold> include the following:&#x000a0;<xref ref-type="bibr" rid="article-18354.r13">[13]</xref><xref ref-type="bibr" rid="article-18354.r235">[235]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>MIBC with no known nodes or metastases&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Very high-risk NMIBC (Lymphovascular invasion, variant or divergent histology, extensive lamina propria involvement, large (&#x0003e;5 cm) high-grade T1 tumors, persistent or unresectable malignant tissue after repeat TURBT, and prostatic urethral involvement)</p>
          </list-item>
          <list-item>
            <p>CIS not responding to BCG&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Extensive papillary tumors are not controllable with TURBT and intravesical therapy&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Salvage cystectomy</bold> should be considered in the following:&#x000a0;<xref ref-type="bibr" rid="article-18354.r13">[13]</xref><xref ref-type="bibr" rid="article-18354.r30">[30]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Recurrence after bladder-sparing procedures&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Palliation for intractable pain, unmanageable hematuria, or extensive fistula formation&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>The limits of dissection for the lymphadenectomy </bold>are as follows:<bold>&#x000a0;</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Distal: Node of Cloquet (The uppermost of the deep inguinal nodes, the node of Cloquet, is located under the inguinal ligament and is the lowest of the external iliac lymph nodes.)<xref ref-type="bibr" rid="article-18354.r241">[241]</xref><xref ref-type="bibr" rid="article-18354.r242">[242]</xref><xref ref-type="bibr" rid="article-18354.r243">[243]</xref><xref ref-type="bibr" rid="article-18354.r244">[244]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Inferior: Internal iliac lymph nodes and the pelvic floor&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Lateral: Genitofemoral nerve&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Posterior: Sacrum&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Proximal: Up to the bifurcation of the iliac arteries is standard, but the dissection may be extended to the aortic bifurcation. Further extension up to the inferior mesenteric artery (superextended dissection) does not appear to offer any additional survival benefit and is not recommended.</p>
          </list-item>
        </list>
        <p>An extended dissection may also include the presacral lymph nodes and the triangle of Marcille (medial edge of the psoas major, lateral border of the vertebra, and the iliolumbar ligament below. The obturator nerve passes through this area.)<xref ref-type="bibr" rid="article-18354.r245">[245]</xref>&#x000a0;Currently, most surgeries use the standard template, and the benefits of extended dissections are unclear.<xref ref-type="bibr" rid="article-18354.r246">[246]</xref><xref ref-type="bibr" rid="article-18354.r247">[247]</xref><xref ref-type="bibr" rid="article-18354.r248">[248]</xref></p>
        <p><bold>Neoadjuvant therapy</bold>&#x000a0;for&#x000a0;MIBC has been proven beneficial as demonstrated in results of several large randomized clinical trials and systematic meta-analyses.<xref ref-type="bibr" rid="article-18354.r249">[249]</xref><xref ref-type="bibr" rid="article-18354.r250">[250]</xref><xref ref-type="bibr" rid="article-18354.r251">[251]</xref><xref ref-type="bibr" rid="article-18354.r252">[252]</xref><xref ref-type="bibr" rid="article-18354.r253">[253]</xref><xref ref-type="bibr" rid="article-18354.r254">[254]</xref><xref ref-type="bibr" rid="article-18354.r255">[255]</xref>&#x000a0;Neoadjuvant chemotherapy for bladder cancer typically consists of&#x000a0;methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC).<xref ref-type="bibr" rid="article-18354.r30">[30]</xref>&#x000a0;These medicines are usually given now in a&#x000a0;dose-dense (ddMVAC) manner where the chemotherapy is combined with growth factors.<xref ref-type="bibr" rid="article-18354.r13">[13]</xref><xref ref-type="bibr" rid="article-18354.r30">[30]</xref>&#x000a0;This technique is better tolerated, is less likely to be interrupted by&#x000a0;adverse effects, requires a shorter course of therapy, and may provide a slight improvement in cancer control compared to standard MVAC treatment.<xref ref-type="bibr" rid="article-18354.r256">[256]</xref><xref ref-type="bibr" rid="article-18354.r257">[257]</xref>&#x000a0;</p>
        <p>The combination of gemcitabine and cisplatin appears to be an acceptable, safer, and more tolerable substitute for MVAC, but additional studies are needed for definitive confirmation.<xref ref-type="bibr" rid="article-18354.r258">[258]</xref><xref ref-type="bibr" rid="article-18354.r259">[259]</xref><xref ref-type="bibr" rid="article-18354.r260">[260]</xref>&#x000a0;Patients who responded well to neoadjuvant chemotherapy tend to have better outcomes and improved overall survival, especially if they are complete responders.<xref ref-type="bibr" rid="article-18354.r261">[261]</xref><xref ref-type="bibr" rid="article-18354.r262">[262]</xref></p>
        <p><bold>Adjuvant chemotherapy</bold> is given after surgery and reserved for patients with a high recurrence risk. This would include patients with extravesical disease and those with positive lymph nodes at the time of surgery who did not receive preoperative chemotherapy.&#x000a0;Nivolumab, an immune checkpoint inhibitor, is also FDA-approved for adjuvant therapy in patients with urothelial bladder cancer at high risk for a recurrence who refused, could not tolerate, or were ineligible for prior chemotherapy.<xref ref-type="bibr" rid="article-18354.r263">[263]</xref><xref ref-type="bibr" rid="article-18354.r264">[264]</xref>&#x000a0;Unlike neoadjuvant chemotherapy, there is no definitive evidence of any significant benefit to adjuvant chemotherapy. However, adjuvant radiation therapy may help with local control and disease-specific survival but has not demonstrated any overall survival benefit when used alone. Fiduciary markers can help target radiation therapy.</p>
        <p><bold>Urinary reconstruction after radical cystectomy</bold> is typically a choice between an ileal conduit, continent cutaneous reservoir, or an orthotopic neobladder. The advantages and disadvantages of each of these should be discussed with patients prior to surgery.<xref ref-type="bibr" rid="article-18354.r13">[13]</xref><xref ref-type="bibr" rid="article-18354.r30">[30]</xref>&#x000a0;Patients and their families should be thoroughly taught how to manage their chosen urinary diversion drainage system.<xref ref-type="bibr" rid="article-18354.r30">[30]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>The ileal conduit</bold> remains the most popular urinary diversion after a cystectomy, most likely due to its relative simplicity. A short section of the distal ileum is used to passively pass urine from the anastomosed ureters at the proximal end through a distal stoma on the abdominal skin surface. While technically easier to perform, its associated complications are frequently underappreciated. These include hyperchloremic, hypokalemic metabolic acidosis as well as long-term deterioration of the renal units over time, ureteral strictures, stenosis of the stomal opening, frequent urinary tract infections, stomal hernias, skin irritation and ulceration, and urostomy bag leakage problems. Leaving the terminal 15 cm of the distal ileum can minimize problems of impaired absorption of bile salts and fat-soluble vitamins, particularly vitamin B12.<xref ref-type="bibr" rid="article-18354.r30">[30]</xref><xref ref-type="bibr" rid="article-18354.r265">[265]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Continent cutaneous (Indiana pouch, Miami, and similar) </bold>urinary diversions create a continence reservoir, usually from the right colon, and the ileocecal valve is used as a continence mechanism. The ileal segment may need to be tapered, and the ileocecal valve may require plication or reconstruction to maintain continence. The ileal stomas open onto the abdominal skin surface and are drained periodically by self-catheterization. Variations include using ileal segments to form the reservoir and the appendix as a ready-made continence mechanism and catheterizable access point. Continence rates are reported as high as 90%.<xref ref-type="bibr" rid="article-18354.r266">[266]</xref><xref ref-type="bibr" rid="article-18354.r267">[267]</xref>&#x000a0;The Kock reservoir has been largely abandoned due to its technical complexity and unacceptably high complication/reoperation rate.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Continent orthotopic neobladder&#x000a0;</bold>diversions&#x000a0;require a clear margin at the urethral margin. If this is positive on a frozen section, a neobladder is absolutely contraindicated. Neobladders are constructed from a tabularized intestinal segment, usually the ileum, which is folded back on itself to minimize any contractions. The ileum is usually selected because of its reduced complication rate and superior mobility, which means it can easily reach the urethra without tension. The Studor, Hartmann, and&#x000a0;Y-pouch ileal orthotopic neobladder techniques are frequently utilized.<xref ref-type="bibr" rid="article-18354.r268">[268]</xref><xref ref-type="bibr" rid="article-18354.r269">[269]</xref><xref ref-type="bibr" rid="article-18354.r270">[270]</xref>&#x000a0;Daytime continence rates of 85% have been reported.<xref ref-type="bibr" rid="article-18354.r271">[271]</xref></p>
          </list-item>
        </list>
        <p>All of these urinary reconstruction methods are associated with many possible complications, such as hyperchloremic, hypokalemic metabolic acidosis, as well as kidney failure, decreased bone density, chronic diarrhea, vitamin B12 deficiency, calcium oxalate nephrolithiasis (from enteric hyperoxaluria), and hyperammonemia. Overall, patient satisfaction and quality of life scores are similar between the various urinary reconstructive surgical options, although a few studies indicated marginally higher quality of life scores with neobladders.<xref ref-type="bibr" rid="article-18354.r272">[272]</xref><xref ref-type="bibr" rid="article-18354.r273">[273]</xref><xref ref-type="bibr" rid="article-18354.r274">[274]</xref><xref ref-type="bibr" rid="article-18354.r275">[275]</xref><xref ref-type="bibr" rid="article-18354.r276">[276]</xref></p>
        <p><bold>Bladder preservation techniques</bold> may be considered in selected patients with&#x000a0;MIBC who are not candidates for cystectomy or who refuse such treatment.<xref ref-type="bibr" rid="article-18354.r30">[30]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>A partial cystectomy</bold>&#x000a0;may be considered in carefully selected patients with a solitary tumor without CIS or a malignancy in a bladder diverticulum that TURBT cannot completely or safely remove. A lymph node dissection is recommended in patients undergoing a partial cystectomy. Patients with isolated tumors of the bladder dome would be the best candidates for this treatment option. Overall, 5-year survival is reported to be about 70%.<xref ref-type="bibr" rid="article-18354.r277">[277]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Maximal or radical transurethral resection</bold> has been recommended as a treatment for selected patients with MIBC who are not candidates for a radical cystectomy. Essentially, a repeat TURBT is performed until no residual tumor is left. Enhanced cystoscopic detection techniques are suggested to maximize the results. Mandatory regular upper tract imaging with surveillance cystoscopies is required due to the high rate of local recurrence. Understaging is common with this treatment modality. Five-year survival rates have been reported as only 30% in an older series.<xref ref-type="bibr" rid="article-18354.r278">[278]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Maximal transurethral resection of the bladder tumor with chemoradiation ("trimodal therapy")</bold> has been reported to achieve a 5-year survival of 60% to 76%. This therapy appears to be the best alternative to radical cystectomy in selected patients based on the limited available data.<xref ref-type="bibr" rid="article-18354.r279">[279]</xref>&#x000a0;This data makes it comparable to the 5-year overall survival (73%) in patients who underwent radical cystectomy surgery.<xref ref-type="bibr" rid="article-18354.r280">[280]</xref>&#x000a0;Good long-term studies are not available. The AUA and EAU guidelines, therefore, recommend trimodal and multimodal bladder-preserving therapy for selected patients unable or unwilling to undergo radical cystectomy and who clearly understand the risks and the mandatory need for careful follow-up.<xref ref-type="bibr" rid="article-18354.r13">[13]</xref><xref ref-type="bibr" rid="article-18354.r30">[30]</xref></p>
          </list-item>
        </list>
        <p>About 30% of patients who undergo bladder-preserving therapy will develop a recurrence of their muscle-invasive disease.<xref ref-type="bibr" rid="article-18354.r281">[281]</xref> These patients should be offered radical cystectomy surgery.<xref ref-type="bibr" rid="article-18354.r30">[30]</xref>&#x000a0;They will experience a higher recurrence rate if treated with local therapy (TURBT, etc) and not treated with cystectomy.<xref ref-type="bibr" rid="article-18354.r282">[282]</xref></p>
        <p><bold>Trimodal therapy&#x000a0;</bold>(maximum transurethral tumor resection followed by radiochemotherapy and/or systemic immunotherapy together with close cystoscopic follow-up) studies have reports of equivalent oncological outcomes, suggesting that optimized bladder preservation techniques may approach equivalence with standard radical cystectomy-based surgery in selected patients.<xref ref-type="bibr" rid="article-18354.r283">[283]</xref><xref ref-type="bibr" rid="article-18354.r284">[284]</xref>&#x000a0;Future developments to improve patient selection by using optimized genetic and other biomarkers may lead to improved outcomes without the need for cystectomy, at least in some carefully selected patients.<xref ref-type="bibr" rid="article-18354.r283">[283]</xref><xref ref-type="bibr" rid="article-18354.r284">[284]</xref></p>
      </sec>
      <sec id="article-18354.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Accurate diagnosis is crucial for ensuring appropriate treatment and management.&#x000a0;When evaluating a patient for bladder cancer, it is essential to consider a range of differential diagnoses due to the overlap of symptoms with other urological and systemic conditions. The differential diagnosis for bladder cancer includes the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Amyloidosis</p>
          </list-item>
          <list-item>
            <p>Benign prostatic hyperplasia</p>
          </list-item>
          <list-item>
            <p>Bladder wall thickening from obstruction or infection</p>
          </list-item>
          <list-item>
            <p>Cystitis cystica and glandularis</p>
          </list-item>
          <list-item>
            <p>Diverticulitis</p>
          </list-item>
          <list-item>
            <p>Enterovesical fistula</p>
          </list-item>
          <list-item>
            <p>Gynecologic and other pelvic malignancies</p>
          </list-item>
          <list-item>
            <p>Hemangioma</p>
          </list-item>
          <list-item>
            <p>Hematuria unrelated to urothelial carcinoma</p>
          </list-item>
          <list-item>
            <p>Hemorrhagic cystitis</p>
          </list-item>
          <list-item>
            <p>Inverted papilloma</p>
          </list-item>
          <list-item>
            <p>Interstitial cystitis</p>
          </list-item>
          <list-item>
            <p>Leiomyoma</p>
          </list-item>
          <list-item>
            <p>Malakoplakia</p>
          </list-item>
          <list-item>
            <p>Median lobe of the prostate with intravesical extension</p>
          </list-item>
          <list-item>
            <p>Nephrogenic adenoma</p>
          </list-item>
          <list-item>
            <p>Nephrolithiasis</p>
          </list-item>
          <list-item>
            <p>Overactive bladder&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Paraganglioma</p>
          </list-item>
          <list-item>
            <p>Prostatitis</p>
          </list-item>
          <list-item>
            <p>Radiation cystitis</p>
          </list-item>
          <list-item>
            <p>Renal masses and neoplasms</p>
          </list-item>
          <list-item>
            <p>Urinary tract infection</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18354.s11" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>
<bold>Metastatic Urothelial Disease</bold>
</p>
        <p>The National Comprehensive Cancer Network has indicated that FDG-PET/CT scanning may be useful in identifying metastases in selected patients with muscle-invasive disease and may change treatment in patients with stage T3 or higher disease. The initial spread of urothelial bladder cancer is by direct extension into adjacent organs and/or the pelvic side wall, through the lymph nodes, or hematogenously. The most likely locations for distant metastases are bone, liver, and lung.</p>
        <p>An extensive review of chemotherapy for metastatic bladder cancer is beyond the scope of this review. Metastatic urothelial cancer generally has a good response rate to chemotherapy (about 70%), but the overall prognosis is still poor as the duration of the benefit is short. MVAC given in a dose-dense manner has been the most studied, but cisplatin and gemcitabine offer similar results with greater safety and less morbidity.<xref ref-type="bibr" rid="article-18354.r258">[258]</xref></p>
        <p>Paclitaxel binds to tubulin and halts intracellular microtubule production, which blocks cell mitosis.<xref ref-type="bibr" rid="article-18354.r285">[285]</xref><xref ref-type="bibr" rid="article-18354.r286">[286]</xref>&#x000a0;This therapy has demonstrated a very good response rate, with 27% of patients exhibiting a complete response.<xref ref-type="bibr" rid="article-18354.r285">[285]</xref><xref ref-type="bibr" rid="article-18354.r287">[287]</xref>&#x000a0;Immune checkpoint inhibitors have shown activity in metastatic urothelial malignancies. These drugs reduce natural T-cell inhibition from their programmed death protein-1 (PD-1) cell surface protein, essentially releasing the T-cell's full immune potential. Examples include pembrolizumab, atezolizumab, avelumab, and nivolumab, which have all been approved for use in bladder cancer patients. Avelumab and pembrolizumab have shown improved overall survival in clinical trials.<xref ref-type="bibr" rid="article-18354.r288">[288]</xref><xref ref-type="bibr" rid="article-18354.r289">[289]</xref><xref ref-type="bibr" rid="article-18354.r290">[290]</xref><xref ref-type="bibr" rid="article-18354.r291">[291]</xref></p>
        <p>Erdafitinib is a tyrosine kinase inhibitor, which acts as a fibroblast growth factor blocker that is indicated for metastatic urothelial cancer patients who progressed on cisplatin-based chemotherapy.&#x000a0;Hyperphosphatemia is common, and up to 25% of patients will need to stop therapy due to significant&#x000a0;retinal eye issues.<xref ref-type="bibr" rid="article-18354.r292">[292]</xref><xref ref-type="bibr" rid="article-18354.r293">[293]</xref><xref ref-type="bibr" rid="article-18354.r294">[294]</xref><xref ref-type="bibr" rid="article-18354.r295">[295]</xref>&#x000a0;Enfortumab vedotin is an antibody-drug conjugate, where a monoclonal antibody is attached to an anticancer drug.<xref ref-type="bibr" rid="article-18354.r296">[296]</xref><xref ref-type="bibr" rid="article-18354.r297">[297]</xref>&#x000a0;Pembrolizumab is an immune checkpoint (PD-1) inhibitor. Results from a large, multinational trial involving 185 centers in 25 different countries recently demonstrated that combination therapy with enfortumab vedotin and pembrolizumab (EF+P) in advanced urothelial cancer patients nearly doubled their progression-free and overall survival.<xref ref-type="bibr" rid="article-18354.r298">[298]</xref><xref ref-type="bibr" rid="article-18354.r299">[299]</xref></p>
        <p><bold>The latest recommendation from the FDA and the European Society of Medical Oncology </bold>is to use a combination of&#x000a0;enfortumab vedotin and pembrolizumab (EV+P) as first-line chemotherapy for advanced or metastatic urothelial (bladder) cancer.<xref ref-type="bibr" rid="article-18354.r288">[288]</xref><xref ref-type="bibr" rid="article-18354.r297">[297]</xref></p>
      </sec>
      <sec id="article-18354.s12" sec-type="Staging">
        <title>Staging</title>
        <p>
<bold> TNM system: The American Joint Committee on Cancer&#x000a0;</bold>
</p>
        <p>Tumor T Stage</p>
        <list list-type="bullet">
          <list-item>
            <p>Ta lesions: Ta tumors are papillary (exophytic) lesions that tend to&#x000a0;recur</p>
          </list-item>
          <list-item>
            <p>Tis lesions: High-grade intraepithelial neoplasm without invasion into subepithelial connective tissue</p>
          </list-item>
          <list-item>
            <p>T1 lesions: T1 tumors invade the submucosa or lamina propria</p>
          </list-item>
          <list-item>
            <p>T2 lesions: Invasion into muscle is present in T2 lesions
<list list-type="bullet"><list-item><p>T2a: Invasion into superficial muscle</p></list-item><list-item><p>T2b: Invasion into deep muscle</p></list-item><list-item><p>T3 lesions: T3 tumors extend beyond muscle into the perivesical fat
<list list-type="bullet"><list-item><p>T3a: Microscopic invasion only</p></list-item><list-item><p>T3b: Macroscopic extension or invasion, extravesical mass</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>T4 lesions: Tumor invading surrounding structures
<list list-type="bullet"><list-item><p>T4a: Invasion of the prostate, vagina, uterus, or bowel</p></list-item><list-item><p>T4b: Invasion of the abdominal or pelvic wall structures or other organs</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Lymph Node N Stage</p>
        <list list-type="bullet">
          <list-item>
            <p>NX: Lymph nodes cannot be assessed</p>
          </list-item>
          <list-item>
            <p>N0: No lymph node metastasis</p>
          </list-item>
          <list-item>
            <p>N1: Single regional lymph node metastasis within the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node)</p>
          </list-item>
          <list-item>
            <p>N2: Multiple regional lymph node metastases within the true pelvis</p>
          </list-item>
          <list-item>
            <p>N3: Lymph node metastasis spread to the common iliac lymph nodes</p>
          </list-item>
        </list>
        <p>Distant Metastasis M Stage</p>
        <list list-type="bullet">
          <list-item>
            <p>M0: No distant metastasis</p>
          </list-item>
          <list-item>
            <p>M1: Distant metastasis
<list list-type="bullet"><list-item><p>M1a: Distant metastasis limited to lymph nodes beyond the common iliac arteries</p></list-item><list-item><p>M1b: Non-lymph node distant metastases</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Clinical Staging</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage I: T1, N0, M0</p>
          </list-item>
          <list-item>
            <p>Stage II: T2, N0, M0</p>
          </list-item>
          <list-item>
            <p>Stage III:
<list list-type="bullet"><list-item><p>Stage IIIA: T3a, T3b, or T4a; N0; M0 or T1 to T4a, N1, M0</p></list-item><list-item><p>Stage IIIB: T1 to T4a, N2 or N3, M0</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Stage IV:
<list list-type="bullet"><list-item><p>Stage IVA: T4b, any N, M0 or any T, any N, M1a</p></list-item><list-item><p>Stage IVB: any T, any N, M1b</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18354.s13" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of urothelial bladder cancer depends on multiple factors. TNM stage is the single most important prognostic factor of urinary bladder carcinoma. The 5-year overall survival for pT1 is 75%, pT2 is 50%, and pT3 is 20%. Invasion of the muscularis propria determines whether the patient's staging is pT1 (NMIBC) or pT2 (MIBC).</p>
        <p>Histological variants of urothelial carcinomas tend to have a poorer prognosis than typical bladder cancer.&#x000a0;These variants include urothelial carcinoma with rhabdoid features, urothelial micropapillary carcinoma, plasmacytoid carcinoma, sarcomatoid carcinoma, small cell carcinoma, and undifferentiated carcinoma. Other poor prognostic factors of urothelial carcinoma include high histological cancer grade, lymphovascular invasion, the presence of CIS, recurrence, large tumor size, sessile nature, incomplete tumor removal, positive margins, and multicentricity.<xref ref-type="bibr" rid="article-18354.r46">[46]</xref></p>
        <p>The National Cancer Institute reports that the 5-year relative bladder cancer survival rates are as follows:&#x000a0;<xref ref-type="bibr" rid="article-18354.r300">[300]</xref><xref ref-type="bibr" rid="article-18354.r301">[301]</xref><xref ref-type="bibr" rid="article-18354.r302">[302]</xref><xref ref-type="bibr" rid="article-18354.r303">[303]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>CIS: 97%.&#x000a0;About 50% will become invasive within 5 years, and just over half will demonstrate tumor progression unless treated with BCG, in which case the risk of progression is less than 10%.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Localized bladder cancer: 71%.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Regional bladder cancer (spread to adjacent organs or nearby lymph nodes): 39%.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Metastatic bladder cancer: 8%.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18354.s14" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of urothelial cancer of the bladder include symptoms related to the tumor and adverse effects of treatment. Complications related to the tumor include weight loss, fatigue, urinary tract infection, metastasis, and urinary obstruction leading to chronic kidney failure.<xref ref-type="bibr" rid="article-18354.r304">[304]</xref>&#x000a0;The adverse&#x000a0;effects of surgical management include urinary tract infections, urinary leak, pouch stones, urinary tract obstruction, erectile dysfunction, and vaginal narrowing. Almost two-thirds of patients who receive a radical cystectomy will develop at least&#x000a0;1 postoperative problem within the first 3 months after surgery, and 13% will have a severe (grade 3 or more) complication.<xref ref-type="bibr" rid="article-18354.r305">[305]</xref></p>
        <p><bold>Complications of a neobladder</bold> include voiding dysfunction, ureteroenteric strictures, urinary infections, bladder stones, metabolic abnormalities, urinary retention, and rupture.<xref ref-type="bibr" rid="article-18354.r306">[306]</xref> Of these, rupture or leakage of a neobladder is potentially the most dangerous and should be suspected in all patients after cystectomy with neobladders who develop abdominal pain.<xref ref-type="bibr" rid="article-18354.r306">[306]</xref><xref ref-type="bibr" rid="article-18354.r307">[307]</xref><xref ref-type="bibr" rid="article-18354.r308">[308]</xref>&#x000a0;A CT cystogram&#x000a0;is diagnostic.<xref ref-type="bibr" rid="article-18354.r306">[306]</xref>&#x000a0; Standard treatment of a ruptured neobladder is laparotomy with surgical repair, but selected cases (diagnosed early, hemodynamically stable, no significant comorbidities, neobladders are well drained and empty well)&#x000a0;may be treated conservatively.<xref ref-type="bibr" rid="article-18354.r306">[306]</xref><xref ref-type="bibr" rid="article-18354.r309">[309]</xref>&#x000a0;Failure of the patient to clinically improve or persistence of leakage from the neobladder should be treated surgically.<xref ref-type="bibr" rid="article-18354.r310">[310]</xref></p>
        <p>The list of potential complications is exceptionally long. In addition to all of the standard complications associated with general anesthesia and surgical procedures, the&#x000a0;possibilities include the following:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Bleeding and vascular: Anemia, coagulopathy, deep vein thrombosis, hematoma formation, phlebitis, prolonged hematuria, pulmonary embolism, and the need for transfusions</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal: Anastomotic bowel leak, ascites, diarrhea, emesis, enterocutaneous fistulas, gastrointestinal hemorrhage, ileus, peptic ulcers, pseudomembranous colitis, and&#x000a0;small bowel obstruction</p>
          </list-item>
          <list-item>
            <p>Genitourinary: Bladder dysfunction or perforation, bladder neck stricture, erectile dysfunction, fistula formation, hydronephrosis, parastomal hernias, renal failure, stomal issues, ureteral or urethral strictures, voiding issues including urinary retention and incontinence</p>
          </list-item>
          <list-item>
            <p>Infections: Abscesses, cellulitis, cholecystitis, diverticulitis, incisional and wound infections, peritonitis, pyelonephritis, sepsis, and unexplained fevers</p>
          </list-item>
          <list-item>
            <p>Surgical: Bladder perforation, cellulitis, failure to identify CIS, fistula formation, iatrogenic obturator nerve injury, incomplete tumor resection, incisional hernia, intestinal injury (unrecognized), parastomal hernia, rectal trauma, retained drain, seromas, stomal ischemia, vascular injury, and wound dehiscence/infections.<xref ref-type="bibr" rid="article-18354.r235">[235]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18354.s15" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Patients with a history of NMIBC who have a negative cystoscopy but a positive cytology should be considered suspicious for a recurrence or of hidden disease. Upper tract imaging, ureteroscopy, random bladder biopsies, prostatic urethral biopsies, and photodynamic enhanced cystoscopy (blue light or narrow band imaging) should be considered.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref></p>
        <p>
<bold>AUA NMIBC Cancer Risk Stratification</bold>
<bold>Low risk: </bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Solitary Ta tumor &#x02264;3 cm</p>
          </list-item>
        </list>
        <p><bold>Intermediate risk:</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Solitary Ta tumor &#x0003e;3 cm</p>
          </list-item>
          <list-item>
            <p>Low-grade Ta tumor, which has recurred within 1 year</p>
          </list-item>
          <list-item>
            <p>Low-grade Ta multifocal tumors (at least 2 separate locations)</p>
          </list-item>
          <list-item>
            <p>Low-grade T1 tumor</p>
          </list-item>
          <list-item>
            <p>High-grade Ta tumor &#x02264;3 cm</p>
          </list-item>
        </list>
        <p>
<bold>High risk:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>High-grade Ta tumor that is recurrent, &#x0003e;3 cm, or multifocal</p>
          </list-item>
          <list-item>
            <p>High-grade T1 tumor</p>
          </list-item>
          <list-item>
            <p>Any&#x000a0;CIS</p>
          </list-item>
          <list-item>
            <p>Any BCG failure in a patient with a history of high-grade tumor histology</p>
          </list-item>
          <list-item>
            <p>Prostatic urethral involvement with high-grade histology</p>
          </list-item>
          <list-item>
            <p>Lymphovascular invasion&#x000a0;<xref ref-type="bibr" rid="article-18354.r311">[311]</xref></p>
          </list-item>
          <list-item>
            <p>Any variant histology (extensive squamous or glandular differentiation, micropapillary, neuroendocrine, nested, plasmacytoid, or sarcomatoid changes)&#x000a0;<xref ref-type="bibr" rid="article-18354.r312">[312]</xref></p>
          </list-item>
        </list>
        <p><bold>Follow-up Cystoscopic Surveillance after TURBT Surgery for NMIBC - AUA Guidelines</bold>&#x000a0;</p>
        <p>The first surveillance cystoscopy should be 3 to 4 months after surgery. If negative, follow-up depends on the risk stratification.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref>&#x000a0;</p>
        <p>
<bold>Low-risk cancers</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The next surveillance cystoscopy can be postponed for an additional 6 to 9 months and then performed annually for at least 5 years.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Continued annual surveillance cystoscopies after 5 years without a recurrence is optional and should be decided on a shared decision-making basis with the patient.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cytologies and urinary biomarkers with negative cystoscopies are not recommended for surveillance in low-risk cancers.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Routine surveillance imaging of the upper tracts is unnecessary.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Overall, the 5-year recurrence rate is 30% to 40%.<xref ref-type="bibr" rid="article-18354.r313">[313]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Intermediate-risk cancers</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Surveillance cystoscopy with cytology should be performed every 3 to 6 months for 2 years.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>After 2 years, surveillance cystoscopy with cytology should be repeated every 6 to 12 months for an additional 2 years, and then annually.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Upper tract imaging should be considered every 1 to 2 years.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>The reported recurrence rate for intermediate-risk bladder cancers is 45%.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref><xref ref-type="bibr" rid="article-18354.r314">[314]</xref></p>
          </list-item>
        </list>
        <p>
<bold>High-risk cancers</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Surveillance cystoscopy with cytology should be performed every 3 to 4 months for 2 years.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>After 2 years, surveillance cystoscopy with cytology should be performed every 6 months for an additional 2 years, and then annually.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Some practitioners will add a bladder washing for cytology at every cystoscopy in patients with a history of high-grade cancer or CIS.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Upper tract imaging should be considered every 1 to 2 years.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>One-fifth (20%) of patients with high-grade NMIBC will develop metastases.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Consider early cystectomy in patients with variant histology due to the high rate of tumor upstaging in such cases.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Overall, the 5-year recurrence rate is 60% to 70%, with a 10% to 45% risk of progression to muscle-invasive or metastatic disease.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref><xref ref-type="bibr" rid="article-18354.r313">[313]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Follow-up MIBC Post-Cystectomy: AUA Guidelines&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Imaging of the chest together with an MRI or CT of the abdomen and pelvis should be obtained at 6- to 12-month intervals for 2 to 3 years.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>After the first 2 to 3 years, this may be continued annually.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>If the urethra was not removed, it should be evaluated regularly for possible recurrences.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;
<list list-type="bullet"><list-item><p>Cytology examinations of urethral washings can accomplish this evaluation.<xref ref-type="bibr" rid="article-18354.r315">[315]</xref><xref ref-type="bibr" rid="article-18354.r316">[316]</xref><xref ref-type="bibr" rid="article-18354.r317">[317]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p></list-item><list-item><p>The risk of a urethral recurrence can be as high as 17%.<xref ref-type="bibr" rid="article-18354.r30">[30]</xref><xref ref-type="bibr" rid="article-18354.r318">[318]</xref><xref ref-type="bibr" rid="article-18354.r319">[319]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Follow-up after MIBC Bladder Preservation Therapy: AUA Guidelines&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Surveillance cystoscopy with cytology should be performed every 3 months for the first year.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>After the first year, surveillance cystoscopy with cytology should be done every 4 to 6 months for another year, then every 6 to 12 months.<xref ref-type="bibr" rid="article-18354.r320">[320]</xref><xref ref-type="bibr" rid="article-18354.r321">[321]</xref>&#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Imaging of the chest together with an MRI or CT of the abdomen and pelvis should be obtained at 6-month intervals for 2 years.<xref ref-type="bibr" rid="article-18354.r30">[30]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18354.s16" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Deterrence and patient education are pivotal in managing and preventing bladder cancer. Educating patients about reducing risk factors, such as smoking cessation and minimizing exposure to industrial chemicals, can significantly reduce their overall risk.&#x000a0;Help for&#x000a0;smoking cessation may be found at the American Cancer Society and SmokeFree.gov. Healthcare professionals should emphasize the importance of early symptom recognition, such as noticing blood in the urine and seeking prompt medical attention.&#x000a0;Patients should know&#x000a0;that&#x000a0;painless gross or microscopic hematuria, urinary tract infection symptoms unrelated to infections and unresponsive to antibiotics, or irritative bladder symptoms may be early symptoms of urothelial bladder cancer.</p>
        <p>Regular follow-up and monitoring are crucial for those with a history of bladder cancer due to the high recurrence rate.&#x000a0;Patients who have been diagnosed with NMIBC should be given a clear schedule for their surveillance cystoscopies and strongly encouraged to stop smoking if they haven't already. The National Comprehensive Cancer Network offers a free guideline for patients with bladder cancer at NCCN.org/patientguidelines. Additionally, discussing lifestyle modifications, including maintaining a healthy diet and staying hydrated, can support overall urinary tract health. Empowering patients with knowledge fosters proactive health behaviors, ultimately improving outcomes and quality of life.</p>
      </sec>
      <sec id="article-18354.s17" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Essential clinical pearls for bladder cancer management can enhance clinical practice. These insights aim to provide practical tips and key considerations for diagnosing, treating, and monitoring this prevalent malignancy effectively and include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>A persistently positive FISH test after BCG induction therapy is a poor prognostic indicator.<xref ref-type="bibr" rid="article-18354.r36">[36]</xref>&#x000a0;&#x000a0;&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>FISH and similar urinary biomarkers for borderline or equivocal cases should be considered.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cytology is not recommended for the routine initial evaluation of patients with microscopic hematuria, but it may be used selectively, such as in patients with a significant smoking history.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Enfortumab vedotin and pembrolizumab (EV+P) have replaced cisplatin-based treatments as first-line chemotherapy for advanced or metastatic urothelial (bladder) cancer.<xref ref-type="bibr" rid="article-18354.r297">[297]</xref><xref ref-type="bibr" rid="article-18354.r298">[298]</xref><xref ref-type="bibr" rid="article-18354.r299">[299]</xref></p>
          </list-item>
          <list-item>
            <p>High-volume centers (&#x0003e;20 cases annually) have demonstrated substantially reduced perioperative mortality rates for radical cystectomy surgery.<xref ref-type="bibr" rid="article-18354.r322">[322]</xref></p>
          </list-item>
          <list-item>
            <p>Inflammatory areas on cystoscopic examination of the bladder in patients with known urothelial cancers should be considered suspicious for&#x000a0;CIS&#x000a0;and biopsied.</p>
          </list-item>
          <list-item>
            <p>Intravesical nogapendekin alfa inbakicept plus BCG therapy is now approved for high-risk BCG-unresponsive patients with CIS with or without Ta or T1 disease.<xref ref-type="bibr" rid="article-18354.r220">[220]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Most bladder cancer cases are low-grade and superficial, with minimal health risks if treated promptly and monitored appropriately according to guidelines.</p>
          </list-item>
          <list-item>
            <p>Photodynamic-enhanced cystoscopic diagnostic technology ("blue light") and narrow-band imaging are probably underutilized with TURBT and could substantially improve outcomes.<xref ref-type="bibr" rid="article-18354.r127">[127]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Screening patients who are at high risk for bladder cancer is not recommended, but a routine urinalysis would not be unreasonable, especially in patients who express concern.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Trimodal therapy utilizing maximal TURBT with chemoradiation has shown equivalent survival to radical cystectomy in carefully selected patients.<xref ref-type="bibr" rid="article-18354.r283">[283]</xref><xref ref-type="bibr" rid="article-18354.r284">[284]</xref></p>
          </list-item>
          <list-item>
            <p>When performing a TURBT, the bladder should be filled enough so there are no significant mucosal folds and the surface is relatively flat, but the walls should not be thinned or attenuated.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>When there is doubt about the risk stratification for determining the workup, it is never wrong to go with a CT urogram and cystoscopy. The consequences of a missed bladder cancer far outweigh the negatives of an unnecessary but more comprehensive evaluation.&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18354.s18" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Bladder cancer is a prevalent disease in the United States and around the world, with substantial morbidity and mortality that requires interprofessional medical and surgical management. Patients with high-risk factors such as a family history of urothelial cancer, prolonged chemical exposure, and smoking &#x0003e;10-pack-years should be routinely screened with periodic urinalyses to identify any unexplained microhematuria that might be an early warning sign of bladder cancer.</p>
        <p>The interprofessional team includes primary care clinicians, urologists, radiologists, radiation oncologists, medical oncologists, intensive care unit specialists, hospitalists, anesthesiologists, pharmacologists, physical therapists, laboratory technicians, a cancer coordinator, specialty-trained nurses, such as stomal therapists and other healthcare professionals. Nurses assist in patient and family education, patient monitoring, and reporting significant clinical issues to the healthcare team.&#x000a0;Nurses also arrange close follow-ups when needed.</p>
        <p>Effective interprofessional communication fosters a collaborative environment where information is shared, questions are encouraged, and concerns are addressed promptly. Care coordination is critical to ensuring seamless and efficient patient care and optimizing outcomes.&#x000a0;The interprofessional team must work together to streamline the patient's journey, from diagnosis through treatment and follow-up. This coordination minimizes errors, reduces delays, and enhances patient safety, ultimately leading to improved outcomes and patient-centered care that prioritizes the well-being and satisfaction of those affected by bladder cancer and their families.</p>
      </sec>
      <sec id="article-18354.s19">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18354&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18354">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/bladder-cancer/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=18354">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18354/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18354">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-18354.s20">
        <fig id="article-18354.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Bladder Cancer, Magnetic Resonance Image. The arrow points to cancer cells growing on the lateral side of the bladder. Contributed by&#x000a0;S Bhimji, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bladderca" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-18354.s21">
        <fig id="article-18354.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Urothelial Carcinoma In Situ. Urothelial carcinoma in situ in the setting of cystitis cystica glandularis. CoRus13, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://commons.wikimedia.org/w/index.php?search=+Urothelial+Carcinoma+in+situ+CoRus13&#x00026;title=Special:MediaSearch&#x00026;go=Go&#x00026;type=image">Public Domain</ext-link>, via&#x000a0;Wikimedia Commons</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="1280px-Cystitis_cystica_et_glandularis_with_urothelial_carcinoma_in_situx_intermed._mag.3" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-18354.s22">
        <fig id="article-18354.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Poorly Differentiated Urothelial Carcinoma With Metaplastic Squamous Appearance. 10&#x000d7; H/E. Contributed by F Farci, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="urothelial__ca08" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-18354.s23">
        <fig id="article-18354.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Urothelial Carcinoma, Perineural Invasion. 10&#x000d7; H/E. Contributed by F Farci, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="urothelial__ca05" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-18354.s24">
        <fig id="article-18354.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Urothelial Carcinoma, Prostatic Infiltration. 10&#x000d7; H/E. Contributed by F Farci, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="urothelial__ca07" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-18354.s25">
        <title>References</title>
        <ref id="article-18354.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matulewicz</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Non-muscle-invasive Bladder Cancer: Overview and Contemporary Treatment Landscape of Neoadjuvant Chemoablative Therapies.</article-title>
            <source>Rev Urol</source>
            <year>2020</year>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>43</fpage>
            <page-range>43-51</page-range>
            <pub-id pub-id-type="pmid">32760227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Humphrey</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Moch</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cubilla</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Ulbright</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Reuter</surname>
                <given-names>VE</given-names>
              </name>
            </person-group>
            <article-title>The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours.</article-title>
            <source>Eur Urol</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>70</volume>
            <issue>1</issue>
            <fpage>106</fpage>
            <page-range>106-119</page-range>
            <pub-id pub-id-type="pmid">26996659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Linn</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Sesterhenn</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mostofi</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Schoenberg</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The molecular characteristics of bladder cancer in young patients.</article-title>
            <source>J Urol</source>
            <year>1998</year>
            <month>May</month>
            <volume>159</volume>
            <issue>5</issue>
            <fpage>1493</fpage>
            <page-range>1493-6</page-range>
            <pub-id pub-id-type="pmid">9554340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindskrog</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Prip</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lamy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Taber</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Groeneveld</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Birkenkamp-Demtr&#x000f6;der</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Strandgaard</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nordentoft</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sokac</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Birkbak</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Maretty</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hermann</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Weyerer</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Grimm</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Horstmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sj&#x000f6;dahl</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>H&#x000f6;glund</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Steiniche</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mogensen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>de Reyni&#x000e8;s</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nawroth</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Dragicevic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Goel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hurst</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Raman</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Warrick</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Segersten</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Sikic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>van Kessel</surname>
                <given-names>KEM</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Meeks</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>DeGraff</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Bryan</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Knowles</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Simic</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zwarthoff</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Malmstr&#x000f6;m</surname>
                <given-names>PU</given-names>
              </name>
              <name>
                <surname>Malats</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Real</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Dyrskj&#x000f8;t</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer.</article-title>
            <source>Nat Commun</source>
            <year>2021</year>
            <month>Apr</month>
            <day>16</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>2301</fpage>
            <pub-id pub-id-type="pmid">33863885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hinotsu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Akaza</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Miki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fujimoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shinohara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kikuchi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mizutani</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Koga</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Okajima</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Okuyama</surname>
                <given-names>A</given-names>
              </name>
              <collab>Japanese Urological Association</collab>
            </person-group>
            <article-title>Bladder cancer develops 6 years earlier in current smokers: analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association.</article-title>
            <source>Int J Urol</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>64</fpage>
            <page-range>64-9</page-range>
            <pub-id pub-id-type="pmid">19054170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pelucchi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bosetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Negri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Malvezzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>La Vecchia</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of disease: The epidemiology of bladder cancer.</article-title>
            <source>Nat Clin Pract Urol</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>3</volume>
            <issue>6</issue>
            <fpage>327</fpage>
            <page-range>327-40</page-range>
            <pub-id pub-id-type="pmid">16763645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freedman</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Hollenbeck</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Schatzkin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abnet</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Association between smoking and risk of bladder cancer among men and women.</article-title>
            <source>JAMA</source>
            <year>2011</year>
            <month>Aug</month>
            <day>17</day>
            <volume>306</volume>
            <issue>7</issue>
            <fpage>737</fpage>
            <page-range>737-45</page-range>
            <pub-id pub-id-type="pmid">21846855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Osch</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Jochems</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>van Schooten</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Bryan</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Zeegers</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies.</article-title>
            <source>Int J Epidemiol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>857</fpage>
            <page-range>857-70</page-range>
            <pub-id pub-id-type="pmid">27097748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masaoka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Matsuo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wakai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nagata</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nakayama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sadakane</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tamakoshi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sugawara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mizoue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sawada</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tsugane</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sasazuki</surname>
                <given-names>S</given-names>
              </name>
              <collab>Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan</collab>
            </person-group>
            <article-title>Cigarette smoking and bladder cancer risk: an evaluation based on a systematic review of epidemiologic evidence in the Japanese population.</article-title>
            <source>Jpn J Clin Oncol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>46</volume>
            <issue>3</issue>
            <fpage>273</fpage>
            <page-range>273-83</page-range>
            <pub-id pub-id-type="pmid">26941372</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masaoka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Matsuo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Oze</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tamakoshi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sugawara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tsuji</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sawada</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tsugane</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nagata</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kitamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zha</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sakata</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ozasa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mizoue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cigarette Smoking, Smoking Cessation, and Bladder Cancer Risk: A Pooled Analysis of 10 Cohort Studies in Japan.</article-title>
            <source>J Epidemiol</source>
            <year>2023</year>
            <month>Nov</month>
            <day>05</day>
            <volume>33</volume>
            <issue>11</issue>
            <fpage>582</fpage>
            <page-range>582-588</page-range>
            <pub-id pub-id-type="pmid">36310059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Osch</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Jochems</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>van Schooten</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Bryan</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Zeegers</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Significant Role of Lifetime Cigarette Smoking in Worsening Bladder Cancer and Upper Tract Urothelial Carcinoma Prognosis: A Meta-Analysis.</article-title>
            <source>J Urol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>195</volume>
            <issue>4 Pt 1</issue>
            <fpage>872</fpage>
            <page-range>872-9</page-range>
            <pub-id pub-id-type="pmid">26523878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brennan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bogillot</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Cordier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Greiser</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schill</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Vineis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lopez-Abente</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tzonou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chang-Claude</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bolm-Audorff</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>J&#x000f6;ckel</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Donato</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Serra</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wahrendorf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hours</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>T'Mannetje</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kogevinas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boffetta</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies.</article-title>
            <source>Int J Cancer</source>
            <year>2000</year>
            <month>Apr</month>
            <day>15</day>
            <volume>86</volume>
            <issue>2</issue>
            <fpage>289</fpage>
            <page-range>289-94</page-range>
            <pub-id pub-id-type="pmid">10738259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alfred Witjes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Max Bruins</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Carri&#x000f3;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cathomas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Comp&#x000e9;rat</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Efstathiou</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Fietkau</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gakis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lorch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mertens</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Meijer</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Milowsky</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Neuzillet</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Panebianco</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Redlef</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rink</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rouanne</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thalmann</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>S&#x000e6;bj&#x000f8;rnsen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Veskim&#x000e4;e</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>van der Heijden</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines.</article-title>
            <source>Eur Urol</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>85</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-31</page-range>
            <pub-id pub-id-type="pmid">37858453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leiser</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>O'Neil</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lowrance</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Kohlmann</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pathak</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Hanson</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2018</year>
            <month>May</month>
            <day>01</day>
            <volume>110</volume>
            <issue>5</issue>
            <fpage>527</fpage>
            <page-range>527-533</page-range>
            <pub-id pub-id-type="pmid">29228305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Figueroa</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Siddiq</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garcia-Closas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chatterjee</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Prokunina-Olsson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cortessis</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Kooperberg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cussenot</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Benhamou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prescott</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Porru</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dinney</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Malats</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Baris</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Purdue</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Albanes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bas Bueno-de-Mesquita</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Trichopoulos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ljungberg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Clavel-Chapelon</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Weiderpass</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Krogh</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dorronsoro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Travis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tj&#x000f8;nneland</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brenan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chang-Claude</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Riboli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Conti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gago-Dominguez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Pike</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Van Den Berg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hohensee</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rodabough</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cancel-Tassin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Roupret</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Comperat</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>De Vivo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Giovannucci</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Kraft</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lindstrom</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pavanello</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arici</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mastrangelo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kamat</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lerner</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Barton Grossman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hutchinson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burdette</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kogevinas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tard&#x000f3;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Serra</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Carrato</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Closas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lloreta</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schwenn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Karagas</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schned</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Armenti</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Hosain</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Andriole</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Grubb</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ryan Diver</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gapstur</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Virtamo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Haiman</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Landi</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Caporaso</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fraumeni</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Vineis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Chanock</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rothman</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Genome-wide association study identifies multiple loci associated with bladder cancer risk.</article-title>
            <source>Hum Mol Genet</source>
            <year>2014</year>
            <month>Mar</month>
            <day>01</day>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>1387</fpage>
            <page-range>1387-98</page-range>
            <pub-id pub-id-type="pmid">24163127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rothman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Garcia-Closas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chatterjee</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Malats</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Figueroa</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Real</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Van Den Berg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Matullo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Baris</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Thun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kiemeney</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Vineis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>De Vivo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Albanes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Purdue</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Rafnar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hildebrandt</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kiltie</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Cussenot</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Golka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Mayordomo</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Kogevinas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hutchinson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Prokunina-Olsson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Burdett</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yeager</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Tard&#x000f3;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Serra</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Carrato</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Closas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lloreta</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schwenn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Karagas</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Schned</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Andriole</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Grubb</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Diver</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Gapstur</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Virtamo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cortessis</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Gago-Dominguez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pike</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>McGrath</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dinney</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Czerniak</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Vermeulen</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Aben</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Witjes</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Makkinje</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Sulem</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Besenbacher</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stefansson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Riboli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Panico</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Bueno-de-Mesquita</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Trichopoulos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Caporaso</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Landi</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Canzian</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ljungberg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tjonneland</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Clavel-Chapelon</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bishop</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Teo</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Knowles</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Guarrera</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Polidoro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ricceri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sacerdote</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Allione</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cancel-Tassin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Selinski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hengstler</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Dietrich</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fletcher</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rudnai</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gurzau</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Koppova</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bolick</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Godfrey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Sanz-Velez</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>D Garc&#x000ed;a-Prats</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sanchez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Valdivia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Porru</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Benhamou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hoover</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Fraumeni</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Chanock</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci.</article-title>
            <source>Nat Genet</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>42</volume>
            <issue>11</issue>
            <fpage>978</fpage>
            <page-range>978-84</page-range>
            <pub-id pub-id-type="pmid">20972438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiemeney</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Thorlacius</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sulem</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Geller</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Aben</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Stacey</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Gudmundsson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jakobsdottir</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bergthorsson</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Sigurdsson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blondal</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Witjes</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Vermeulen</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Hulsbergen-van de Kaa</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Swinkels</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Ploeg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cornel</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Vergunst</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Thorgeirsson</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Gudbjartsson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gudjonsson</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Thorleifsson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kristinsson</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Mouy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Snorradottir</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Placidi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Campagna</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arici</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Koppova</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gurzau</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rudnai</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kellen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Polidoro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guarrera</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sacerdote</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sanchez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Valdivia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ryk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>de Verdier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lindblom</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Golka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bishop</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Knowles</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Nikulasson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Petursdottir</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jonsson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Geirsson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kristjansson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mayordomo</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Steineck</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Porru</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Buntinx</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zeegers</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Fletcher</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Matullo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vineis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kiltie</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Gulcher</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Thorsteinsdottir</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rafnar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stefansson</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Sequence variant on 8q24 confers susceptibility to urinary bladder cancer.</article-title>
            <source>Nat Genet</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>40</volume>
            <issue>11</issue>
            <fpage>1307</fpage>
            <page-range>1307-12</page-range>
            <pub-id pub-id-type="pmid">18794855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Zalabani</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Wesselius</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schols</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Zeegers</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Modifiable risk factors for the prevention of bladder cancer: a systematic review of meta-analyses.</article-title>
            <source>Eur J Epidemiol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>31</volume>
            <issue>9</issue>
            <fpage>811</fpage>
            <page-range>811-51</page-range>
            <pub-id pub-id-type="pmid">27000312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cumberbatch</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Rota</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Catto</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>La Vecchia</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks.</article-title>
            <source>Eur Urol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>70</volume>
            <issue>3</issue>
            <fpage>458</fpage>
            <page-range>458-66</page-range>
            <pub-id pub-id-type="pmid">26149669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeegers</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Swaen</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Kant</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Goldbohm</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>van den Brandt</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Occupational risk factors for male bladder cancer: results from a population based case cohort study in the Netherlands.</article-title>
            <source>Occup Environ Med</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>58</volume>
            <issue>9</issue>
            <fpage>590</fpage>
            <page-range>590-6</page-range>
            <pub-id pub-id-type="pmid">11511746</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ames</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Kammen</surname>
                <given-names>HO</given-names>
              </name>
              <name>
                <surname>Yamasaki</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Hair dyes are mutagenic: identification of a variety of mutagenic ingredients.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>1975</year>
            <month>Jun</month>
            <volume>72</volume>
            <issue>6</issue>
            <fpage>2423</fpage>
            <page-range>2423-7</page-range>
            <pub-id pub-id-type="pmid">1094469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaertner</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Trpeski</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>KC</given-names>
              </name>
              <collab>Canadian Cancer Registries Epidemiology Research Group</collab>
            </person-group>
            <article-title>A case-control study of occupational risk factors for bladder cancer in Canada.</article-title>
            <source>Cancer Causes Control</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>10</issue>
            <fpage>1007</fpage>
            <page-range>1007-19</page-range>
            <pub-id pub-id-type="pmid">15801485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cassidy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Risk of urinary bladder cancer: a case-control analysis of industry and occupation.</article-title>
            <source>BMC Cancer</source>
            <year>2009</year>
            <month>Dec</month>
            <day>15</day>
            <volume>9</volume>
            <fpage>443</fpage>
            <pub-id pub-id-type="pmid">20003537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ploeg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aben</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Kiemeney</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>The present and future burden of urinary bladder cancer in the world.</article-title>
            <source>World J Urol</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>289</fpage>
            <page-range>289-93</page-range>
            <pub-id pub-id-type="pmid">19219610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Na</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>The impact of female gender on bladder cancer-specific death risk after radical cystectomy: a meta-analysis of 27,912 patients.</article-title>
            <source>Int Urol Nephrol</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>47</volume>
            <issue>6</issue>
            <fpage>951</fpage>
            <page-range>951-8</page-range>
            <pub-id pub-id-type="pmid">25894962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uhlig</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Seif Amir Hosseini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lotz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Trojan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schmid</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Uhlig</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Gender Specific Differences in Disease-Free, Cancer Specific and Overall Survival after Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis.</article-title>
            <source>J Urol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>200</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-60</page-range>
            <pub-id pub-id-type="pmid">29477716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Toren</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wilkins</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Burley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gris</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kockelbergh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lodhi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Choudhury</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bryan</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>The sex gap in bladder cancer survival - a missing link in bladder cancer care?</article-title>
            <source>Nat Rev Urol</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>181</fpage>
            <page-range>181-192</page-range>
            <pub-id pub-id-type="pmid">37604983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patafio</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Robert Siemens</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Booth</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Is there a gender effect in bladder cancer? A population-based study of practice and outcomes.</article-title>
            <source>Can Urol Assoc J</source>
            <year>2015</year>
            <season>Jul-Aug</season>
            <volume>9</volume>
            <issue>7-8</issue>
            <fpage>269</fpage>
            <page-range>269-74</page-range>
            <pub-id pub-id-type="pmid">26316913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohn</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Vekhter</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lyttle</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Large</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claims-based investigation.</article-title>
            <source>Cancer</source>
            <year>2014</year>
            <month>Feb</month>
            <day>15</day>
            <volume>120</volume>
            <issue>4</issue>
            <fpage>555</fpage>
            <page-range>555-61</page-range>
            <pub-id pub-id-type="pmid">24496869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Bochner</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dreicer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kamat</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lerner</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Meeks</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Michalski</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Quale</surname>
                <given-names>DZ</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Zietman</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Holzbeierlein</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.</article-title>
            <source>J Urol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>198</volume>
            <issue>3</issue>
            <fpage>552</fpage>
            <page-range>552-559</page-range>
            <pub-id pub-id-type="pmid">28456635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Catto</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Dalbagni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Herr</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Karakiewicz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kassouf</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kiemeney</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>La Vecchia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shariat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and risk factors of urothelial bladder cancer.</article-title>
            <source>Eur Urol</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>63</volume>
            <issue>2</issue>
            <fpage>234</fpage>
            <page-range>234-41</page-range>
            <pub-id pub-id-type="pmid">22877502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stephenson</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Kolka</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Acetylcholinesterase inhibitor, pyridostigmine bromide, reduces skin blood flow in humans.</article-title>
            <source>Am J Physiol</source>
            <year>1990</year>
            <month>Apr</month>
            <volume>258</volume>
            <issue>4 Pt 2</issue>
            <fpage>R951</fpage>
            <page-range>R951-7</page-range>
            <pub-id pub-id-type="pmid">2184685</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abern</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Dude</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Tsivian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coogan</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>The characteristics of bladder cancer after radiotherapy for prostate cancer.</article-title>
            <source>Urol Oncol</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>31</volume>
            <issue>8</issue>
            <fpage>1628</fpage>
            <page-range>1628-34</page-range>
            <pub-id pub-id-type="pmid">22575239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rumgay</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ni</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040.</article-title>
            <source>J Glob Health</source>
            <year>2023</year>
            <month>Sep</month>
            <day>15</day>
            <volume>13</volume>
            <fpage>04109</fpage>
            <pub-id pub-id-type="pmid">37712386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Identifying non-muscle-invasive and muscle-invasive bladder cancer based on blood serum surface-enhanced Raman spectroscopy.</article-title>
            <source>Biomed Opt Express</source>
            <year>2019</year>
            <month>Jul</month>
            <day>01</day>
            <volume>10</volume>
            <issue>7</issue>
            <fpage>3533</fpage>
            <page-range>3533-3544</page-range>
            <pub-id pub-id-type="pmid">31467792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holzbeierlein</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bixler</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Kirkby</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McKiernan</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Schuckman</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment.</article-title>
            <source>J Urol</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>211</volume>
            <issue>4</issue>
            <fpage>533</fpage>
            <page-range>533-538</page-range>
            <pub-id pub-id-type="pmid">38265030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kirkali</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Manoharan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Algaba</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Busch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kiemeney</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kriegmair</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Montironi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Sesterhenn</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Tachibana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weider</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Bladder cancer: epidemiology, staging and grading, and diagnosis.</article-title>
            <source>Urology</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>66</volume>
            <issue>6 Suppl 1</issue>
            <fpage>4</fpage>
            <page-range>4-34</page-range>
            <pub-id pub-id-type="pmid">16399414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tang</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Management of carcinoma in situ of the bladder: best practice and recent developments.</article-title>
            <source>Ther Adv Urol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>6</issue>
            <fpage>351</fpage>
            <page-range>351-64</page-range>
            <pub-id pub-id-type="pmid">26622320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Straten</surname>
                <given-names>CGJI</given-names>
              </name>
              <name>
                <surname>Bruins</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dijkstra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cornel</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Kortleve</surname>
                <given-names>MDH</given-names>
              </name>
              <name>
                <surname>de Vocht</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Kiemeney</surname>
                <given-names>LALM</given-names>
              </name>
              <name>
                <surname>van der Heijden</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>The accuracy of cystoscopy in predicting muscle invasion in newly diagnosed bladder cancer patients.</article-title>
            <source>World J Urol</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>41</volume>
            <issue>7</issue>
            <fpage>1829</fpage>
            <page-range>1829-1835</page-range>
            <pub-id pub-id-type="pmid">37195314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harland</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kynaston</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Grigor</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Beacock</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kockelbergh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Clawson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barlow</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Parmar</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>GO</given-names>
              </name>
              <collab>National Cancer Research Institute Bladder Clinical Studies Group</collab>
            </person-group>
            <article-title>A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder.</article-title>
            <source>J Urol</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>178</volume>
            <issue>3 Pt 1</issue>
            <fpage>807</fpage>
            <page-range>807-13; discussion 813</page-range>
            <pub-id pub-id-type="pmid">17631326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Everything you wanted to know about the bladder epithelium but were afraid to ask.</article-title>
            <source>Am J Physiol Renal Physiol</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>278</volume>
            <issue>6</issue>
            <fpage>F867</fpage>
            <page-range>F867-74</page-range>
            <pub-id pub-id-type="pmid">10836974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>MacLennan</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Lopez-Beltran</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Histologic grading of urothelial carcinoma: a reappraisal.</article-title>
            <source>Hum Pathol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>43</volume>
            <issue>12</issue>
            <fpage>2097</fpage>
            <page-range>2097-108</page-range>
            <pub-id pub-id-type="pmid">22542126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nese</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bui</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-57</page-range>
            <pub-id pub-id-type="pmid">19176205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elliott</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Moloney</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>"Denuding cystitis" and in situ urothelial carcinoma.</article-title>
            <source>Arch Pathol</source>
            <year>1973</year>
            <month>Aug</month>
            <volume>96</volume>
            <issue>2</issue>
            <fpage>91</fpage>
            <page-range>91-4</page-range>
            <pub-id pub-id-type="pmid">4718234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gandhi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Al-Ahmadie</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Urothelial Carcinoma: Divergent Differentiation and Morphologic Subtypes.</article-title>
            <source>Surg Pathol Clin</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>641</fpage>
            <page-range>641-659</page-range>
            <pub-id pub-id-type="pmid">36344181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Babjuk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Capoun</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Comp&#x000e9;rat</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kaasinen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Palou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Roupr&#x000ea;t</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Rhijn</surname>
                <given-names>BWG</given-names>
              </name>
              <name>
                <surname>Shariat</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Soukup</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sylvester</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Zigeuner</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.</article-title>
            <source>Eur Urol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>447</fpage>
            <page-range>447-461</page-range>
            <pub-id pub-id-type="pmid">27324428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Babjuk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Capoun</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Comp&#x000e9;rat</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Dominguez Escrig</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Gontero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Liedberg</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Masson-Lecomte</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mostafid</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Palou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van Rhijn</surname>
                <given-names>BWG</given-names>
              </name>
              <name>
                <surname>Roupr&#x000ea;t</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shariat</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Seisen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Soukup</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sylvester</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).</article-title>
            <source>Eur Urol</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>81</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-94</page-range>
            <pub-id pub-id-type="pmid">34511303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Comp&#x000e9;rat</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Berney</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Cree</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Menon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moch</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Netto</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Raspollini</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Srigley</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Tickoo</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Turajlic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tsuzuki</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>What's new in WHO fifth edition&#x02009;-&#x02009;urinary tract.</article-title>
            <source>Histopathology</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>81</volume>
            <issue>4</issue>
            <fpage>439</fpage>
            <page-range>439-446</page-range>
            <pub-id pub-id-type="pmid">35942645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Willis</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Dickstein</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Parikh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Pisters</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Czerniak</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Dinney</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Kamat</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Clinical outcomes of cT1 micropapillary bladder cancer.</article-title>
            <source>J Urol</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>193</volume>
            <issue>4</issue>
            <fpage>1129</fpage>
            <page-range>1129-34</page-range>
            <pub-id pub-id-type="pmid">25254936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saginala</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Barsouk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aluru</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Rawla</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Padala</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Barsouk</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of Bladder Cancer.</article-title>
            <source>Med Sci (Basel)</source>
            <year>2020</year>
            <month>Mar</month>
            <day>13</day>
            <volume>8</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">32183076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reuter</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Hansel</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Non-urothelial carcinomas of the bladder.</article-title>
            <source>Histopathology</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>74</volume>
            <issue>1</issue>
            <fpage>97</fpage>
            <page-range>97-111</page-range>
            <pub-id pub-id-type="pmid">30565306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dahm</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gschwend</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Malignant non-urothelial neoplasms of the urinary bladder: a review.</article-title>
            <source>Eur Urol</source>
            <year>2003</year>
            <month>Dec</month>
            <volume>44</volume>
            <issue>6</issue>
            <fpage>672</fpage>
            <page-range>672-81</page-range>
            <pub-id pub-id-type="pmid">14644119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Larkins</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Pasli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Squamous cell carcinoma of the bladder: Demographics and outcomes associated with surgery and radiotherapy.</article-title>
            <source>J Surg Oncol</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>129</volume>
            <issue>3</issue>
            <fpage>649</fpage>
            <page-range>649-658</page-range>
            <pub-id pub-id-type="pmid">37985369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hussain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vaishampayan</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Redman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer.</article-title>
            <source>J Clin Oncol</source>
            <year>2001</year>
            <month>May</month>
            <day>01</day>
            <volume>19</volume>
            <issue>9</issue>
            <fpage>2527</fpage>
            <page-range>2527-33</page-range>
            <pub-id pub-id-type="pmid">11331332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Hodge</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Abdul-Karim</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Ayala</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Urachal carcinoma.</article-title>
            <source>Urology</source>
            <year>1985</year>
            <month>Sep</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>218</fpage>
            <page-range>218-21</page-range>
            <pub-id pub-id-type="pmid">4035835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kakizoe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Andoh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nishio</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kishi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Adenocarcinoma of urachus. Report of 7 cases and review of literature.</article-title>
            <source>Urology</source>
            <year>1983</year>
            <month>Apr</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>360</fpage>
            <page-range>360-6</page-range>
            <pub-id pub-id-type="pmid">6836822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheldon</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Clayman</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Fraley</surname>
                <given-names>EE</given-names>
              </name>
            </person-group>
            <article-title>Malignant urachal lesions.</article-title>
            <source>J Urol</source>
            <year>1984</year>
            <month>Jan</month>
            <volume>131</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-8</page-range>
            <pub-id pub-id-type="pmid">6361280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ashley</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Inman</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Sebo</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Leibovich</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Blute</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Zincke</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy.</article-title>
            <source>Cancer</source>
            <year>2006</year>
            <month>Aug</month>
            <day>15</day>
            <volume>107</volume>
            <issue>4</issue>
            <fpage>712</fpage>
            <page-range>712-20</page-range>
            <pub-id pub-id-type="pmid">16826585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>CULP</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>THE HISTOLOGY OF THE EXSTROPHIED BLADDER.</article-title>
            <source>J Urol</source>
            <year>1964</year>
            <month>May</month>
            <volume>91</volume>
            <fpage>538</fpage>
            <page-range>538-48</page-range>
            <pub-id pub-id-type="pmid">14154540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Parwani</surname>
                <given-names>AV</given-names>
              </name>
            </person-group>
            <article-title>Adenocarcinoma of the urinary bladder.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>135</volume>
            <issue>12</issue>
            <fpage>1601</fpage>
            <page-range>1601-5</page-range>
            <pub-id pub-id-type="pmid">22129192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hughes</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sohaib</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Imaging features of primary nonurachal adenocarcinoma of the bladder.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>183</volume>
            <issue>5</issue>
            <fpage>1397</fpage>
            <page-range>1397-401</page-range>
            <pub-id pub-id-type="pmid">15505310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xiaoxu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jianhong</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jinfeng</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Klotz</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Bladder adenocarcinoma: 31 reported cases.</article-title>
            <source>Can J Urol</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>1380</fpage>
            <page-range>1380-3</page-range>
            <pub-id pub-id-type="pmid">11718635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>A study of 52 cases of adenocarcinoma of the bladder.</article-title>
            <source>Br J Urol</source>
            <year>1971</year>
            <month>Feb</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-15</page-range>
            <pub-id pub-id-type="pmid">4926456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abenoza</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Manivel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fraley</surname>
                <given-names>EE</given-names>
              </name>
            </person-group>
            <article-title>Primary adenocarcinoma of urinary bladder. Clinicopathologic study of 16 cases.</article-title>
            <source>Urology</source>
            <year>1987</year>
            <month>Jan</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-14</page-range>
            <pub-id pub-id-type="pmid">2432717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderstr&#x000f6;m</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Johansson</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>von Schultz</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Primary adenocarcinoma of the urinary bladder. A clinicopathologic and prognostic study.</article-title>
            <source>Cancer</source>
            <year>1983</year>
            <month>Oct</month>
            <day>01</day>
            <volume>52</volume>
            <issue>7</issue>
            <fpage>1273</fpage>
            <page-range>1273-80</page-range>
            <pub-id pub-id-type="pmid">6883290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wright</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder.</article-title>
            <source>Cancer</source>
            <year>2006</year>
            <month>Aug</month>
            <day>15</day>
            <volume>107</volume>
            <issue>4</issue>
            <fpage>721</fpage>
            <page-range>721-8</page-range>
            <pub-id pub-id-type="pmid">16826584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barocas</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Boorjian</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Alvarez</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Downs</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Kobashi</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Lipman</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Raman</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Smith-Bindman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Souter</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Microhematuria: AUA/SUFU Guideline.</article-title>
            <source>J Urol</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>204</volume>
            <issue>4</issue>
            <fpage>778</fpage>
            <page-range>778-786</page-range>
            <pub-id pub-id-type="pmid">32698717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khadra</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Pickard</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Charlton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Neal</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice.</article-title>
            <source>J Urol</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>163</volume>
            <issue>2</issue>
            <fpage>524</fpage>
            <page-range>524-7</page-range>
            <pub-id pub-id-type="pmid">10647670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeong</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Byun</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>No increase in risk of microscopic hematuria with aspirin use by asymptomatic healthy people.</article-title>
            <source>JAMA Intern Med</source>
            <year>2013</year>
            <month>Jun</month>
            <day>24</day>
            <volume>173</volume>
            <issue>12</issue>
            <fpage>1145</fpage>
            <page-range>1145-6</page-range>
            <pub-id pub-id-type="pmid">23609065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Culclasure</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Bray</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Hasbargen</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>The significance of hematuria in the anticoagulated patient.</article-title>
            <source>Arch Intern Med</source>
            <year>1994</year>
            <month>Mar</month>
            <day>28</day>
            <volume>154</volume>
            <issue>6</issue>
            <fpage>649</fpage>
            <page-range>649-52</page-range>
            <pub-id pub-id-type="pmid">8129498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Sarpong</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Khetrapal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rodney</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mostafid</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cresswell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rane</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cherian</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brew-Graves</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Feber</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>JD</given-names>
              </name>
              <collab>DETECT I Trial Collaborators</collab>
            </person-group>
            <article-title>Can Renal and Bladder Ultrasound Replace Computerized Tomography Urogram in Patients Investigated for Microscopic Hematuria?</article-title>
            <source>J Urol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>200</volume>
            <issue>5</issue>
            <fpage>973</fpage>
            <page-range>973-980</page-range>
            <pub-id pub-id-type="pmid">29702097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gharibvand</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Kazemi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Motamedfar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sametzadeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sahraeizadeh</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The role of ultrasound in diagnosis and evaluation of bladder tumors.</article-title>
            <source>J Family Med Prim Care</source>
            <year>2017</year>
            <season>Oct-Dec</season>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>840</fpage>
            <page-range>840-843</page-range>
            <pub-id pub-id-type="pmid">29564274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trinh</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Glazer</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Sadow</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Sahni</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Geller</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Bladder cancer diagnosis with CT urography: test characteristics and reasons for false-positive and false-negative results.</article-title>
            <source>Abdom Radiol (NY)</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>663</fpage>
            <page-range>663-671</page-range>
            <pub-id pub-id-type="pmid">28677000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Rubio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Huguet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Segarra</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ribal</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Alcaraz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Villavicencio</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor.</article-title>
            <source>J Urol</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>174</volume>
            <issue>3</issue>
            <fpage>859</fpage>
            <page-range>859-61; discussion 861</page-range>
            <pub-id pub-id-type="pmid">16093970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>The Diagnostic Value of MR Imaging in Differentiating T Staging of Bladder Cancer: A Meta-Analysis.</article-title>
            <source>Radiology</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>286</volume>
            <issue>2</issue>
            <fpage>502</fpage>
            <page-range>502-511</page-range>
            <pub-id pub-id-type="pmid">29206594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajesh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sokhi</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Fung</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mulcahy</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Bankart</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Bladder cancer: evaluation of staging accuracy using dynamic MRI.</article-title>
            <source>Clin Radiol</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>66</volume>
            <issue>12</issue>
            <fpage>1140</fpage>
            <page-range>1140-5</page-range>
            <pub-id pub-id-type="pmid">21924408</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mallampati</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Siegelman</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>MR imaging of the bladder.</article-title>
            <source>Magn Reson Imaging Clin N Am</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>545</fpage>
            <page-range>545-55, vii</page-range>
            <pub-id pub-id-type="pmid">15271370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yun</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Differentiation of Muscular Invasion in Bladder Cancer: Additional Value of Synthetic Magnetic Resonance Imaging.</article-title>
            <source>Acad Radiol</source>
            <year>2024</year>
            <month>Mar</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">38548534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhe</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lei</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Prediction of histopathologic grades of bladder cancer with radiomics based on MRI: Comparison with traditional MRI.</article-title>
            <source>Urol Oncol</source>
            <year>2024</year>
            <month>Jun</month>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>176.e9</fpage>
            <page-range>176.e9-176.e20</page-range>
            <pub-id pub-id-type="pmid">38556403</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Enhancing recurrence risk prediction for bladder cancer using multi-sequence MRI radiomics.</article-title>
            <source>Insights Imaging</source>
            <year>2024</year>
            <month>Mar</month>
            <day>25</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>88</fpage>
            <pub-id pub-id-type="pmid">38526620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barentsz</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Engelbrecht</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Witjes</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>de la Rosette</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>van der Graaf</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>MR imaging of the male pelvis.</article-title>
            <source>Eur Radiol</source>
            <year>1999</year>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>1722</fpage>
            <page-range>1722-36</page-range>
            <pub-id pub-id-type="pmid">10602944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ate&#x0015f;</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Demirel</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Ba&#x0015f;ar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>U&#x000e7;mak</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The Added-value of Staging <sup>18</sup>F-FDG PET/CT in the Prediction of Overall Survival in the Patients with Bladder Cancer.</article-title>
            <source>Mol Imaging Radionucl Ther</source>
            <year>2024</year>
            <month>Feb</month>
            <day>22</day>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-18</page-range>
            <pub-id pub-id-type="pmid">38390706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Longoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scilipoti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Re</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rosiello</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nocera</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pellegrino</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Basile</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>de Angelis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Quarta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Burgio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Necchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cigliola</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chiti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Picchio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salonia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Briganti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Montorsi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Moschini</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Use of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients.</article-title>
            <source>BJU Int</source>
            <year>2024</year>
            <month>Oct</month>
            <volume>134</volume>
            <issue>4</issue>
            <fpage>636</fpage>
            <page-range>636-643</page-range>
            <pub-id pub-id-type="pmid">38621771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jena</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bhargava</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tripathi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Taywade</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yadav</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Navriya</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Bhirud</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Aggarwal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Choudhary</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>18F-fluoro-2-deoxy-2-d-glucose PET-CT (FDG PET-CT) in staging of high-risk renal and urothelial bladder cancers (COPPER-T) trial protocol.</article-title>
            <source>BJUI Compass</source>
            <year>2023</year>
            <month>Nov</month>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>662</fpage>
            <page-range>662-667</page-range>
            <pub-id pub-id-type="pmid">37818027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bacchiani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salamone</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Massaro</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sandulli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mariottini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cadenar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di Maida</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pradere</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mertens</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Longoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krajewski</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Del Giudice</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>D'Andrea</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Laukhtina</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shariat</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Minervini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moschini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>On Behalf Of European Association Of Urology-Young Academic Urologists Eau-Yau Urothelial Carcinoma Working Group</surname>
              </name>
            </person-group>
            <article-title>Assessing the Performance of 18F-FDG PET/CT in Bladder Cancer: A Narrative Review of Current Evidence.</article-title>
            <source>Cancers (Basel)</source>
            <year>2023</year>
            <month>May</month>
            <day>28</day>
            <volume>15</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">37296913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marandino</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Capozza</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bandini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Raggi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Far&#x000e8;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pederzoli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gallina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Capitanio</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Bianchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gandaglia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fossati</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Colecchia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Giannatempo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Serafini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Padovano</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Salonia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Briganti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Montorsi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Alessi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Necchi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab.</article-title>
            <source>Urol Oncol</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>235.e15</fpage>
            <page-range>235.e15-235.e21</page-range>
            <pub-id pub-id-type="pmid">33071107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vind-Kezunovic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bouchelouche</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ipsen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>H&#x000f8;yer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bjerggaard Jensen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Detection of Lymph Node Metastasis in Patients with Bladder Cancer using Maximum Standardised Uptake Value and <sup>18</sup>F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Results from a High-volume Centre Including Long-term Follow-up.</article-title>
            <source>Eur Urol Focus</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>90</fpage>
            <page-range>90-96</page-range>
            <pub-id pub-id-type="pmid">28753817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mertens</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Meijer</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Alfred Witjes</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Positron Emission Tomography/Computed Tomography for Staging of Bladder Cancer: A Continuing Clinical Controversy.</article-title>
            <source>Eur Urol</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>83</volume>
            <issue>2</issue>
            <fpage>95</fpage>
            <page-range>95-96</page-range>
            <pub-id pub-id-type="pmid">36202686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ha</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Koo</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic Accuracy of F-18 FDG PET/CT for Preoperative Lymph Node Staging in Newly Diagnosed Bladder Cancer Patients: A Systematic Review and Meta-Analysis.</article-title>
            <source>Oncology</source>
            <year>2018</year>
            <volume>95</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-38</page-range>
            <pub-id pub-id-type="pmid">29847834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Einerhand</surname>
                <given-names>SMH</given-names>
              </name>
              <name>
                <surname>van Gennep</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Mertens</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Hendricksen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Donswijk</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>van der Poel</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>van Rhijn</surname>
                <given-names>BWG</given-names>
              </name>
            </person-group>
            <article-title>18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in muscle-invasive bladder cancer.</article-title>
            <source>Curr Opin Urol</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>654</fpage>
            <page-range>654-664</page-range>
            <pub-id pub-id-type="pmid">32701719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blick</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Nazir</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Mallett</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Turney</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Onwu</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Crew</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Cowan</surname>
                <given-names>NC</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.</article-title>
            <source>BJU Int</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>110</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <page-range>84-94</page-range>
            <pub-id pub-id-type="pmid">22122739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guldhammer</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>V&#x000e1;squez</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kristensen</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Norus</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nadler</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Azawi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Cystoscopy Accuracy in Detecting Bladder Tumors: A Prospective Video-Confirmed Study.</article-title>
            <source>Cancers (Basel)</source>
            <year>2023</year>
            <month>Dec</month>
            <day>28</day>
            <volume>16</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">38201586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>During</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Sole</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Jha</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bryan</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Prediction of histological stage based on cystoscopic appearances of newly diagnosed bladder tumours.</article-title>
            <source>Ann R Coll Surg Engl</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>98</volume>
            <issue>8</issue>
            <fpage>547</fpage>
            <page-range>547-551</page-range>
            <pub-id pub-id-type="pmid">27502337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohr</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Offord</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Owen</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Melton</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Asymptomatic microhematuria and urologic disease. A population-based study.</article-title>
            <source>JAMA</source>
            <year>1986</year>
            <month>Jul</month>
            <day>11</day>
            <volume>256</volume>
            <issue>2</issue>
            <fpage>224</fpage>
            <page-range>224-9</page-range>
            <pub-id pub-id-type="pmid">3723707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zincke</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Utz</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Farrow</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Review of Mayo Clinic experience with carcinoma in situ.</article-title>
            <source>Urology</source>
            <year>1985</year>
            <month>Oct</month>
            <volume>26</volume>
            <issue>4 Suppl</issue>
            <fpage>39</fpage>
            <page-range>39-46</page-range>
            <pub-id pub-id-type="pmid">3931327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dutta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Abdelhalim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Vernez</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Faltas</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Youssef</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis.</article-title>
            <source>Urol Oncol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>34</volume>
            <issue>12</issue>
            <fpage>531.e1</fpage>
            <page-range>531.e1-531.e6</page-range>
            <pub-id pub-id-type="pmid">27427223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Svatek</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Clinton</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Kamat</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Dinney</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy.</article-title>
            <source>Urology</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>84</volume>
            <issue>5</issue>
            <fpage>1147</fpage>
            <page-range>1147-51</page-range>
            <pub-id pub-id-type="pmid">25174656</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Donat</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Genega</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Herr</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Reuter</surname>
                <given-names>VE</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of prostatic stromal invasion in patients with bladder cancer: clinical significance.</article-title>
            <source>J Urol</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>165</volume>
            <issue>4</issue>
            <fpage>1117</fpage>
            <page-range>1117-20</page-range>
            <pub-id pub-id-type="pmid">11257650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moschini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Soria</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Susani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Korn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Briganti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roupret</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seitz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gust</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Haitel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Montorsi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wirth</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Karakiewicz</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>&#x000d6;zsoy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rink</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shariat</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy.</article-title>
            <source>Bladder Cancer</source>
            <year>2017</year>
            <month>Jul</month>
            <day>27</day>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>161</fpage>
            <page-range>161-169</page-range>
            <pub-id pub-id-type="pmid">28824943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kravchuk</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Wolff</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gilfrich</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wirtz</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Soares</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Brookman-May</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Kollitsch</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hauner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Burchardt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Br&#x000fc;ndl</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Urine-Based Biomarker Test Uromonitor<sup>&#x000ae;</sup> in the Detection and Disease Monitoring of Non-Muscle-Invasive Bladder Cancer-A Systematic Review and Meta-Analysis of Diagnostic Test Performance.</article-title>
            <source>Cancers (Basel)</source>
            <year>2024</year>
            <month>Feb</month>
            <day>11</day>
            <volume>16</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">38398144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r101">
          <label>101</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Azawi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>V&#x000e1;squez</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Dreyer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Guldhammer</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Saber Al-Juboori</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Surveillance of Low-Grade Non-Muscle Invasive Bladder Tumors Using Uromonitor: SOLUSION Trial.</article-title>
            <source>Cancers (Basel)</source>
            <year>2023</year>
            <month>Apr</month>
            <day>17</day>
            <volume>15</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">37190269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r102">
          <label>102</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laukhtina</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shim</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>D'Andrea</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Soria</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rajwa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mostafaei</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Comp&#x000e9;rat</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cimadamore</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moschini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Teoh</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Enikeev</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Xylinas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Palou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gontero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Babjuk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Witjes</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kamat</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Roupret</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shariat</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Pradere</surname>
                <given-names>B</given-names>
              </name>
              <collab>European Association of Urology&#x02013;Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group</collab>
            </person-group>
            <article-title>Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis.</article-title>
            <source>Eur Urol Oncol</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>927</fpage>
            <page-range>927-942</page-range>
            <pub-id pub-id-type="pmid">34753702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r103">
          <label>103</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daneshmand</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pohar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Trabulsi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Downs</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bivalacqua</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>DeCastro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kamat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Resnick</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Konety</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schoenberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>JS</given-names>
              </name>
              <collab>Flexible Blue Light Study Group Collaborators</collab>
            </person-group>
            <article-title>Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study.</article-title>
            <source>J Urol</source>
            <year>2018</year>
            <month>May</month>
            <volume>199</volume>
            <issue>5</issue>
            <fpage>1158</fpage>
            <page-range>1158-1165</page-range>
            <pub-id pub-id-type="pmid">29203268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r104">
          <label>104</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raitanen</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Aine</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rintala</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kallio</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rajala</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Juusela</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tammela</surname>
                <given-names>TL</given-names>
              </name>
              <collab>FinnBladder Group</collab>
            </person-group>
            <article-title>Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis.</article-title>
            <source>Eur Urol</source>
            <year>2002</year>
            <month>Mar</month>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>284</fpage>
            <page-range>284-9</page-range>
            <pub-id pub-id-type="pmid">12180229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r105">
          <label>105</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casey</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Catto</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cookson</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Herr</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shariat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Witjes</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review.</article-title>
            <source>Eur Urol</source>
            <year>2015</year>
            <month>May</month>
            <volume>67</volume>
            <issue>5</issue>
            <fpage>876</fpage>
            <page-range>876-88</page-range>
            <pub-id pub-id-type="pmid">25466937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r106">
          <label>106</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Spiess</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Current and emerging bladder cancer urinary biomarkers.</article-title>
            <source>ScientificWorldJournal</source>
            <year>2011</year>
            <month>May</month>
            <day>26</day>
            <volume>11</volume>
            <fpage>1103</fpage>
            <page-range>1103-12</page-range>
            <pub-id pub-id-type="pmid">21623456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r107">
          <label>107</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flezar</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Urine and bladder washing cytology for detection of urothelial carcinoma: standard test with new possibilities.</article-title>
            <source>Radiol Oncol</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>207</fpage>
            <page-range>207-14</page-range>
            <pub-id pub-id-type="pmid">22933917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r108">
          <label>108</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zein</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wajsman</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Englander</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Gamarra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Huben</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Pontes</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of bladder washings and urine cytology in the diagnosis of bladder cancer and its correlation with selected biopsies of the bladder mucosa.</article-title>
            <source>J Urol</source>
            <year>1984</year>
            <month>Oct</month>
            <volume>132</volume>
            <issue>4</issue>
            <fpage>670</fpage>
            <page-range>670-1</page-range>
            <pub-id pub-id-type="pmid">6471209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r109">
          <label>109</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kili&#x000e7;arslan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>S&#x000fc;ng&#x000fc;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Balci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Canda</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Altinova</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>G&#x000fc;ler</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The role of collecting bladder wash fluid before biopsy procedure to help the cytological diagnosis of residual tumor.</article-title>
            <source>J Cytol</source>
            <year>2015</year>
            <season>Apr-Jun</season>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>85</fpage>
            <page-range>85-9</page-range>
            <pub-id pub-id-type="pmid">26229243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r110">
          <label>110</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bieri</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kranzb&#x000fc;hler</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wettstein</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Fankhauser</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Kaufmann</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Seifert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bode</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Poyet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lenggenhager</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hermanns</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Limited Value of Bladder Wash Cytology During Follow-Up of Patients With Non-muscle Invasive Bladder Cancer.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>e40283</fpage>
            <pub-id pub-id-type="pmid">37448431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r111">
          <label>111</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Qu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Application of fluorescence <italic>in situ</italic> hybridization in the detection of bladder transitional-cell carcinoma: A multi-center clinical study based on Chinese population.</article-title>
            <source>Asian J Urol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>114</fpage>
            <page-range>114-121</page-range>
            <pub-id pub-id-type="pmid">30775255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r112">
          <label>112</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoder</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Skacel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hedgepeth</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Babineau</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ulchaker</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Liou</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Brainard</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Biscotti</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Tubbs</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings.</article-title>
            <source>Am J Clin Pathol</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>127</volume>
            <issue>2</issue>
            <fpage>295</fpage>
            <page-range>295-301</page-range>
            <pub-id pub-id-type="pmid">17210520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r113">
          <label>113</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zheng</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>The Role of Fluorescence In Situ Hybridization in the Surveillance of Non-Muscle Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis.</article-title>
            <source>Diagnostics (Basel)</source>
            <year>2022</year>
            <month>Aug</month>
            <day>19</day>
            <volume>12</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">36010354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r114">
          <label>114</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Fluorescence in situ hybridization (FISH) to predict the efficacy of Bacillus Calmette-Gu&#x000e9;rin perfusion in bladder cancer.</article-title>
            <source>Transl Cancer Res</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>10</issue>
            <fpage>3448</fpage>
            <page-range>3448-3457</page-range>
            <pub-id pub-id-type="pmid">36388029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r115">
          <label>115</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mengual</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mar&#x000ed;n-Aguilera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ribal</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Burset</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Villavicencio</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Oliver</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alcaraz</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Gu&#x000e9;rin therapy.</article-title>
            <source>Eur Urol</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>52</volume>
            <issue>3</issue>
            <fpage>752</fpage>
            <page-range>752-9</page-range>
            <pub-id pub-id-type="pmid">17379395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r116">
          <label>116</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lotan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Inman</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Kassouf</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Messing</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Daneshmand</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Canter</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Marble</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Jewell</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boorjian</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Gu&#x000e9;rin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.</article-title>
            <source>J Urol</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>202</volume>
            <issue>5</issue>
            <fpage>920</fpage>
            <page-range>920-926</page-range>
            <pub-id pub-id-type="pmid">31120373</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r117">
          <label>117</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kamat</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Dickstein</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Messetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pretzsch</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zaidi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Dinney</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Gu&#x000e9;rin therapy for bladder cancer: results of a prospective trial.</article-title>
            <source>J Urol</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>187</volume>
            <issue>3</issue>
            <fpage>862</fpage>
            <page-range>862-7</page-range>
            <pub-id pub-id-type="pmid">22245325</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r118">
          <label>118</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Krishna</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Devana</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Xpert bladder cancer monitor in surveillance of bladder cancer: Systematic review and meta-analysis.</article-title>
            <source>Urol Oncol</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>163.e1</fpage>
            <page-range>163.e1-163.e9</page-range>
            <pub-id pub-id-type="pmid">34535354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r119">
          <label>119</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cancel-Tassin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Roupret</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pinar</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Gaffory</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vanie</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ondet</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Comp&#x000e9;rat</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cussenot</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up.</article-title>
            <source>World J Urol</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>39</volume>
            <issue>9</issue>
            <fpage>3329</fpage>
            <page-range>3329-3335</page-range>
            <pub-id pub-id-type="pmid">33770241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r120">
          <label>120</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smrkolj</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cegovnik Primozic</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Fabjan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sterpin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Osredkar</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The performance of the Xpert Bladder Cancer Monitor Test and voided urinary cytology in the follow-up of urinary bladder tumors.</article-title>
            <source>Radiol Oncol</source>
            <year>2020</year>
            <month>Dec</month>
            <day>29</day>
            <volume>55</volume>
            <issue>2</issue>
            <fpage>196</fpage>
            <page-range>196-202</page-range>
            <pub-id pub-id-type="pmid">33764701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r121">
          <label>121</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valenberg</surname>
                <given-names>FJPV</given-names>
              </name>
              <name>
                <surname>Hiar</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bridge</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Mayne</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Beqaj</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sexton</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Weizer</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Jansz</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Stenzl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Danella</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Cline</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>David</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Bradford</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Wolk</surname>
                <given-names>FN</given-names>
              </name>
              <name>
                <surname>Westenfelder</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Trainer</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Egerdie</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Goldfarb</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zadra</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Higuchi</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Witjes</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria.</article-title>
            <source>Eur Urol Oncol</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>93</fpage>
            <page-range>93-101</page-range>
            <pub-id pub-id-type="pmid">33004290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r122">
          <label>122</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic and therapeutic effects of fluorescence cystoscopy and narrow-band imaging in bladder cancer: a systematic review and network meta-analysis.</article-title>
            <source>Int J Surg</source>
            <year>2023</year>
            <month>Oct</month>
            <day>01</day>
            <volume>109</volume>
            <issue>10</issue>
            <fpage>3169</fpage>
            <page-range>3169-3177</page-range>
            <pub-id pub-id-type="pmid">37526087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r123">
          <label>123</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Russo</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Sholklapper</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Cocci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Broggi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Caltabiano</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Morgia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kamat</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Witjes</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Daneshmand</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Cacciamani</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review and Lesion-Level Diagnostic Meta-Analysis.</article-title>
            <source>Cancers (Basel)</source>
            <year>2021</year>
            <month>Aug</month>
            <day>30</day>
            <volume>13</volume>
            <issue>17</issue>
            <pub-id pub-id-type="pmid">34503188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r124">
          <label>124</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cahill</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Chua</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Doppalapudi</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Ghodoussipour</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The use of blue-light cystoscopy in the detection and surveillance of nonmuscle invasive bladder cancer.</article-title>
            <source>Curr Urol</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>121</fpage>
            <page-range>121-126</page-range>
            <pub-id pub-id-type="pmid">36204358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r125">
          <label>125</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hagimoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Makita</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mine</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kokubun</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Murata</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kubota</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tsutsumi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yamasaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kawakita</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Comparison between 5-aminolevulinic acid photodynamic diagnosis and narrow-band imaging for bladder cancer detection.</article-title>
            <source>BMC Urol</source>
            <year>2021</year>
            <month>Dec</month>
            <day>22</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>180</fpage>
            <pub-id pub-id-type="pmid">34937543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r126">
          <label>126</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fukuhara</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Karashima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kurabayashi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Furihata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT.</article-title>
            <source>Photodiagnosis Photodyn Ther</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>38</volume>
            <fpage>102757</fpage>
            <pub-id pub-id-type="pmid">35151889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r127">
          <label>127</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewicki</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Arenas-Gallo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Venkat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Basourakos</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Scherr</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shoag</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Underutilization of Blue Light Cystoscopy for Bladder Cancer in the United States.</article-title>
            <source>Eur Urol Focus</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>968</fpage>
            <page-range>968-971</page-range>
            <pub-id pub-id-type="pmid">34711530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r128">
          <label>128</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daniltchenko</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Riedl</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Sachs</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Koenig</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Daha</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Pflueger</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Loening</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Schnorr</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study.</article-title>
            <source>J Urol</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>174</volume>
            <issue>6</issue>
            <fpage>2129</fpage>
            <page-range>2129-33, discussion 2133</page-range>
            <pub-id pub-id-type="pmid">16280742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r129">
          <label>129</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Witjes</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Douglass</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer.</article-title>
            <source>Nat Clin Pract Urol</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>4</volume>
            <issue>10</issue>
            <fpage>542</fpage>
            <page-range>542-9</page-range>
            <pub-id pub-id-type="pmid">17921969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r130">
          <label>130</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mowatt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>N'Dow</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vale</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nabi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Boachie</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>TR</given-names>
              </name>
              <collab>Aberdeen Technology Assessment Review (TAR) Group</collab>
            </person-group>
            <article-title>Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis.</article-title>
            <source>Int J Technol Assess Health Care</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-10</page-range>
            <pub-id pub-id-type="pmid">21262078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r131">
          <label>131</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tsuzuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shimamoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shuin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nagao</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Matsuyama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Oyama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Furuse</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ozono</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miyake</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fujimoto</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A multicenter phase III study.</article-title>
            <source>Int J Urol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>25</volume>
            <issue>8</issue>
            <fpage>723</fpage>
            <page-range>723-729</page-range>
            <pub-id pub-id-type="pmid">29999205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r132">
          <label>132</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Dominicis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liberti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perugia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Nunzio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sciobica</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zuccal&#x000e0;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sarkozy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Iori</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Role of 5-aminolevulinic acid in the diagnosis and treatment of superficial bladder cancer: improvement in diagnostic sensitivity.</article-title>
            <source>Urology</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>1059</fpage>
            <page-range>1059-62</page-range>
            <pub-id pub-id-type="pmid">11377304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r133">
          <label>133</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fukuhara</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hagiwara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Oba</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (3rd report): Cost impact of transurethral resection of bladder tumor in Japan.</article-title>
            <source>Photodiagnosis Photodyn Ther</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>44</volume>
            <fpage>103758</fpage>
            <pub-id pub-id-type="pmid">37604217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r134">
          <label>134</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pohar</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Trabulsi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Downs</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bivalacqua</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>DeCastro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kamat</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Resnick</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Konety</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schoenberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Daneshmand</surname>
                <given-names>S</given-names>
              </name>
              <collab>Flexible Blue Light Study Group Collaborators</collab>
            </person-group>
            <article-title>Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study.</article-title>
            <source>Urol Oncol</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>40</volume>
            <issue>8</issue>
            <fpage>382.e1</fpage>
            <page-range>382.e1-382.e6</page-range>
            <pub-id pub-id-type="pmid">35750559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r135">
          <label>135</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daneshmand</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schuckman</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Bochner</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Cookson</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Downs</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Gomella</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Kamat</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Konety</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Pohar</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Pruthi</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Resnick</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Witjes</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Schoenberg</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA.</article-title>
            <source>Nat Rev Urol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>10</issue>
            <fpage>589</fpage>
            <page-range>589-96</page-range>
            <pub-id pub-id-type="pmid">25245244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r136">
          <label>136</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Renninger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fahmy</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Schubert</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schmid</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stenzl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gakis</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The prognostic impact of hexaminolevulinate-based bladder tumor resection in patients with primary non-muscle invasive bladder cancer treated with radical cystectomy.</article-title>
            <source>World J Urol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>397</fpage>
            <page-range>397-406</page-range>
            <pub-id pub-id-type="pmid">31030231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r137">
          <label>137</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pederzoli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Murati Amador</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Samarska</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lombardo</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Kates</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bivalacqua</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Matoso</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of urothelial carcinoma in situ using blue light cystoscopy and the utility of immunohistochemistry in blue light-positive lesions diagnosed as atypical.</article-title>
            <source>Hum Pathol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>90</volume>
            <fpage>1</fpage>
            <page-range>1-7</page-range>
            <pub-id pub-id-type="pmid">31071342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r138">
          <label>138</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ray</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Chatterton</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Chandra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dasgupta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>TS</given-names>
              </name>
            </person-group>
            <article-title>Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Gu&#x000e9;rin.</article-title>
            <source>BJU Int</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>105</volume>
            <issue>6</issue>
            <fpage>789</fpage>
            <page-range>789-94</page-range>
            <pub-id pub-id-type="pmid">19832725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r139">
          <label>139</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Draga</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Grimbergen</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Kok</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Jonges</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>van Swol</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Gu&#x000e9;rin immunotherapy and mitomycin C intravesical therapy.</article-title>
            <source>Eur Urol</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>57</volume>
            <issue>4</issue>
            <fpage>655</fpage>
            <page-range>655-60</page-range>
            <pub-id pub-id-type="pmid">19819064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r140">
          <label>140</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bermoy</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Scarpato</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Luckenbaugh</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Kolouri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bowden</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Enhancing the image quality of blue light cystoscopy through green-hue correction and fogginess removal.</article-title>
            <source>Sci Rep</source>
            <year>2023</year>
            <month>Dec</month>
            <day>06</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>21484</fpage>
            <pub-id pub-id-type="pmid">38057491</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r141">
          <label>141</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naito</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Algaba</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Babjuk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bryan</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Valiquette</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>de la Rosette</surname>
                <given-names>J</given-names>
              </name>
              <collab>CROES Narrow Band Imaging Global Study Group</collab>
            </person-group>
            <article-title>The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted TURBT in Primary Non-Muscle-invasive Bladder Cancer Patients: Trial Protocol and 1-year Results.</article-title>
            <source>Eur Urol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>70</volume>
            <issue>3</issue>
            <fpage>506</fpage>
            <page-range>506-15</page-range>
            <pub-id pub-id-type="pmid">27117749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r142">
          <label>142</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naselli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Introini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Timossi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Spina</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pezzi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Germinale</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bertolotto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Puppo</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence.</article-title>
            <source>Eur Urol</source>
            <year>2012</year>
            <month>May</month>
            <volume>61</volume>
            <issue>5</issue>
            <fpage>908</fpage>
            <page-range>908-13</page-range>
            <pub-id pub-id-type="pmid">22280855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r143">
          <label>143</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ye</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>A comparison of NBI and WLI cystoscopy in detecting non-muscle-invasive bladder cancer: A prospective, randomized and multi-center study.</article-title>
            <source>Sci Rep</source>
            <year>2015</year>
            <month>Jun</month>
            <day>05</day>
            <volume>5</volume>
            <fpage>10905</fpage>
            <pub-id pub-id-type="pmid">26046790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r144">
          <label>144</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Foss&#x000e5;</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Ous</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Berner</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinical significance of the "palpable mass" in patients with muscle-infiltrating bladder cancer undergoing cystectomy after pre-operative radiotherapy.</article-title>
            <source>Br J Urol</source>
            <year>1991</year>
            <month>Jan</month>
            <volume>67</volume>
            <issue>1</issue>
            <fpage>54</fpage>
            <page-range>54-60</page-range>
            <pub-id pub-id-type="pmid">1993277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r145">
          <label>145</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wijkstr&#x000f6;m</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Norming</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Lagerkvist</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>N&#x000e4;slund</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wiklund</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma: a long-term follow-up of 276 consecutive patients.</article-title>
            <source>Br J Urol</source>
            <year>1998</year>
            <month>May</month>
            <volume>81</volume>
            <issue>5</issue>
            <fpage>686</fpage>
            <page-range>686-91</page-range>
            <pub-id pub-id-type="pmid">9634042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r146">
          <label>146</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varinot</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Camparo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Roupret</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bitker</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Capron</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cussenot</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Witjes</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Comp&#x000e9;rat</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Full analysis of the prostatic urethra at the time of radical cystoprostatectomy for bladder cancer: impact on final disease stage.</article-title>
            <source>Virchows Arch</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>455</volume>
            <issue>5</issue>
            <fpage>449</fpage>
            <page-range>449-53</page-range>
            <pub-id pub-id-type="pmid">19841937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r147">
          <label>147</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tabibi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Simforoosh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Parvin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abdi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Javaherforooshzadeh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Farrokhi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Soltani</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Predictive factors for prostatic involvement by transitional cell carcinoma of the bladder.</article-title>
            <source>Urol J</source>
            <year>2011</year>
            <season>Winter</season>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-7</page-range>
            <pub-id pub-id-type="pmid">21404202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r148">
          <label>148</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mazzucchelli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Barbisan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Santinelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scarpelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Galosi</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Lopez-Beltran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kirkali</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Montironi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Prediction of prostatic involvement by urothelial carcinoma in radical cystoprostatectomy for bladder cancer.</article-title>
            <source>Urology</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>74</volume>
            <issue>2</issue>
            <fpage>385</fpage>
            <page-range>385-90</page-range>
            <pub-id pub-id-type="pmid">19501882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r149">
          <label>149</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pettus</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Al-Ahmadie</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Barocas</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Koppie</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Herr</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Donat</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Dalbagni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Reuter</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Olgac</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bochner</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy.</article-title>
            <source>Eur Urol</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>53</volume>
            <issue>2</issue>
            <fpage>370</fpage>
            <page-range>370-5</page-range>
            <pub-id pub-id-type="pmid">17689003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r150">
          <label>150</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kirkali</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Canda</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Superficial urothelial cancer in the prostatic urethra.</article-title>
            <source>ScientificWorldJournal</source>
            <year>2006</year>
            <month>Feb</month>
            <day>28</day>
            <volume>6</volume>
            <fpage>2603</fpage>
            <page-range>2603-10</page-range>
            <pub-id pub-id-type="pmid">17619737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r151">
          <label>151</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weiner</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Meeks</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Tumor Location May Predict Adverse Pathology and Survival Following Definitive Treatment for Bladder Cancer: A National Cohort Study.</article-title>
            <source>Eur Urol Oncol</source>
            <year>2019</year>
            <month>May</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>304</fpage>
            <page-range>304-310</page-range>
            <pub-id pub-id-type="pmid">31200845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r152">
          <label>152</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matzkin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Soloway</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Hardeman</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Transitional cell carcinoma of the prostate.</article-title>
            <source>J Urol</source>
            <year>1991</year>
            <month>Nov</month>
            <volume>146</volume>
            <issue>5</issue>
            <fpage>1207</fpage>
            <page-range>1207-12</page-range>
            <pub-id pub-id-type="pmid">1942262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r153">
          <label>153</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mungan</surname>
                <given-names>MU</given-names>
              </name>
              <name>
                <surname>Canda</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Tuzel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yorukoglu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kirkali</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder.</article-title>
            <source>Eur Urol</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>48</volume>
            <issue>5</issue>
            <fpage>760</fpage>
            <page-range>760-3</page-range>
            <pub-id pub-id-type="pmid">16005563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r154">
          <label>154</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kulkarni</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Hakenberg</surname>
                <given-names>OW</given-names>
              </name>
              <name>
                <surname>Gschwend</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Thalmann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kassouf</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kamat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zlotta</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer.</article-title>
            <source>Eur Urol</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-70</page-range>
            <pub-id pub-id-type="pmid">19740595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r155">
          <label>155</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lonati</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baumeister</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ornaghi</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>Di Trapani</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>De Cobelli</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Rink</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Karnes</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Poyet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Simone</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Afferi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Necchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Briganti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Montorsi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Krajewski</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Antonelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cerruto</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Zamboni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Simeone</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mordasini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mattei</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moschini</surname>
                <given-names>M</given-names>
              </name>
              <collab>EAU-YAU Urothelial Cancer Working Party</collab>
            </person-group>
            <article-title>Accuracy of Transurethral Resection of the Bladder in Detecting Variant Histology of Bladder Cancer Compared with Radical Cystectomy.</article-title>
            <source>Eur Urol Focus</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>457</fpage>
            <page-range>457-464</page-range>
            <pub-id pub-id-type="pmid">33867307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r156">
          <label>156</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yanagisawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Motlagh</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Kawada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mostafaei</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Quhal</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Laukhtina</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rajwa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aydh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>K&#x000f6;nig</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pallauf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pradere</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>D'Andrea</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Comp&#x000e9;rat</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Miki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Egawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shariat</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title><italic>En Bloc</italic> Resection for Bladder Tumors: An Updated Systematic Review and Meta-Analysis of Its Differential Effect on Safety, Recurrence and Histopathology.</article-title>
            <source>J Urol</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>207</volume>
            <issue>4</issue>
            <fpage>754</fpage>
            <page-range>754-768</page-range>
            <pub-id pub-id-type="pmid">35060770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r157">
          <label>157</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Creta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Celentano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Califano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>La Rocca</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Longo</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>En-bloc Laser Resection of Bladder Tumors: Where Are We Now?</article-title>
            <source>J Clin Med</source>
            <year>2022</year>
            <month>Jun</month>
            <day>16</day>
            <volume>11</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">35743533</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r158">
          <label>158</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Augspurger</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Donohue</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Prevention of obturator nerve stimulation during transurethral surgery.</article-title>
            <source>J Urol</source>
            <year>1980</year>
            <month>Feb</month>
            <volume>123</volume>
            <issue>2</issue>
            <fpage>170</fpage>
            <page-range>170-2</page-range>
            <pub-id pub-id-type="pmid">7188780</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r159">
          <label>159</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Panagoda</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>Vasdev</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gowrie-Mohan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Avoiding the Obturator Jerk during TURBT.</article-title>
            <source>Curr Urol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-5</page-range>
            <pub-id pub-id-type="pmid">30374273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r160">
          <label>160</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Horsanali</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Gorgel</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Ozbek</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Bladder injury secondary to obturator reflex is more common with plasmakinetic transurethral resection than monopolar transurethral resection of bladder cancer.</article-title>
            <source>Cent European J Urol</source>
            <year>2015</year>
            <volume>68</volume>
            <issue>3</issue>
            <fpage>284</fpage>
            <page-range>284-8</page-range>
            <pub-id pub-id-type="pmid">26568867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r161">
          <label>161</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cesur</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Erdem</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Alici</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Yapanoglu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yuksek</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Aksoy</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>The role of succinylcholine in the prevention of the obturator nerve reflex during transurethral resection of bladder tumors.</article-title>
            <source>Saudi Med J</source>
            <year>2008</year>
            <month>May</month>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>668</fpage>
            <page-range>668-71</page-range>
            <pub-id pub-id-type="pmid">18454211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r162">
          <label>162</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deng</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>A Systematic Review and Meta-Analysis Comparing the Safety and Efficacy of Spinal Anesthesia and Spinal Anesthesia Combined with Obturator Nerve Block in Transurethral Resection of Bladder Tumors.</article-title>
            <source>Emerg Med Int</source>
            <year>2022</year>
            <volume>2022</volume>
            <fpage>8490462</fpage>
            <pub-id pub-id-type="pmid">35811608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r163">
          <label>163</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erbay</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Akyol</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Karabakan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Celebi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Keskin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hirik</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Effect of obturator nerve block during transurethral resection of lateral bladder wall tumors on the presence of detrusor muscle in tumor specimens and recurrence of the disease.</article-title>
            <source>Kaohsiung J Med Sci</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>86</fpage>
            <page-range>86-90</page-range>
            <pub-id pub-id-type="pmid">28137416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r164">
          <label>164</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akand</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Muilwijk</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Raskin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>De Vrieze</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Joniau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Van Der Aa</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Quality Control Indicators for Transurethral Resection of Non-Muscle-Invasive Bladder Cancer.</article-title>
            <source>Clin Genitourin Cancer</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>e784</fpage>
            <page-range>e784-e792</page-range>
            <pub-id pub-id-type="pmid">31097388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r165">
          <label>165</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mariappan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Padovani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Trail</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hamid</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hollins</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Hasan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nandwani</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>IDC</given-names>
              </name>
              <name>
                <surname>Hendry</surname>
                <given-names>D</given-names>
              </name>
              <collab>for members of the Scottish Bladder Cancer QPI Research Collaborative</collab>
            </person-group>
            <article-title>Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.</article-title>
            <source>Eur Urol</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>78</volume>
            <issue>4</issue>
            <fpage>520</fpage>
            <page-range>520-530</page-range>
            <pub-id pub-id-type="pmid">32690321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r166">
          <label>166</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ersoy</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yaytokgil</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Karakoyunlu</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Topaloglu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sagnak</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ozok</surname>
                <given-names>HU</given-names>
              </name>
            </person-group>
            <article-title>Single early instillation of mitomycin C and urinary alkalinization in low-risk non-muscle-invasive bladder cancer: a preliminary study.</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2013</year>
            <volume>7</volume>
            <fpage>1</fpage>
            <page-range>1-6</page-range>
            <pub-id pub-id-type="pmid">23300343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r167">
          <label>167</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barghi</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Rahmani</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Hosseini Moghaddam</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Jahanbin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Immediate intravesical instillation of mitomycin C after transurethral resection of bladder tumor in patients with low-risk superficial transitional cell carcinoma of bladder.</article-title>
            <source>Urol J</source>
            <year>2006</year>
            <season>Fall</season>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>220</fpage>
            <page-range>220-4</page-range>
            <pub-id pub-id-type="pmid">17559045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r168">
          <label>168</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Maisch</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Narayan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cleves</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Dahm</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Intravesical gemcitabine for non-muscle invasive bladder cancer.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2021</year>
            <month>Jun</month>
            <day>14</day>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>CD009294</fpage>
            <pub-id pub-id-type="pmid">34125951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r169">
          <label>169</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manoharan</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Intravesical therapy for urothelial carcinoma of the bladder.</article-title>
            <source>Indian J Urol</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>252</fpage>
            <page-range>252-61</page-range>
            <pub-id pub-id-type="pmid">21814318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r170">
          <label>170</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ali-el-Dein</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nabeeh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>el-Baz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shamaa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ashamallah</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study.</article-title>
            <source>Br J Urol</source>
            <year>1997</year>
            <month>May</month>
            <volume>79</volume>
            <issue>5</issue>
            <fpage>731</fpage>
            <page-range>731-5</page-range>
            <pub-id pub-id-type="pmid">9158511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r171">
          <label>171</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitsumori</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tsuchiya</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Habuchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Akao</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohyama</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection.</article-title>
            <source>BJU Int</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>94</volume>
            <issue>3</issue>
            <fpage>317</fpage>
            <page-range>317-21</page-range>
            <pub-id pub-id-type="pmid">15291859</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r172">
          <label>172</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Au</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Badalament</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wientjes</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Warner</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Venema</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Pollifrone</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Harbrecht</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Lerner</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Miles</surname>
                <given-names>BJ</given-names>
              </name>
              <collab>International Mitomycin C Consortium</collab>
            </person-group>
            <article-title>Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2001</year>
            <month>Apr</month>
            <day>18</day>
            <volume>93</volume>
            <issue>8</issue>
            <fpage>597</fpage>
            <page-range>597-604</page-range>
            <pub-id pub-id-type="pmid">11309436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r173">
          <label>173</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giesbers</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Van Helsdingen</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times.</article-title>
            <source>Br J Urol</source>
            <year>1989</year>
            <month>Feb</month>
            <volume>63</volume>
            <issue>2</issue>
            <fpage>176</fpage>
            <page-range>176-9</page-range>
            <pub-id pub-id-type="pmid">2495144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r174">
          <label>174</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuroda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Niijima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kotake</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Akaza</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hinotsu</surname>
                <given-names>S</given-names>
              </name>
              <collab>6th Trial of the Japanese Urological Cancer Research Group</collab>
            </person-group>
            <article-title>Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml.</article-title>
            <source>Eur Urol</source>
            <year>2004</year>
            <month>May</month>
            <volume>45</volume>
            <issue>5</issue>
            <fpage>600</fpage>
            <page-range>600-5</page-range>
            <pub-id pub-id-type="pmid">15082202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r175">
          <label>175</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Tobert</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Kahnoski</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Humphrey</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>BR</given-names>
              </name>
            </person-group>
            <article-title>The value of a comprehensive primary outcome - results of a negative randomized control trial in the non-muscle invasive bladder cancer population.</article-title>
            <source>Can J Urol</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>10756</fpage>
            <page-range>10756-10761</page-range>
            <pub-id pub-id-type="pmid">34378511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r176">
          <label>176</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sylvester</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Oosterlinck</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Holmang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sydes</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Birtle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gudjonsson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>De Nunzio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Okamura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kaasinen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Solsona</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ali-El-Dein</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tatar</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Inman</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>N'Dow</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Oddens</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Babjuk</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?</article-title>
            <source>Eur Urol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>69</volume>
            <issue>2</issue>
            <fpage>231</fpage>
            <page-range>231-44</page-range>
            <pub-id pub-id-type="pmid">26091833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r177">
          <label>177</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sylvester</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Oosterlinck</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>An immediate instillation after transurethral resection of bladder tumor in non-muscle-invasive bladder cancer: has the evidence changed?</article-title>
            <source>Eur Urol</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-5</page-range>
            <pub-id pub-id-type="pmid">19375216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r178">
          <label>178</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sylvester</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Oosterlinck</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>van der Meijden</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials.</article-title>
            <source>J Urol</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>171</volume>
            <issue>6 Pt 1</issue>
            <fpage>2186</fpage>
            <page-range>2186-90, quiz 2435</page-range>
            <pub-id pub-id-type="pmid">15126782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r179">
          <label>179</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abern</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Owusu</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Rampersaud</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Inman</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2013</year>
            <month>Apr</month>
            <day>01</day>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>477</fpage>
            <page-range>477-84</page-range>
            <pub-id pub-id-type="pmid">23584348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r180">
          <label>180</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perlis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zlotta</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Beyene</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Finelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fleshner</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Kulkarni</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review.</article-title>
            <source>Eur Urol</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>64</volume>
            <issue>3</issue>
            <fpage>421</fpage>
            <page-range>421-30</page-range>
            <pub-id pub-id-type="pmid">23830475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r181">
          <label>181</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Kwak</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Ku</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Single, immediate postoperative instillation of chemotherapy in non-muscle invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials using different drugs.</article-title>
            <source>Oncotarget</source>
            <year>2016</year>
            <month>Jul</month>
            <day>19</day>
            <volume>7</volume>
            <issue>29</issue>
            <fpage>45479</fpage>
            <page-range>45479-45488</page-range>
            <pub-id pub-id-type="pmid">27323781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r182">
          <label>182</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daryanto</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Purnomo</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Seputra</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Budaya</surname>
                <given-names>TN</given-names>
              </name>
            </person-group>
            <article-title>Comparison Between Intravesical Chemotherapy Epirubicin and Mitomycin-C after TURB vs TURB Alone With Recurrence Rate of Non-Muscle Invasive Bladder Cancer: Meta-Analysis.</article-title>
            <source>Med Arch</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>76</volume>
            <issue>3</issue>
            <fpage>198</fpage>
            <page-range>198-201</page-range>
            <pub-id pub-id-type="pmid">36200115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r183">
          <label>183</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pode</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alon</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Horowitz</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Vlodavsky</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Biran</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The mechanism of human bladder tumor implantation in an in vitro model.</article-title>
            <source>J Urol</source>
            <year>1986</year>
            <month>Aug</month>
            <volume>136</volume>
            <issue>2</issue>
            <fpage>482</fpage>
            <page-range>482-6</page-range>
            <pub-id pub-id-type="pmid">3525861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r184">
          <label>184</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lowrance</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mellis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cookson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barocas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Newberger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Weizer</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Kava</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meraney</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sjoberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bochner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dalbagni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Donat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Herr</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>A 10-Item Checklist Improves Reporting of Critical Procedural Elements during Transurethral Resection of Bladder Tumor.</article-title>
            <source>J Urol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>196</volume>
            <issue>4</issue>
            <fpage>1014</fpage>
            <page-range>1014-20</page-range>
            <pub-id pub-id-type="pmid">27044571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r185">
          <label>185</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haddad</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Heinlen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stratton</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mellis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Herr</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cookson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Improving the quality of operative reports for transurethral resection of bladder tumor surgery in resident education.</article-title>
            <source>Can J Urol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>8976</fpage>
            <page-range>8976-8981</page-range>
            <pub-id pub-id-type="pmid">28971783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r186">
          <label>186</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eroglu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ekin</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Koc</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Divrik</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial.</article-title>
            <source>Int J Clin Oncol</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>698</fpage>
            <page-range>698-704</page-range>
            <pub-id pub-id-type="pmid">31760524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r187">
          <label>187</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gordon</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Noon</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Rosario</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Catto</surname>
                <given-names>JWF</given-names>
              </name>
            </person-group>
            <article-title>Long-term Outcomes from Re-resection for High-risk Non-muscle-invasive Bladder Cancer: A Potential to Rationalize Use.</article-title>
            <source>Eur Urol Focus</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>650</fpage>
            <page-range>650-657</page-range>
            <pub-id pub-id-type="pmid">29089252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r188">
          <label>188</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bishr</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lattouf</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Latour</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saad</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer.</article-title>
            <source>Can Urol Assoc J</source>
            <year>2014</year>
            <month>May</month>
            <volume>8</volume>
            <issue>5-6</issue>
            <fpage>E306</fpage>
            <page-range>E306-10</page-range>
            <pub-id pub-id-type="pmid">24940455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r189">
          <label>189</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pisano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sylvester</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Joniau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Serretta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Larr&#x000e9;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Di Stasi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van Rhijn</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Witjes</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Grotenhuis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Colombo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Briganti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Babjuk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Soukup</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Malmstrom</surname>
                <given-names>PU</given-names>
              </name>
              <name>
                <surname>Irani</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Malats</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Baniel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mano</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cha</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Ardelt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Varkarakis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bartoletti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dalbagni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shariat</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Xylinas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Karnes</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Gontero</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought.</article-title>
            <source>World J Urol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>36</volume>
            <issue>10</issue>
            <fpage>1621</fpage>
            <page-range>1621-1627</page-range>
            <pub-id pub-id-type="pmid">29721611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r190">
          <label>190</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gontero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sylvester</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pisano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Joniau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oderda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Serretta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Larr&#x000e9;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Di Stasi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Van Rhijn</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Witjes</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Grotenhuis</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Colombo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Briganti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Babjuk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Soukup</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Malmstr&#x000f6;m</surname>
                <given-names>PU</given-names>
              </name>
              <name>
                <surname>Irani</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Malats</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Baniel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mano</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cha</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Ardelt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vakarakis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bartoletti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dalbagni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shariat</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Xylinas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Karnes</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Palou</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Gu&#x000e9;rin.</article-title>
            <source>BJU Int</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>118</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-52</page-range>
            <pub-id pub-id-type="pmid">26469362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r191">
          <label>191</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baltac&#x00131;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bozlu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Y&#x00131;ld&#x00131;r&#x00131;m</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>G&#x000f6;k&#x000e7;e</surname>
                <given-names>M&#x00130;</given-names>
              </name>
              <name>
                <surname>Tinay</surname>
                <given-names>&#x00130;</given-names>
              </name>
              <name>
                <surname>Aslan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Can</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>T&#x000fc;rkeri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kuyumcuo&#x0011f;lu</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Mungan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Gu&#x000e9;rin.</article-title>
            <source>BJU Int</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>116</volume>
            <issue>5</issue>
            <fpage>721</fpage>
            <page-range>721-6</page-range>
            <pub-id pub-id-type="pmid">25715815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r192">
          <label>192</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tolley</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Parmar</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Grigor</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Lallemand</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Benyon</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Fellows</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Grigor</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Hargreave</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Munson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Newling</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Richards</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up.</article-title>
            <source>J Urol</source>
            <year>1996</year>
            <month>Apr</month>
            <volume>155</volume>
            <issue>4</issue>
            <fpage>1233</fpage>
            <page-range>1233-8</page-range>
            <pub-id pub-id-type="pmid">8632538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r193">
          <label>193</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ali-el-Dein</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>el-Baz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aly</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Shamaa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ashamallah</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.</article-title>
            <source>J Urol</source>
            <year>1997</year>
            <month>Jul</month>
            <volume>158</volume>
            <issue>1</issue>
            <fpage>68</fpage>
            <page-range>68-73; discussion 73-4</page-range>
            <pub-id pub-id-type="pmid">9186325</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r194">
          <label>194</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Randomized study of single instillation of epirubicin for superficial bladder carcinoma: long-term clinical outcomes.</article-title>
            <source>Cancer Invest</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>160</fpage>
            <page-range>160-3</page-range>
            <pub-id pub-id-type="pmid">16537185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r195">
          <label>195</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>T&#x000fc;rkeri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tan&#x00131;d&#x00131;r</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>&#x000c7;al</surname>
                <given-names>&#x000c7;</given-names>
              </name>
              <name>
                <surname>&#x000d6;zen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>&#x0015e;ahin</surname>
                <given-names>H</given-names>
              </name>
              <collab>Turkish Urooncology Society</collab>
            </person-group>
            <article-title>Comparison of the efficacy of single or double intravesical epirubicin instillation in the early postoperative period to prevent recurrences in non-muscle-invasive urothelial carcinoma of the bladder: prospective, randomized multicenter study.</article-title>
            <source>Urol Int</source>
            <year>2010</year>
            <volume>85</volume>
            <issue>3</issue>
            <fpage>261</fpage>
            <page-range>261-5</page-range>
            <pub-id pub-id-type="pmid">20332605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r196">
          <label>196</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>B&#x000f6;hle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jocham</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bock</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.</article-title>
            <source>J Urol</source>
            <year>2003</year>
            <month>Jan</month>
            <volume>169</volume>
            <issue>1</issue>
            <fpage>90</fpage>
            <page-range>90-5</page-range>
            <pub-id pub-id-type="pmid">12478111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r197">
          <label>197</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Can intravesical bacillus Calmette-Gu&#x000e9;rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials.</article-title>
            <source>Urology</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>67</volume>
            <issue>6</issue>
            <fpage>1216</fpage>
            <page-range>1216-23</page-range>
            <pub-id pub-id-type="pmid">16765182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r198">
          <label>198</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shelley</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Wilt</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Court</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Coles</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kynaston</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Intravesical bacillus Calmette-Gu&#x000e9;rin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.</article-title>
            <source>BJU Int</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>93</volume>
            <issue>4</issue>
            <fpage>485</fpage>
            <page-range>485-90</page-range>
            <pub-id pub-id-type="pmid">15008714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r199">
          <label>199</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shelley</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Kynaston</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Court</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wilt</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Coles</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Burgon</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>A systematic review of intravesical bacillus Calmette-Gu&#x000e9;rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer.</article-title>
            <source>BJU Int</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>88</volume>
            <issue>3</issue>
            <fpage>209</fpage>
            <page-range>209-16</page-range>
            <pub-id pub-id-type="pmid">11488731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r200">
          <label>200</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Okafor</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Rewane</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Momodu</surname>
                <given-names>II</given-names>
              </name>
            </person-group>
            <chapter-title>Bacillus Calmette Guerin</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">30844212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r201">
          <label>201</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kawai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Miyazaki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Joraku</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nishiyama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Akaza</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine.</article-title>
            <source>Cancer Sci</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>104</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-7</page-range>
            <pub-id pub-id-type="pmid">23181987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r202">
          <label>202</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fuge</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vasdev</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Allchorne</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Immunotherapy for bladder cancer.</article-title>
            <source>Res Rep Urol</source>
            <year>2015</year>
            <volume>7</volume>
            <fpage>65</fpage>
            <page-range>65-79</page-range>
            <pub-id pub-id-type="pmid">26000263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r203">
          <label>203</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sylvester</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>van der Meijden</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Witjes</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kurth</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials.</article-title>
            <source>J Urol</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>174</volume>
            <issue>1</issue>
            <fpage>86</fpage>
            <page-range>86-91; discussion 91-2</page-range>
            <pub-id pub-id-type="pmid">15947584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r204">
          <label>204</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kalyanaraman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>See</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>iNOS expression and NO production contribute to the direct effects of BCG on urothelial carcinoma cell biology.</article-title>
            <source>Urol Oncol</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>45.e1</fpage>
            <page-range>45.e1-9</page-range>
            <pub-id pub-id-type="pmid">24054867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r205">
          <label>205</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morcos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jansson</surname>
                <given-names>OT</given-names>
              </name>
              <name>
                <surname>Adolfsson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ehr&#x000e9;n</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wiklund</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>Bacillus Calmette-Guerin induces long-term local formation of nitric oxide in the bladder via the induction of nitric oxide synthase activity in urothelial cells.</article-title>
            <source>J Urol</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>165</volume>
            <issue>2</issue>
            <fpage>678</fpage>
            <page-range>678-82</page-range>
            <pub-id pub-id-type="pmid">11176457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r206">
          <label>206</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lamm</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Morales</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment.</article-title>
            <source>Vaccine</source>
            <year>2021</year>
            <month>Dec</month>
            <day>08</day>
            <volume>39</volume>
            <issue>50</issue>
            <fpage>7308</fpage>
            <page-range>7308-7318</page-range>
            <pub-id pub-id-type="pmid">34417051</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r207">
          <label>207</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oddens</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brausi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sylvester</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bono</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van de Beek</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>van Andel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gontero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hoeltl</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Turkeri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Marreaud</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Collette</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oosterlinck</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu&#x000e9;rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.</article-title>
            <source>Eur Urol</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>63</volume>
            <issue>3</issue>
            <fpage>462</fpage>
            <page-range>462-72</page-range>
            <pub-id pub-id-type="pmid">23141049</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r208">
          <label>208</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lamm</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Blumenstein</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Crissman</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Montie</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Gottesman</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Lowe</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Sarosdy</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Bohl</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Leimert</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Crawford</surname>
                <given-names>ED</given-names>
              </name>
            </person-group>
            <article-title>Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.</article-title>
            <source>J Urol</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>163</volume>
            <issue>4</issue>
            <fpage>1124</fpage>
            <page-range>1124-9</page-range>
            <pub-id pub-id-type="pmid">10737480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r209">
          <label>209</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grabe-Heyne</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Henne</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mariappan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Geiges</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>P&#x000f6;hlmann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pollock</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs.</article-title>
            <source>Front Oncol</source>
            <year>2023</year>
            <volume>13</volume>
            <fpage>1170124</fpage>
            <pub-id pub-id-type="pmid">37333804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r210">
          <label>210</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katims</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Tallman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vertosick</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Porwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dalbagni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cha</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Benfante</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Herr</surname>
                <given-names>HW</given-names>
              </name>
            </person-group>
            <article-title>Response to 2 Induction Courses of Bacillus Calmette-Gu&#x000e8;rin Therapy Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer: 5-year Follow-Up of a Phase 2 Clinical Trial.</article-title>
            <source>JAMA Oncol</source>
            <year>2024</year>
            <month>Apr</month>
            <day>01</day>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>522</fpage>
            <page-range>522-525</page-range>
            <pub-id pub-id-type="pmid">38358761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r211">
          <label>211</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Llano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kuk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kassouf</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zlotta</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Carcinoma In Situ (CIS): Is There a Difference in Efficacy between Various BCG Strains? A Comprehensive Review of the Literature.</article-title>
            <source>Cancers (Basel)</source>
            <year>2024</year>
            <month>Jan</month>
            <day>05</day>
            <volume>16</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">38254736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r212">
          <label>212</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Gu&#x000e9;rin for Bladder Cancer.</article-title>
            <source>J Oncol</source>
            <year>2019</year>
            <volume>2019</volume>
            <fpage>6230409</fpage>
            <pub-id pub-id-type="pmid">30984262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r213">
          <label>213</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lukacs</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tschobotko</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Szabo</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Symes</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer.</article-title>
            <source>Case Rep Urol</source>
            <year>2013</year>
            <volume>2013</volume>
            <fpage>821526</fpage>
            <pub-id pub-id-type="pmid">23844314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r214">
          <label>214</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>P&#x000e9;rez-Jacoiste As&#x000ed;n</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Ruiz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Medrano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lumbreras</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tejido</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>San Juan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arrebola-Pajares</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lizasoain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Prieto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aguado</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Bacillus Calmette-Gu&#x000e9;rin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>93</volume>
            <issue>17</issue>
            <fpage>236</fpage>
            <page-range>236-254</page-range>
            <pub-id pub-id-type="pmid">25398060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r215">
          <label>215</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fernandes</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Nunes</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Figueiredo</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Septic Shock After Intravesical Therapy With Bacillus Calmette-Guerin: A Case Report of a Rare Life-Threatening Complication.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>10</issue>
            <fpage>e46563</fpage>
            <pub-id pub-id-type="pmid">37933342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r216">
          <label>216</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liaw</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Hendry</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Systemic BCG-osis following intravesical BCG instillation for bladder carcinoma.</article-title>
            <source>Clin Case Rep</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>5</volume>
            <issue>10</issue>
            <fpage>1569</fpage>
            <page-range>1569-1572</page-range>
            <pub-id pub-id-type="pmid">29026546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r217">
          <label>217</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oladiran</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Nwosu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Oladunjoye</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oladunjoye</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Disseminated BCG sepsis following intravesical therapy for Bladder Carcinoma: A case report and review of literature.</article-title>
            <source>J Community Hosp Intern Med Perspect</source>
            <year>2020</year>
            <month>May</month>
            <day>21</day>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>168</fpage>
            <page-range>168-170</page-range>
            <pub-id pub-id-type="pmid">32850058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r218">
          <label>218</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dinney</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Gu&#x000e9;rin.</article-title>
            <source>Urol Oncol</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>31</volume>
            <issue>8</issue>
            <fpage>1635</fpage>
            <page-range>1635-42</page-range>
            <pub-id pub-id-type="pmid">22575238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r219">
          <label>219</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boorjian</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Alemozaffar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Konety</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Shore</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Gomella</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Kamat</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bivalacqua</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Lerner</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Busby</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Poch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Crispen</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Schuckman</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Downs</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Svatek</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Mashni</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Guzzo</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Bratslavsky</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Karsh</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Canter</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Luchey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Krupski</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Inman</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Cookson</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Keegan</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Andriole</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Sankin</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Boyd</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Sawutz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Philipson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Coll</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Narayan</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Treasure</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Yla-Herttuala</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Dinney</surname>
                <given-names>CPN</given-names>
              </name>
            </person-group>
            <article-title>Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>107</fpage>
            <page-range>107-117</page-range>
            <pub-id pub-id-type="pmid">33253641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r220">
          <label>220</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chamie</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Kramolowsky</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gonzalgo</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Bassett</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Bjurlin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cher</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cowan</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>David</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Goldfischer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Guru</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jalkut</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Kaffenberger</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Kaminetsky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Koo</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Sexton</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Tikhonenkov</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Trabulsi</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Trainer</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Spilman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bhar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Taha</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Sender</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Soon-Shiong</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive&#x000a0;Bladder Cancer.</article-title>
            <source>NEJM Evid</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>EVIDoa2200167</fpage>
            <pub-id pub-id-type="pmid">38320011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r221">
          <label>221</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McElree</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Richards</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mott</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Gellhaus</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Nepple</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Packiam</surname>
                <given-names>VT</given-names>
              </name>
            </person-group>
            <article-title>Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Gu&#x000e9;rin-Na&#x000ef;ve High-Risk Nonmuscle-Invasive Bladder Cancer.</article-title>
            <source>J Urol</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>208</volume>
            <issue>3</issue>
            <fpage>589</fpage>
            <page-range>589-599</page-range>
            <pub-id pub-id-type="pmid">35892270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r222">
          <label>222</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chevuru</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>McElree</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Mott</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Packiam</surname>
                <given-names>VT</given-names>
              </name>
            </person-group>
            <article-title>Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer.</article-title>
            <source>Urol Oncol</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>148.e1</fpage>
            <page-range>148.e1-148.e7</page-range>
            <pub-id pub-id-type="pmid">36456454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r223">
          <label>223</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carosella</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Ploussard</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>LeMaoult</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Desgrandchamps</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.</article-title>
            <source>Eur Urol</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>68</volume>
            <issue>2</issue>
            <fpage>267</fpage>
            <page-range>267-79</page-range>
            <pub-id pub-id-type="pmid">25824720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r224">
          <label>224</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Syed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Israr</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anwar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khatroth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Safi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kamran</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A systematic review on the available treatment modalities for Bacillus Calmette-Gu&#x000e9;rin-unresponsive carcinoma in situ and tumors in patients who are ineligible for or decline radical cystectomy.</article-title>
            <source>SAGE Open Med</source>
            <year>2023</year>
            <volume>11</volume>
            <fpage>20503121231160408</fpage>
            <pub-id pub-id-type="pmid">36949824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r225">
          <label>225</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McElree</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Mott</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Packiam</surname>
                <given-names>VT</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Gu&#x000e9;rin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer.</article-title>
            <source>JAMA Netw Open</source>
            <year>2023</year>
            <month>Feb</month>
            <day>01</day>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>e230849</fpage>
            <pub-id pub-id-type="pmid">36853609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r226">
          <label>226</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McElree</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Packiam</surname>
                <given-names>VT</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Mott</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Gellhaus</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Nepple</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non-Muscle-Invasive Bladder Cancer.</article-title>
            <source>J Urol</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>208</volume>
            <issue>5</issue>
            <fpage>969</fpage>
            <page-range>969-977</page-range>
            <pub-id pub-id-type="pmid">35830552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r227">
          <label>227</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Intravesical device-assisted therapies&#x000a0;for non-muscle-invasive bladder cancer.</article-title>
            <source>Nat Rev Urol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>15</volume>
            <issue>11</issue>
            <fpage>667</fpage>
            <page-range>667-685</page-range>
            <pub-id pub-id-type="pmid">30254383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r228">
          <label>228</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jung</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Gudeloglu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kiziloz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kuntz</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Konety</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Dahm</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Intravesical electromotive drug administration for non-muscle invasive bladder cancer.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Sep</month>
            <day>12</day>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>CD011864</fpage>
            <pub-id pub-id-type="pmid">28898400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r229">
          <label>229</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Melgarejo Segura</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Morales Mart&#x000ed;nez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Y&#x000e1;&#x000f1;ez Castillo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Arrabal Polo</surname>
                <given-names>M&#x000c1;</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez Lechuga</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pareja V&#x000ed;lchez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arrabal Mart&#x000ed;n</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.</article-title>
            <source>Urol Oncol</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>109.e1</fpage>
            <page-range>109.e1-109.e8</page-range>
            <pub-id pub-id-type="pmid">36379812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r230">
          <label>230</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guerrero-Ramos</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Padilla</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-D&#x000ed;az</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de la Rosa-Kehrmann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Antol&#x000ed;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Inman</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Villacampa-Aub&#x000e1;</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial.</article-title>
            <source>World J Urol</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>999</fpage>
            <page-range>999-1004</page-range>
            <pub-id pub-id-type="pmid">35037963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r231">
          <label>231</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Deal</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Wallen</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Pruthi</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Milowsky</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base.</article-title>
            <source>BJU Int</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>114</volume>
            <issue>5</issue>
            <fpage>719</fpage>
            <page-range>719-26</page-range>
            <pub-id pub-id-type="pmid">24325202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r232">
          <label>232</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Svatek</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Shariat</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Novara</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Skinner</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Fradet</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bastian</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Kamat</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kassouf</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Karakiewicz</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>Fritsche</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Izawa</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Tilki</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ficarra</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Volkmer</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Isbarn</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dinney</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort.</article-title>
            <source>BJU Int</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>107</volume>
            <issue>6</issue>
            <fpage>898</fpage>
            <page-range>898-904</page-range>
            <pub-id pub-id-type="pmid">21244604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r233">
          <label>233</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turker</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bostrom</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Wroclawski</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>van Rhijn</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kortekangas</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kuk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mirtti</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fleshner</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Jewett</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Finelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kwast</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sweet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Laato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zlotta</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome.</article-title>
            <source>BJU Int</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>110</volume>
            <issue>6</issue>
            <fpage>804</fpage>
            <page-range>804-11</page-range>
            <pub-id pub-id-type="pmid">22321341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r234">
          <label>234</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmadi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mitra</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Abdelsayed</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Djaladat</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bruins</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Daneshmand</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Principal component analysis based pre-cystectomy model to predict pathological stage in patients with clinical organ-confined bladder cancer.</article-title>
            <source>BJU Int</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>111</volume>
            <issue>4 Pt B</issue>
            <fpage>E167</fpage>
            <page-range>E167-72</page-range>
            <pub-id pub-id-type="pmid">23035696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r235">
          <label>235</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aminoltejari</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Radical cystectomy: a review of techniques, developments and controversies.</article-title>
            <source>Transl Androl Urol</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>9</volume>
            <issue>6</issue>
            <fpage>3073</fpage>
            <page-range>3073-3081</page-range>
            <pub-id pub-id-type="pmid">33457280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r236">
          <label>236</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Venkatramani</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Reis</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Castle</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Gonzalgo</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Svatek</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Weizer</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Konety</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Tollefson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krupski</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Shabsigh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barocas</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Quek</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Dash</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kibel</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Pruthi</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Weight</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Sharp</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Cookson</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Gorbonos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Uchio</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Skinner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Soodana-Prakash</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Becerra</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Swain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kendrick</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Parekh</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup.</article-title>
            <source>J Urol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>203</volume>
            <issue>3</issue>
            <fpage>522</fpage>
            <page-range>522-529</page-range>
            <pub-id pub-id-type="pmid">31549935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r237">
          <label>237</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Venkatramani</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Reis</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Gonzalgo</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Castle</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Svatek</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Weizer</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Konety</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Tollefson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krupski</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Shabsigh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barocas</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Quek</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Dash</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Parekh</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Robot-Assisted and Open Radical Cystectomy in Recovery of Patient-Reported and Performance-Related Measures of Independence: A Secondary Analysis of a Randomized Clinical Trial.</article-title>
            <source>JAMA Netw Open</source>
            <year>2022</year>
            <month>Feb</month>
            <day>01</day>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>e2148329</fpage>
            <pub-id pub-id-type="pmid">35171260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r238">
          <label>238</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parekh</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Reis</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Castle</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Gonzalgo</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Svatek</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Weizer</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Konety</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Tollefson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krupski</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Shabsigh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barocas</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Quek</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Dash</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kibel</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Shemanski</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pruthi</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Weight</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Sharp</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Cookson</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Gorbonos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Uchio</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Skinner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Venkatramani</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Soodana-Prakash</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kendrick</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial.</article-title>
            <source>Lancet</source>
            <year>2018</year>
            <month>Jun</month>
            <day>23</day>
            <volume>391</volume>
            <issue>10139</issue>
            <fpage>2525</fpage>
            <page-range>2525-2536</page-range>
            <pub-id pub-id-type="pmid">29976469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r239">
          <label>239</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bochner</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Dalbagni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sjoberg</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Keren Paz</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Donat</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Mathew</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vickers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schnorr</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Feuerstein</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Rapkin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Parra</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Herr</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Laudone</surname>
                <given-names>VP</given-names>
              </name>
            </person-group>
            <article-title>Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial.</article-title>
            <source>Eur Urol</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>67</volume>
            <issue>6</issue>
            <fpage>1042</fpage>
            <page-range>1042-1050</page-range>
            <pub-id pub-id-type="pmid">25496767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r240">
          <label>240</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bochner</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Dalbagni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marzouk</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Sjoberg</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Donat</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Vickers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Herr</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Laudone</surname>
                <given-names>VP</given-names>
              </name>
            </person-group>
            <article-title>Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes.</article-title>
            <source>Eur Urol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>74</volume>
            <issue>4</issue>
            <fpage>465</fpage>
            <page-range>465-471</page-range>
            <pub-id pub-id-type="pmid">29784190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r241">
          <label>241</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bui</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bordoni</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <chapter-title>Anatomy, Abdomen and Pelvis: Inguinal Lymph Node</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">32491571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r242">
          <label>242</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Which lymph node dissection template is optimal for radical cystectomy? A systematic review and Bayesian network meta-analysis.</article-title>
            <source>Front Oncol</source>
            <year>2022</year>
            <volume>12</volume>
            <fpage>986150</fpage>
            <pub-id pub-id-type="pmid">36505883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r243">
          <label>243</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muilwijk</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Akand</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gevaert</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Joniau</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>No survival difference between super extended and standard lymph node dissection at radical cystectomy: what can we learn from the first prospective randomized phase III trial?</article-title>
            <source>Transl Androl Urol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>8</volume>
            <issue>Suppl 1</issue>
            <fpage>S112</fpage>
            <page-range>S112-S115</page-range>
            <pub-id pub-id-type="pmid">31143684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r244">
          <label>244</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000f8;ller</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>H&#x000f8;yer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Extended versus superextended lymph-node dissection in radical cystectomy: subgroup analysis of possible recurrence-free survival benefit.</article-title>
            <source>Scand J Urol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>50</volume>
            <issue>3</issue>
            <fpage>175</fpage>
            <page-range>175-80</page-range>
            <pub-id pub-id-type="pmid">27049808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r245">
          <label>245</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Svatek</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zehnder</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Role and extent of lymphadenectomy during radical cystectomy for invasive bladder cancer.</article-title>
            <source>Curr Urol Rep</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>115</fpage>
            <page-range>115-21</page-range>
            <pub-id pub-id-type="pmid">22328190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r246">
          <label>246</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bruins</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Veskimae</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Imamura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Neuberger</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Dahm</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>N'Dow</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van der Heijden</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Comp&#x000e9;rat</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cowan</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>De Santis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gakis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lebret</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ribal</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Sherif</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Witjes</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review.</article-title>
            <source>Eur Urol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>66</volume>
            <issue>6</issue>
            <fpage>1065</fpage>
            <page-range>1065-77</page-range>
            <pub-id pub-id-type="pmid">25074764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r247">
          <label>247</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gschwend</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Heck</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lehmann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>R&#x000fc;bben</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Albers</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wolff</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Frohneberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>de Geeter</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Heidenreich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>K&#x000e4;lble</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>St&#x000f6;ckle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schn&#x000f6;ller</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stenzl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Truss</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liehr</surname>
                <given-names>UB</given-names>
              </name>
              <name>
                <surname>Lei&#x000df;ner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bregenzer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Retz</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.</article-title>
            <source>Eur Urol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>75</volume>
            <issue>4</issue>
            <fpage>604</fpage>
            <page-range>604-611</page-range>
            <pub-id pub-id-type="pmid">30337060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r248">
          <label>248</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sasaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Izumi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fukuta</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kadoriku</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Atagi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Daizumoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shiozaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tomida</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kusuhara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fukawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yanagihara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Izaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Okamoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamanaka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Furukawa</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Impact of lymph node dissection on surgical and oncological outcomes in patients undergoing robot-assisted radical cystectomy for bladder cancer: a multicenter retrospective study.</article-title>
            <source>J Robot Surg</source>
            <year>2024</year>
            <month>Mar</month>
            <day>30</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>141</fpage>
            <pub-id pub-id-type="pmid">38554230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r249">
          <label>249</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>International Collaboration of Trialists</collab>
              <collab>Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group)</collab>
              <collab>European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group</collab>
              <collab>Australian Bladder Cancer Study Group</collab>
              <collab>National Cancer Institute of Canada Clinical Trials Group</collab>
              <collab>Finnbladder</collab>
              <collab>Norwegian Bladder Cancer Study Group</collab>
              <collab>Club Urologico Espanol de Tratamiento Oncologico Group</collab>
              <name>
                <surname>Griffiths</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sylvester</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Raghavan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Parmar</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.</article-title>
            <source>J Clin Oncol</source>
            <year>2011</year>
            <month>Jun</month>
            <day>01</day>
            <volume>29</volume>
            <issue>16</issue>
            <fpage>2171</fpage>
            <page-range>2171-7</page-range>
            <pub-id pub-id-type="pmid">21502557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r250">
          <label>250</label>
          <element-citation publication-type="journal">
            <collab>Advanced Bladder Cancer Meta-analysis Collaboration</collab>
            <article-title>Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis.</article-title>
            <source>Lancet</source>
            <year>2003</year>
            <month>Jun</month>
            <day>07</day>
            <volume>361</volume>
            <issue>9373</issue>
            <fpage>1927</fpage>
            <page-range>1927-34</page-range>
            <pub-id pub-id-type="pmid">12801735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r251">
          <label>251</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Winquist</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kirchner</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lukka</surname>
                <given-names>H</given-names>
              </name>
              <collab>Genitourinary Cancer Disease Site Group, Cancer Care Ontario Program in Evidence-based Care Practice Guidelines Initiative</collab>
            </person-group>
            <article-title>Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis.</article-title>
            <source>J Urol</source>
            <year>2004</year>
            <month>Feb</month>
            <volume>171</volume>
            <issue>2 Pt 1</issue>
            <fpage>561</fpage>
            <page-range>561-9</page-range>
            <pub-id pub-id-type="pmid">14713760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r252">
          <label>252</label>
          <element-citation publication-type="journal">
            <collab>Advanced Bladder Cancer (ABC) Meta-analysis Collaboration</collab>
            <article-title>Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration.</article-title>
            <source>Eur Urol</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>48</volume>
            <issue>2</issue>
            <fpage>202</fpage>
            <page-range>202-5; discussion 205-6</page-range>
            <pub-id pub-id-type="pmid">15939524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r253">
          <label>253</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malmstr&#x000f6;m</surname>
                <given-names>PU</given-names>
              </name>
              <name>
                <surname>Rintala</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wahlqvist</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hellstr&#x000f6;m</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hellsten</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hannisdal</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group.</article-title>
            <source>J Urol</source>
            <year>1996</year>
            <month>Jun</month>
            <volume>155</volume>
            <issue>6</issue>
            <fpage>1903</fpage>
            <page-range>1903-6</page-range>
            <pub-id pub-id-type="pmid">8618283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r254">
          <label>254</label>
          <element-citation publication-type="journal">
            <article-title>Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.</article-title>
            <source>Lancet</source>
            <year>1999</year>
            <month>Aug</month>
            <day>14</day>
            <volume>354</volume>
            <issue>9178</issue>
            <fpage>533</fpage>
            <page-range>533-40</page-range>
            <pub-id pub-id-type="pmid">10470696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r255">
          <label>255</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Galsky</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Pal</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Chowdhury</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harshman</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Crabb</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>YN</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Powles</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Moshier</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Ladoire</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hussain</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vaishampayan</surname>
                <given-names>UN</given-names>
              </name>
              <name>
                <surname>Recine</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Berthold</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Necchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Theodore</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Milowsky</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Bellmunt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>JE</given-names>
              </name>
              <collab>Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators</collab>
            </person-group>
            <article-title>Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.</article-title>
            <source>Cancer</source>
            <year>2015</year>
            <month>Aug</month>
            <day>01</day>
            <volume>121</volume>
            <issue>15</issue>
            <fpage>2586</fpage>
            <page-range>2586-93</page-range>
            <pub-id pub-id-type="pmid">25872978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r256">
          <label>256</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sternberg</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Collette</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>What has been learned from meta-analyses of neoadjuvant and adjuvant chemotherapy in bladder cancer?</article-title>
            <source>BJU Int</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>98</volume>
            <issue>3</issue>
            <fpage>487</fpage>
            <page-range>487-9</page-range>
            <pub-id pub-id-type="pmid">16925739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r257">
          <label>257</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van de Putte</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Mertens</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Meijer</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>van der Heijden</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Bex</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van der Poel</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Kerst</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bergman</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Horenblas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van Rhijn</surname>
                <given-names>BW</given-names>
              </name>
            </person-group>
            <article-title>Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.</article-title>
            <source>World J Urol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-62</page-range>
            <pub-id pub-id-type="pmid">26184106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r258">
          <label>258</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>von der Maase</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Dogliotti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Oliver</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bodrogi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Albers</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Knuth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lippert</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Kerbrat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sanchez Rovira</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wersall</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cleall</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Roychowdhury</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Tomlin</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Visseren-Grul</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Conte</surname>
                <given-names>PF</given-names>
              </name>
            </person-group>
            <article-title>Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.</article-title>
            <source>J Clin Oncol</source>
            <year>2023</year>
            <month>Aug</month>
            <day>10</day>
            <volume>41</volume>
            <issue>23</issue>
            <fpage>3881</fpage>
            <page-range>3881-3890</page-range>
            <pub-id pub-id-type="pmid">37549482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r259">
          <label>259</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yuh</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Ruel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Vogelzang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pal</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer.</article-title>
            <source>J Urol</source>
            <year>2013</year>
            <month>May</month>
            <volume>189</volume>
            <issue>5</issue>
            <fpage>1682</fpage>
            <page-range>1682-6</page-range>
            <pub-id pub-id-type="pmid">23123547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r260">
          <label>260</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Shenoi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Champion</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Izard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gore</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer.</article-title>
            <source>Adv Urol</source>
            <year>2013</year>
            <volume>2013</volume>
            <fpage>317190</fpage>
            <pub-id pub-id-type="pmid">24382958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r261">
          <label>261</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenblatt</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sherif</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rintala</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wahlqvist</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ull&#x000e9;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Malmstr&#x000f6;m</surname>
                <given-names>PU</given-names>
              </name>
              <collab>Nordic Urothelial Cancer Group</collab>
            </person-group>
            <article-title>Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.</article-title>
            <source>Eur Urol</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>61</volume>
            <issue>6</issue>
            <fpage>1229</fpage>
            <page-range>1229-38</page-range>
            <pub-id pub-id-type="pmid">22189383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r262">
          <label>262</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Voskuilen</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Oo</surname>
                <given-names>HZ</given-names>
              </name>
              <name>
                <surname>Genitsch</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Smit</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Vidal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meneses</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Necchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Colecchia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xylinas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fontugne</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sibony</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roupr&#x000ea;t</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lenfant</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>C&#x000f4;t&#x000e9;</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Buser</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Saba</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Furrer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>van der Heijden</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Daugaard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>van Rhijn</surname>
                <given-names>BWG</given-names>
              </name>
              <name>
                <surname>Hendricksen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Poyet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Seiler</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>43</volume>
            <issue>12</issue>
            <fpage>1600</fpage>
            <page-range>1600-1610</page-range>
            <pub-id pub-id-type="pmid">31524642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r263">
          <label>263</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brodtkorb</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kamgar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Teitsson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kurt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Poretta</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mamtani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective.</article-title>
            <source>J Med Econ</source>
            <year>2024</year>
            <season>Jan-Dec</season>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>543</fpage>
            <page-range>543-553</page-range>
            <pub-id pub-id-type="pmid">38470512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r264">
          <label>264</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Heijden</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Sonpavde</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Powles</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Necchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burotto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schenker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sade</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Bamias</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beuzeboc</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bedke</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Oldenburg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chatta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>&#x000dc;r&#x000fc;n</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Valderrama</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Ku</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Tomita</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Filian</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Purcea</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Nasroulah</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Galsky</surname>
                <given-names>MD</given-names>
              </name>
              <collab>CheckMate 901 Trial Investigators</collab>
            </person-group>
            <article-title>Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.</article-title>
            <source>N Engl J Med</source>
            <year>2023</year>
            <month>Nov</month>
            <day>09</day>
            <volume>389</volume>
            <issue>19</issue>
            <fpage>1778</fpage>
            <page-range>1778-1789</page-range>
            <pub-id pub-id-type="pmid">37870949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r265">
          <label>265</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madersbacher</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eberle</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Thoeny</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Burkhard</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hochreiter</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Studer</surname>
                <given-names>UE</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcome of ileal conduit diversion.</article-title>
            <source>J Urol</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>169</volume>
            <issue>3</issue>
            <fpage>985</fpage>
            <page-range>985-90</page-range>
            <pub-id pub-id-type="pmid">12576827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r266">
          <label>266</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sumfest</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>The Mitrofanoff principle in urinary reconstruction.</article-title>
            <source>J Urol</source>
            <year>1993</year>
            <month>Dec</month>
            <volume>150</volume>
            <issue>6</issue>
            <fpage>1875</fpage>
            <page-range>1875-7; discussion 1877-8</page-range>
            <pub-id pub-id-type="pmid">8230523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r267">
          <label>267</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bihrle</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The Indiana pouch continent urinary reservoir.</article-title>
            <source>Urol Clin North Am</source>
            <year>1997</year>
            <month>Nov</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>773</fpage>
            <page-range>773-9</page-range>
            <pub-id pub-id-type="pmid">9391530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r268">
          <label>268</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jonsson</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Adding</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Hosseini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Volz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wiklund</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>Robot-assisted radical cystectomy with intracorporeal urinary diversion in patients with transitional cell carcinoma of the bladder.</article-title>
            <source>Eur Urol</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>60</volume>
            <issue>5</issue>
            <fpage>1066</fpage>
            <page-range>1066-73</page-range>
            <pub-id pub-id-type="pmid">21852033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r269">
          <label>269</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lavall&#x000e9;e</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wiklund</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The Studer Neobladder: An Established and Reproducible Technique for Intracorporeal Urinary Diversion.</article-title>
            <source>Eur Urol Open Sci</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>35</volume>
            <fpage>18</fpage>
            <page-range>18-20</page-range>
            <pub-id pub-id-type="pmid">34888533</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r270">
          <label>270</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hussein</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>YE</given-names>
              </name>
              <name>
                <surname>Kozlowski</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Nyquist</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sexton</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Curtin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Peabody</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Abol-Enein</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Guru</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Robot-assisted approach to 'W'-configuration urinary diversion: a step-by-step technique.</article-title>
            <source>BJU Int</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>120</volume>
            <issue>1</issue>
            <fpage>152</fpage>
            <page-range>152-157</page-range>
            <pub-id pub-id-type="pmid">28220593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r271">
          <label>271</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Otaola-Arca</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Seetharam Bhat</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Moschovas</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Orvieto</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Totally intracorporeal robot-assisted urinary diversion for bladder cancer (part 2). Review and detailed characterization of the existing intracorporeal orthotopic ileal neobladder.</article-title>
            <source>Asian J Urol</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-80</page-range>
            <pub-id pub-id-type="pmid">33569273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r272">
          <label>272</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Becerra</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Venkatramani</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Reis</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Soodana-Prakash</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Punnen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gonzalgo</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Raolji</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Castle</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Svatek</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Weizer</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Konety</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Tollefson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krupski</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Shabsigh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barocas</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Quek</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Dash</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Parekh</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Health Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial: A Multi-Institutional Randomized Trial Comparing Robot versus Open Radical Cystectomy.</article-title>
            <source>J Urol</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>204</volume>
            <issue>3</issue>
            <fpage>450</fpage>
            <page-range>450-459</page-range>
            <pub-id pub-id-type="pmid">32271690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r273">
          <label>273</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gerharz</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>M&#x000e5;nsson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Skinner</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>M&#x000e5;nsson</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Quality of life after cystectomy and urinary diversion: an evidence based analysis.</article-title>
            <source>J Urol</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>174</volume>
            <issue>5</issue>
            <fpage>1729</fpage>
            <page-range>1729-36</page-range>
            <pub-id pub-id-type="pmid">16217273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r274">
          <label>274</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ali</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Birch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dudderidge</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Somani</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>Health related quality of life (HRQoL) after cystectomy: comparison between orthotopic neobladder and ileal conduit diversion.</article-title>
            <source>Eur J Surg Oncol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>295</fpage>
            <page-range>295-9</page-range>
            <pub-id pub-id-type="pmid">24913090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r275">
          <label>275</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghosh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Somani</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>Recent Trends in Postcystectomy Health-related Quality of Life (QoL) Favors Neobladder Diversion: Systematic Review of the Literature.</article-title>
            <source>Urology</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>93</volume>
            <fpage>22</fpage>
            <page-range>22-6</page-range>
            <pub-id pub-id-type="pmid">27015941</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r276">
          <label>276</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Philip</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Manikandan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Venugopal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Desouza</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Javl&#x000e9;</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Orthotopic neobladder versus ileal conduit urinary diversion after cystectomy--a quality-of-life based comparison.</article-title>
            <source>Ann R Coll Surg Engl</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>91</volume>
            <issue>7</issue>
            <fpage>565</fpage>
            <page-range>565-9</page-range>
            <pub-id pub-id-type="pmid">19558757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r277">
          <label>277</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holzbeierlein</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lopez-Corona</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bochner</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Herr</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Donat</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dalbagni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sogani</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection.</article-title>
            <source>J Urol</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>172</volume>
            <issue>3</issue>
            <fpage>878</fpage>
            <page-range>878-81</page-range>
            <pub-id pub-id-type="pmid">15310988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r278">
          <label>278</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henry</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Loening</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fallon</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Comparison of transurethral resection to radical therapies for stage B bladder tumors.</article-title>
            <source>J Urol</source>
            <year>1988</year>
            <month>Nov</month>
            <volume>140</volume>
            <issue>5</issue>
            <fpage>964</fpage>
            <page-range>964-7</page-range>
            <pub-id pub-id-type="pmid">3172367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r279">
          <label>279</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Reading</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Radical transurethral resection and chemotherapy in the treatment of muscle-invasive bladder cancer: a long-term follow-up.</article-title>
            <source>BJU Int</source>
            <year>1999</year>
            <month>Mar</month>
            <volume>83</volume>
            <issue>4</issue>
            <fpage>432</fpage>
            <page-range>432-7</page-range>
            <pub-id pub-id-type="pmid">10210567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r280">
          <label>280</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kulkarni</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Hermanns</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bhindi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Satkunasivam</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Athanasopoulos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bostrom</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Kuk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Templeton</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Sridhar</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>van der Kwast</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bristow</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Milosevic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Warde</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fleshner</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Jewett</surname>
                <given-names>MAS</given-names>
              </name>
              <name>
                <surname>Bashir</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zlotta</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.</article-title>
            <source>J Clin Oncol</source>
            <year>2017</year>
            <month>Jul</month>
            <day>10</day>
            <volume>35</volume>
            <issue>20</issue>
            <fpage>2299</fpage>
            <page-range>2299-2305</page-range>
            <pub-id pub-id-type="pmid">28410011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r281">
          <label>281</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coppin</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Gospodarowicz</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tannock</surname>
                <given-names>IF</given-names>
              </name>
              <name>
                <surname>Zee</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pater</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>LD</given-names>
              </name>
            </person-group>
            <article-title>Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group.</article-title>
            <source>J Clin Oncol</source>
            <year>1996</year>
            <month>Nov</month>
            <volume>14</volume>
            <issue>11</issue>
            <fpage>2901</fpage>
            <page-range>2901-7</page-range>
            <pub-id pub-id-type="pmid">8918486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r282">
          <label>282</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zietman</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Grocela</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zehr</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Althausen</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Heney</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Shipley</surname>
                <given-names>WU</given-names>
              </name>
            </person-group>
            <article-title>Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.</article-title>
            <source>Urology</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>380</fpage>
            <page-range>380-5</page-range>
            <pub-id pub-id-type="pmid">11549485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r283">
          <label>283</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hausmann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grunewald</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>[Can muscle invasive bladder cancer be treated without cystectomy in the future? : New data on trimodal therapy and bladder preservation after systemic therapy alone].</article-title>
            <source>Urologie</source>
            <year>2024</year>
            <month>Oct</month>
            <volume>63</volume>
            <issue>10</issue>
            <fpage>985</fpage>
            <page-range>985-993</page-range>
            <pub-id pub-id-type="pmid">39143395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r284">
          <label>284</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pakmanesh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Khajehsalimi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hesamarefi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ebadzadeh</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Bazrafshan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malekpourafshar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mirzaei</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Daneshpajouh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shahesmaeili</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eslami</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the overall survival of different treatment methods in patients with Muscle-invasive bladder cancer: A retrospective study.</article-title>
            <source>Urologia</source>
            <year>2024</year>
            <month>Nov</month>
            <volume>91</volume>
            <issue>4</issue>
            <fpage>687</fpage>
            <page-range>687-694</page-range>
            <pub-id pub-id-type="pmid">38867469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r285">
          <label>285</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balar</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Castellano</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Grivas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vaughn</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Powles</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vuky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fradet</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Fong</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vogelzang</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Climent</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Necchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Petrylak</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Plimack</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>JZ</given-names>
              </name>
              <name>
                <surname>Imai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moreno</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Bellmunt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Wit</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.</article-title>
            <source>Ann Oncol</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>289</fpage>
            <page-range>289-299</page-range>
            <pub-id pub-id-type="pmid">36494006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r286">
          <label>286</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Awosika</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Farrar</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <chapter-title>Paclitaxel</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>11</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">30725602</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r287">
          <label>287</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bamias</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tiliakos</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Karali</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Dimopoulos</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Systemic chemotherapy in inoperable or metastatic bladder cancer.</article-title>
            <source>Ann Oncol</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>553</fpage>
            <page-range>553-61</page-range>
            <pub-id pub-id-type="pmid">16303860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r288">
          <label>288</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Powles</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bellmunt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Comperat</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>De Santis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huddart</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Loriot</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Necchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Valderrama</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Ravaud</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shariat</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Szabados</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>van der Heijden</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Gillessen</surname>
                <given-names>S</given-names>
              </name>
              <collab>ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org</collab>
            </person-group>
            <article-title>ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.</article-title>
            <source>Ann Oncol</source>
            <year>2024</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>485</fpage>
            <page-range>485-490</page-range>
            <pub-id pub-id-type="pmid">38490358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r289">
          <label>289</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Powles</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Voog</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Caserta</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Valderrama</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Gurney</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kalofonos</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Radulovi&#x00107;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Demey</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ull&#x000e9;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Loriot</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sridhar</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Tsuchiya</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kopyltsov</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sternberg</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Bellmunt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Aragon-Ching</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Petrylak</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Laliberte</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fowst</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Blake-Haskins</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>di Pietro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grivas</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>Sep</month>
            <day>24</day>
            <volume>383</volume>
            <issue>13</issue>
            <fpage>1218</fpage>
            <page-range>1218-1230</page-range>
            <pub-id pub-id-type="pmid">32945632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r290">
          <label>290</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grivas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Voog</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Caserta</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gurney</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bellmunt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kalofonos</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ull&#x000e9;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Loriot</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sridhar</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Petrylak</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Sternberg</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Laliberte</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>di Pietro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Valderrama</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Powles</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.</article-title>
            <source>Eur Urol</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>84</volume>
            <issue>1</issue>
            <fpage>95</fpage>
            <page-range>95-108</page-range>
            <pub-id pub-id-type="pmid">37121850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r291">
          <label>291</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Massari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Santoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takeshita</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Okada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tapia</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Basso</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Maruzzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scagliarini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>B&#x000fc;ttner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fornarini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Myint</surname>
                <given-names>ZW</given-names>
              </name>
              <name>
                <surname>Galli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Pichler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>De Giorgi</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Gandur</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Popovic</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Grande</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mammone</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Berardi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Crabb</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kemp</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Molina-Cerrillo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Freitas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Luz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iacovelli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Calabr&#x000f2;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tural</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Atzori</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>K&#x000fc;ronya</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Chiari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Campos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Caffo</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Fay</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Kucharz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zucali</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Rinck</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Zeppellini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bastos</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Aurilio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mota</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trindade</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ortega</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sade</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Rizzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fiala</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vau</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Giannatempo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Barillas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Monteiro</surname>
                <given-names>FSM</given-names>
              </name>
              <name>
                <surname>Dauster</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mennitto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nogueira</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>de Carvalho Fernandes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Seront</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Aceituno</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Grillone</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cutuli</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bassanelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Roviello</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Abahssain</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Procopio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Milella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kopecky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Martignetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Messina</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Caitano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Inman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kanesvaran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Herchhorn</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Santini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bamias</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bisonni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mosca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Morelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Maluf</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Soares</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nunes</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zgura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Incorvaia</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ansari</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zabalza</surname>
                <given-names>IO</given-names>
              </name>
              <name>
                <surname>Landmesser</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rizzo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mollica</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Marchetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosellini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sorgentoni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Battelli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Buti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Porta</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bellmunt</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Global real-world experiences with pembrolizumab&#x000a0;in advanced&#x000a0;urothelial&#x000a0;carcinoma after platinum-based chemotherapy: the ARON-2 study.</article-title>
            <source>Cancer Immunol Immunother</source>
            <year>2024</year>
            <month>Apr</month>
            <day>18</day>
            <volume>73</volume>
            <issue>6</issue>
            <fpage>106</fpage>
            <pub-id pub-id-type="pmid">38634928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r292">
          <label>292</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sassine</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Cakir</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Della Vecchia</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ehlers</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Erdafitinib-associated retinal alterations and rapid onset bilateral white cataracts.</article-title>
            <source>Am J Ophthalmol Case Rep</source>
            <year>2024</year>
            <month>Jun</month>
            <volume>34</volume>
            <fpage>102028</fpage>
            <pub-id pub-id-type="pmid">38572298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r293">
          <label>293</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yuan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study.</article-title>
            <source>Front Pharmacol</source>
            <year>2023</year>
            <volume>14</volume>
            <fpage>1266890</fpage>
            <pub-id pub-id-type="pmid">38074150</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r294">
          <label>294</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Catto</surname>
                <given-names>JWF</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Roupr&#x000ea;t</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gschwend</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Loriot</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nishiyama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Redorta</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Daneshmand</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hussain</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Cutuli</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Procopio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Guadalupi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vasdev</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Naini</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Crow</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Triantos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baig</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>G</given-names>
              </name>
              <collab>THOR-2 Cohort 1 Investigators</collab>
            </person-group>
            <article-title>Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer.</article-title>
            <source>Ann Oncol</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>98</fpage>
            <page-range>98-106</page-range>
            <pub-id pub-id-type="pmid">37871701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r295">
          <label>295</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loriot</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>O'Hagan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Siefker-Radtke</surname>
                <given-names>AO</given-names>
              </name>
            </person-group>
            <article-title>Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-up.</article-title>
            <source>Future Oncol</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>5</issue>
            <fpage>231</fpage>
            <page-range>231-243</page-range>
            <pub-id pub-id-type="pmid">37916514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r296">
          <label>296</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bonate</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Matsangou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kadokura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Choules</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pavese</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nagata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tenmizu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Koibuchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wojtkowski</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hanley</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Poondru</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>63</volume>
            <issue>4</issue>
            <fpage>423</fpage>
            <page-range>423-438</page-range>
            <pub-id pub-id-type="pmid">38609704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r297">
          <label>297</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benjamin</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Rezazadeh Kalebasty</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?</article-title>
            <source>Eur Urol Oncol</source>
            <year>2024</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>313</fpage>
            <page-range>313-315</page-range>
            <pub-id pub-id-type="pmid">38485615</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r298">
          <label>298</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Powles</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Valderrama</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bedke</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kikuchi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hoffman-Censits</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Iyer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vulsteke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Castellano</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fornarini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>G&#x000fc;m&#x000fc;&#x0015f;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Loriot</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fl&#x000e9;chon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Duran</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Drakaki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Narayanan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Gorla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Homet Moreno</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>van der Heijden</surname>
                <given-names>MS</given-names>
              </name>
              <collab>EV-302 Trial Investigators</collab>
            </person-group>
            <article-title>Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2024</year>
            <month>Mar</month>
            <day>07</day>
            <volume>390</volume>
            <issue>10</issue>
            <fpage>875</fpage>
            <page-range>875-888</page-range>
            <pub-id pub-id-type="pmid">38446675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r299">
          <label>299</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoimes</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Flaig</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Milowsky</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Friedlander</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Bilen</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Srinivas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Merchan</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>McKay</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Petrylak</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Sasse</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Moreno</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Carret</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.</article-title>
            <source>J Clin Oncol</source>
            <year>2023</year>
            <month>Jan</month>
            <day>01</day>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-31</page-range>
            <pub-id pub-id-type="pmid">36041086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r300">
          <label>300</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Utz</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Hanash</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Farrow</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>The plight of the patient with carcinoma in situ of the bladder.</article-title>
            <source>J Urol</source>
            <year>1970</year>
            <month>Feb</month>
            <volume>103</volume>
            <issue>2</issue>
            <fpage>160</fpage>
            <page-range>160-4</page-range>
            <pub-id pub-id-type="pmid">5410591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r301">
          <label>301</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stanisic</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Donovan</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lebouton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>5-year experience with intravesical therapy of carcinoma in situ: an inquiry into the risks of "conservative" management.</article-title>
            <source>J Urol</source>
            <year>1987</year>
            <month>Nov</month>
            <volume>138</volume>
            <issue>5</issue>
            <fpage>1158</fpage>
            <page-range>1158-61</page-range>
            <pub-id pub-id-type="pmid">3118055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r302">
          <label>302</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lamm</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Herr</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jakse</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kuroda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mostofi</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Okajima</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sakamoto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sesterhenn</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>da Silva</surname>
                <given-names>FC</given-names>
              </name>
            </person-group>
            <article-title>Updated concepts and treatment of carcinoma in situ.</article-title>
            <source>Urol Oncol</source>
            <year>1998</year>
            <season>Jul-Oct</season>
            <volume>4</volume>
            <issue>4-5</issue>
            <fpage>130</fpage>
            <page-range>130-8</page-range>
            <pub-id pub-id-type="pmid">21227218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r303">
          <label>303</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sylvester</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>van der MEIJDEN</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Lamm</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.</article-title>
            <source>J Urol</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>168</volume>
            <issue>5</issue>
            <fpage>1964</fpage>
            <page-range>1964-70</page-range>
            <pub-id pub-id-type="pmid">12394686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r304">
          <label>304</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Vaidya</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Aeddula</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <chapter-title>Chronic Kidney Disease</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>7</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">30571025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r305">
          <label>305</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shabsigh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Korets</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vora</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Cronin</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Raj</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bochner</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Dalbagni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Herr</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Donat</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology.</article-title>
            <source>Eur Urol</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>164</fpage>
            <page-range>164-74</page-range>
            <pub-id pub-id-type="pmid">18675501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r306">
          <label>306</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gofrit</surname>
                <given-names>ON</given-names>
              </name>
              <name>
                <surname>Hidas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Landau</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Pode</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Diagnosing spontaneous ileal neobladder perforation: Too often delayed.</article-title>
            <source>Can Urol Assoc J</source>
            <year>2013</year>
            <season>Nov-Dec</season>
            <volume>7</volume>
            <issue>11-12</issue>
            <fpage>E817</fpage>
            <page-range>E817-9</page-range>
            <pub-id pub-id-type="pmid">24475003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r307">
          <label>307</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hautmann</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>de Petriconi</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Volkmer</surname>
                <given-names>BG</given-names>
              </name>
            </person-group>
            <article-title>25 years of experience with 1,000 neobladders: long-term complications.</article-title>
            <source>J Urol</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>185</volume>
            <issue>6</issue>
            <fpage>2207</fpage>
            <page-range>2207-12</page-range>
            <pub-id pub-id-type="pmid">21497841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r308">
          <label>308</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kyriakidis</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Fournier's gangrene following delayed rupture of an ileal neobladder (Hautmann).</article-title>
            <source>Br J Urol</source>
            <year>1995</year>
            <month>Nov</month>
            <volume>76</volume>
            <issue>5</issue>
            <fpage>668</fpage>
            <pub-id pub-id-type="pmid">8535701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r309">
          <label>309</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parsons</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Schoenberg</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Successful conservative management of perforated ileal neobladder.</article-title>
            <source>J Urol</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>165</volume>
            <issue>4</issue>
            <fpage>1214</fpage>
            <page-range>1214-5</page-range>
            <pub-id pub-id-type="pmid">11257680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r310">
          <label>310</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khalil</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lilly</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alkassis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mansour</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tayeh</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Sarkis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Aoun</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Late Spontaneous Rupture of the Orthotopic Neobladder, an Unusual Complication.</article-title>
            <source>Indian J Surg Oncol</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>260</fpage>
            <page-range>260-261</page-range>
            <pub-id pub-id-type="pmid">35782804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r311">
          <label>311</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Foerster</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Abufaraj</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D'Andrea</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hassler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Minervini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roupr&#x000ea;t</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Babjuk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shariat</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens.</article-title>
            <source>BJU Int</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>123</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-21</page-range>
            <pub-id pub-id-type="pmid">29807387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r312">
          <label>312</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seisen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Comp&#x000e9;rat</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>L&#x000e9;on</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Roupret</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Impact of histological variants on the outcomes of nonmuscle invasive bladder cancer after transurethral resection.</article-title>
            <source>Curr Opin Urol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>524</fpage>
            <page-range>524-31</page-range>
            <pub-id pub-id-type="pmid">25051021</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r313">
          <label>313</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sylvester</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>van der Meijden</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Oosterlinck</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Witjes</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bouffioux</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Denis</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Newling</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Kurth</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.</article-title>
            <source>Eur Urol</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>49</volume>
            <issue>3</issue>
            <fpage>466</fpage>
            <page-range>466-5; discussion 475-7</page-range>
            <pub-id pub-id-type="pmid">16442208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r314">
          <label>314</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Isharwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Konety</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Non-muscle invasive bladder cancer risk stratification.</article-title>
            <source>Indian J Urol</source>
            <year>2015</year>
            <season>Oct-Dec</season>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>289</fpage>
            <page-range>289-96</page-range>
            <pub-id pub-id-type="pmid">26604439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r315">
          <label>315</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tilki</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Urethral recurrence after cystectomy: current preventative measures, diagnosis and management.</article-title>
            <source>BJU Int</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>117</volume>
            <issue>4</issue>
            <fpage>563</fpage>
            <page-range>563-9</page-range>
            <pub-id pub-id-type="pmid">26556525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r316">
          <label>316</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nieder</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Sved</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Manoharan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Soloway</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Urethral recurrence after cystoprostatectomy: implications for urinary diversion and monitoring.</article-title>
            <source>Urology</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>64</volume>
            <issue>5</issue>
            <fpage>950</fpage>
            <page-range>950-4</page-range>
            <pub-id pub-id-type="pmid">15533484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r317">
          <label>317</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knapik</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>Urethral wash cytopathology for monitoring patients after cystoprostatectomy with urinary diversion.</article-title>
            <source>Cancer</source>
            <year>2003</year>
            <month>Dec</month>
            <day>25</day>
            <volume>99</volume>
            <issue>6</issue>
            <fpage>352</fpage>
            <page-range>352-6</page-range>
            <pub-id pub-id-type="pmid">14681943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r318">
          <label>318</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clark</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Contemporary management of the urethra in patients after radical cystectomy for bladder cancer.</article-title>
            <source>Urol Clin North Am</source>
            <year>2005</year>
            <month>May</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>199</fpage>
            <page-range>199-206</page-range>
            <pub-id pub-id-type="pmid">15862617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r319">
          <label>319</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sherwood</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Sagalowsky</surname>
                <given-names>AI</given-names>
              </name>
            </person-group>
            <article-title>The diagnosis and treatment of urethral recurrence after radical cystectomy.</article-title>
            <source>Urol Oncol</source>
            <year>2006</year>
            <season>Jul-Aug</season>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>356</fpage>
            <page-range>356-61</page-range>
            <pub-id pub-id-type="pmid">16818191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r320">
          <label>320</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mak</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shipley</surname>
                <given-names>WU</given-names>
              </name>
              <name>
                <surname>Efstathiou</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Tester</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Hagan</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Heney</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Zietman</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.</article-title>
            <source>J Clin Oncol</source>
            <year>2014</year>
            <month>Dec</month>
            <day>01</day>
            <volume>32</volume>
            <issue>34</issue>
            <fpage>3801</fpage>
            <page-range>3801-9</page-range>
            <pub-id pub-id-type="pmid">25366678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r321">
          <label>321</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Efstathiou</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Spiegel</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Shipley</surname>
                <given-names>WU</given-names>
              </name>
              <name>
                <surname>Heney</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Niemierko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Coen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Skowronski</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Paly</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>McGovern</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Zietman</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.</article-title>
            <source>Eur Urol</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>61</volume>
            <issue>4</issue>
            <fpage>705</fpage>
            <page-range>705-11</page-range>
            <pub-id pub-id-type="pmid">22101114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18354.r322">
          <label>322</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quek</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Daneshmand</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miranda</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Thangathurai</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Roffey</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Skinner</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Lieskovsky</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Skinner</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>A critical analysis of perioperative mortality from radical cystectomy.</article-title>
            <source>J Urol</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>175</volume>
            <issue>3 Pt 1</issue>
            <fpage>886</fpage>
            <page-range>886-9; discussion 889-90</page-range>
            <pub-id pub-id-type="pmid">16469572</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
